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Abstract 
Inhalation is attractive for treating respiratory diseases since it offers an opportunity 
to achieve lung-selectivity, i.e. high local and low systemic levels of unbound drug. 
Nevertheless, evaluation and prediction of the former is challenging for reasons 
including: 1) the unbound blood concentration cannot be assumed to reflect the free 
lung target site exposure after inhalation, 2) it is not possible directly measure 
unbound drug concentrations locally in the lung, and 3) pulmonary drug disposition 
is known to be a complex interplay between numerous processes. This thesis 
therefore aims to increase the understanding of how different drug- and formulation-
specific properties relate to the free target site exposure to inhaled drug. This was 
done by: 1) developing and subsequently applying an experimental methodology for 
measuring pulmonary and systemic occupancy of a receptor targeted by inhaled 
drugs, and 2) developing a rat physiologically-based pharmacokinetic (PBPK) 
model, which mechanistically describes underlying processes of pulmonary drug 
disposition. Experimental studies provided data on the time-course of the PK and 
receptor occupancy after intravenous (IV) and inhaled drug delivery of fluticasone 
propionate (FP). The binding kinetics parameters, which were estimated from data 
generated after IV-dosing, were used as input parameters to the developed model 
together with other properties specific to FP. The model accurately described the PK 
and receptor binding for several IV-doses. Predictions were consistent with the 
observations from inhalation studies, confirming that FP has a dissolution rate-
limited absorption and highlighting that drug in solid state does not contribute to 
receptor binding. As the model is mechanistic, it can assess how different drug- and 
formulation-specific properties, or combinations thereof, give rise to lung-selectivity. 
Specific findings include lung-selectivity possibly being unattainable in well-
perfused lung regions and that slow drug-receptor dissociation can provide lung-
selectivity. Hence, the model lends itself to guiding the design of inhaled compounds 
and formulations. 
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Chapter 1 Introduction  
 
Inhalation is an attractive route of administration that has been employed for more 
than 2000 years [1]. Delivery of drug directly to the diseased target organ has been 
associated with advantages such as a rapid onset of action and a higher and more 
sustained local tissue concentration [2]. The latter offers an opportunity to increase 
the therapeutic index (TI), which often is defined as the ratio of the dose that causes a 
toxic response to the dose that produces the desired, therapeutic effect in 50% of the 
population [3]. The TI can be increased by achieving lung-selectivity and thereby 
fulfil the aim of locally acting inhaled drugs, i.e. to obtain high drug concentrations 
at the lung target site whilst the systemic concentrations are kept at a minimum [4]. 
In order to minimise the systemic exposure, and thus systemic side-effects, drug 
discovery typically aims to develop inhaled drugs with high hepatic clearance to 
obtain a rapid elimination and to avoid absorption from the gastrointestinal (GI) tract 
[5].  
   However, assessment and prediction of lung-selectivity has so far proven to be 
elusive. Collection of relevant exposure measurements is recognised as a challenge 
both within clinical and preclinical research. Since the appearance of drug in the 
systemic circulation is the result of pulmonary absorption, unbound drug 
concentrations in plasma (Cu,p) cannot be assumed to reflect the unbound target site 
concentration in the lung [2]. In contrast, this assumption can generally be held as 
valid for systemically acting drugs. This constitutes a challenge for evaluation of 
locally acting inhaled drugs since Cu,p usually forms the basis for establishing a 
quantitative relationship between the drug exposure (pharmacokinetics - PK) and the 
2 
 
drug effect (pharmacodynamics - PD), commonly referred to as a PK/PD-
relationship. 
   To date, it is not possible to measure the unbound, and thus pharmacologically 
active, target site concentrations locally in lung tissue. In a preclinical setting, the 
lungs can be collected by destructive sampling at several time points after inhalation 
of drug, where destructive sampling implies that the animal is euthanized during the 
process of sampling (i.e. only one sample/animal). Drug concentrations are 
subsequently measured in lung tissue homogenates, providing a time profile of total 
lung concentrations where the lung, despite its heterogeneous nature, is reflected as 
one anatomical entity. Moreover, the homogenisation process severely distorts data 
interpretation by dissolving solid drug particles [6]. Indeed, the establishment of 
PK/PD-relationships based on total lung concentrations is known to be more 
challenging for poorly soluble compounds [7]. This can be attributed to a large, but 
quantitatively unknown, fraction of the deposited drug still being undissolved when 
the lung is dissected, meaning that it could not have contributed to the 
pharmacological effect. As receptor occupancy is driven by the unbound drug 
concentration at the target site, such measurements would clarify the PK, as well as 
the PK/PD, after topical administration. Developing an experimental methodology 
for measuring receptor occupancy of an inhaled target would thus bring us one step 
closer towards understanding the time course of free target site exposure to inhaled 
drugs. Yet another dimension would be added if such a methodology not only 
allowed for measurements of receptor occupancy in the lung, but also in another 
organ, which thus could be used as a reference organ for the systemic exposure of 
drug after inhalation. Studies utilising such a methodology would not only provide 
results, which inherently contain information about the local target site exposure, but 
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also provide a quantitative readout of the degree of lung-selectivity that was achieved 
by inhalation. The latter information can thus be obtained by comparing the 
pulmonary and the systemic receptor occupancy. 
   Data on local and systemic receptor occupancy would thus inherently contain 
information about the fate of an inhaled drug and thereby be informative about the 
underlying processes in this system. While this doubtlessly would provide one piece 
of the puzzle, these measurements alone would not be sufficient enough to build a 
deeper mechanistic understanding and thereby enabling predictions of how the extent 
and time course of the free target site exposure to inhaled drug would be affected by 
changes in drug- and/or formulation-specific properties (e.g. the solubility and the 
particle size distribution). Hence, it would still remain challenging to identify rational 
strategies for: 1) the chemical design of inhaled compound series, 2) the inhaled 
formulation design for clinical studies, and 3) targeting appropriate dose ranges for 
clinical studies utilising the inhaled route.  
   To understand why predicting the fate of an inhaled drug is held as particularly 
challenging, we need to consider the complexity of pulmonary drug disposition. This 
can be illustrated by considering some of the events that follow inhaled drug 
delivery. In preclinical inhalation studies, rodents are generally exposed via nose-
only inhalation, where a substantial deposition of drug particles will occur in the 
nose [6]. Drug deposited in the lung and the nose will both be subject to a self-
cleansing mechanism called mucociliary clearance (MCC), which transports drug 
particles towards the pharynx where they are eventually swallowed [8]. Accordingly, 
the resulting plasma PK is a result of parallel absorption from the lung, the nose and 
the GI-tract [9,10]. Nevertheless, predicting regional drug concentrations in the lung 
is even more demanding since pulmonary drug disposition involves numerous 
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processes including regional drug deposition, dissolution of solid drug particles and 
MCC. Furthermore, additional complexity comes from the heterogeneous nature of 
the organ with distinct differences between the tracheobronchial and alveolar regions 
[11]. An integrated understanding, which takes the mechanistic processes as well as 
the organ heterogeneity into account, would thus be desirable. 
   Simulation models have previously been used to predict the systemic exposure of 
inhaled drugs in humans. Hochhaus and Weber [12] developed a compartmental 
simulation tool, in which the lung was divided into two subcompartments 
representing the central and peripheral region, respectively. The model also included 
features such as MCC and drug dissolution described by rate constants [12]. 
Chaudhuri et al. used GastroPlus™ to predict the systemic PK of budesonide [13]. 
The simulated plasma profiles of both models proved to agree well with 
experimental data. These simulation studies thus aimed at characterising the systemic 
and not the local exposure. There has also been research focusing on predicting the 
local exposure to inhaled drug. A simulation study by Hochhaus et al. evaluated 
lung-selectivity in terms of pulmonary and systemic receptor occupancy [14]. 
However, those simulations relied on a very simple model structure where the lung 
was described by a single compartment and the receptor binding by a static model. 
Furthermore, the drug dissolution was non-mechanistically described by a single rate 
constant. Thus the simple model structure and the incorporation of only a few, 
empirically described drug disposition processes cannot provide a sufficiently 
detailed description of the system to understand the interplay between different 
processes and thereby e.g. make inferences on the optimal design of inhaled 
compounds and/or formulations. Even so, despite its simplicity, the model by 
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Hochhaus et al. could e.g. identify that lung-selectivity is attained during the 
dissolution process.  
   Nevertheless, a mechanistic model predictive of local tissue concentrations 
combined with measurements such as receptor occupancy for validation is currently 
lacking. Such a model would be necessary to elucidate the highly complex processes 
involved in pulmonary drug disposition [15]. Clearly, some of these processes will 
be affected by pulmonary diseases [16]. For instance, simulations have proposed that 
the drug deposition will be enhanced at the sites of airway narrowing in asthmatic 
patients [17]. Whilst this research focuses on healthy lungs, it opens up for later 
research to evaluate how the pathophysiology of a given disease might affect 
processes of pulmonary drug disposition and thereby the local lung concentrations. 
   In this thesis, a mechanistic and physiologically-based rat inhalation PK and 
receptor occupancy model is developed. The presented model provides the 
pharmaceutical industry with a novel systems modelling tool for understanding how 
the free target site exposure to inhaled drug relates to different drug- and 
formulation-specific properties and thereby enables informed decisions on e.g. the 
chemical and formulation design. 
 
1.1 Aims and objectives 
The aim of this thesis is to increase the understanding of how the level and time 
course of free lung target site exposure to inhaled drug relate to different drug- and 
formulation-specific properties. Therefore the objectives of this thesis are to: 
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1. Continue and complete an ongoing development of an in vivo receptor 
occupancy methodology for an inhaled target, the glucocorticoid receptor 
(GR).  
2. Apply the developed in vivo receptor occupancy methodology to characterise 
and compare the time course of receptor occupancy after intravenous- and 
inhaled drug delivery. 
3. Characterise the binding kinetics of a GR agonist using the intravenous route. 
4. Develop a mechanistic, mathematical framework to predict the time course of 
target site exposure to unbound drug and receptor occupancy after inhalation, 
taking into account the physiology of the species and processes judged to be 
important for pulmonary drug disposition.  
5. Apply the developed model to understand what drug- and formulation-
specific properties, or combinations thereof, that give rise to lung-selectivity 
in terms of local and systemic receptor occupancy. 
 
1.2 Thesis outline 
This thesis will lead up to the development of a mechanistic and physiologically-
based inhalation PK model, which subsequently is used to gain an understanding of 
how different drug- and/or formulation-specific properties can (or cannot) give rise 
to lung-selectivity. As detailed below, this aim can be obtained by conducting the 
research in a stepwise manner. 
   Chapter 2 introduces relevant background information, which has been divided into 
two main categories: inhalation PK and modelling, respectively. The focus of the 
former category is primarily on processes that are unique for pulmonary drug 
disposition, but it also covers e.g. lung anatomy, preclinical inhalation models and 
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general PK concepts. Clearly, it is crucial to build an understanding about these 
different subcategories as it will provide the foundation for the model development 
and the subsequent validation. 
   Chapter 3 presents the development of an in vivo receptor occupancy methodology 
for an inhaled target (the GR) in rats. As outlined in the introduction, such 
measurements will inherently contain information about the free target site exposure 
to inhaled drug, which cannot be directly measured. The developed methodology is 
subsequently evaluated by testing its ability to demonstrate a dose-receptor 
occupancy relationship as well as to characterise the time course of receptor 
occupancy after intravenous administration of a GR agonist (fluticasone propionate, 
FP). 
   In chapter 4, the developed experimental methodology is applied to study the time 
course of receptor occupancy and the PK after nose-only exposure of FP as well as 
after intravenous administration of another GR-agonist (budesonide). Mathematical 
modelling is subsequently used to estimate the unknown in vivo binding kinetics 
parameters for both compounds using the data generated from intravenous dosing.  
   Chapter 5 describes the development of a physiologically based pharmacokinetic 
(PBPK) model, which places emphasis on mechanistically describing the underlying 
processes of pulmonary drug disposition. Here it also becomes clear that chapter 4 
serves two important purposes. Firstly, it provides estimates of the binding kinetics 
parameters Kon and Koff, which are then used as input parameters to the presented 
model. Secondly, the receptor occupancy measurements as well as the PK from the 
nose-only exposure studies can used for model validation purposes. The ability of the 
model to mechanistically describe PK and the receptor binding after intravenous and 
inhaled drug delivery is thus evaluated using FP as a test compound. The developed 
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PBPK model is subsequently used to explore various aspects of pulmonary drug 
disposition, including how the interplay between different drug- and formulation-
specific properties can produce lung-selectivity. 
   The overall project conclusions and recommendations for future research are 
discussed in chapter 6. 
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Chapter 2 Background 
 
 2.1 Introduction 
This thesis is set out to explore how the target site exposure to inhaled drug relates to 
different drug- and formulation-specific properties. Ultimately, this will lead up to 
the development of a new systems model, which is built by formulating 
mathematical descriptions of the system based on the current understanding of 
pulmonary drug disposition and rodent physiology. Such a model can be evaluated 
using drug- and formulation-specific properties as input parameters and subsequently 
be validated using different experimental measurements. Clearly, developing such a 
model requires knowledge about several different areas including inhalation 
pharmacokinetics (PK) and modelling. 
   This chapter, which aims to introduce relevant background information, has 
therefore broadly been divided into two main sections: inhalation PK and modelling, 
respectively. The focus of the former section is primarily on processes that are 
unique for pulmonary drug disposition, but it also covers e.g. lung anatomy, 
preclinical inhalation models and general PK concepts. The latter section will 
introduce various modelling techniques and concepts that are useful for this thesis 
such as physiologically-based pharmacokinetic (PBPK) modelling.  
 
2.2 Inhalation pharmacokinetics 
2.2.1 General background to inhalation 
The ability to deliver drug specifically to its site of action has made inhalation an 
attractive route of administration for respiratory diseases. This feature has been 
associated with advantages such as a rapid onset of action and a higher and more 
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sustained local tissue concentration [2]. The latter can lead to an increased 
therapeutic index by achieving lung-selectivity and thus fulfilling the aim of locally 
acting inhaled drugs, i.e. to obtain high unbound drug concentrations at the lung 
target site while the systemic (unbound) concentrations are kept at a minimum [4]. 
Clearly, the unbound lung target site concentrations are expected to drive the desired 
pharmacological effect, whereas the unbound systemic concentration might exert 
unwanted systemic side-effects [18]. Inhalation is therefore generally held as the 
optimal route of administration of the first-line therapy for asthma [19] and chronic 
obstructive pulmonary disease (COPD) [20].  
   Nevertheless, the large absorptive surface area of the lung has also led to 
widespread interest in using inhalation as an alternative route of administration for 
the systemic delivery of drug. Furthermore, relative to oral administration, inhalation 
might significantly reduce pre-systemic metabolism since the lung is expected to 
have a lower metabolic capacity than the GI-tract [21]. These features thus serve to 
illustrate why inhalation might be advantageous for systemic drug delivery. 
Expressed differently, the utility of using inhalation for both lung-targeted drug 
treatment and systemic drug delivery are two sides of the same coin. Hence, we need 
to understand what combinations of drug- and formulation-specific properties are 
beneficial for either creating a lung-selective drug exposure or for systemic drug 
delivery. 
 
2.2.2 Lung anatomy 
This subsection aims to provide a short overview of the lung anatomy and to 
introduce fundamental terms, which will be used in this thesis. 
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   The respiratory system is often divided into two different regions: the conducting 
airways and the respiratory airways. As can be understood from the terminology, one 
important function of the conducting airways (nose, pharynx, larynx, trachea, 
bronchi and nonalveolized bronchioles) is to conduct inhaled air into the respiratory 
airways (respiratory bronchioles, alveolar ducts and alveolar air sacs) where gas-
exchange takes place [22].  
   There are two different circulatory systems in the lung: bronchial and pulmonary 
circulation, which supply the conducting and the respiratory airways, respectively 
[23]. The primary function of the pulmonary circulation is to carry deoxygenated 
blood from the heart to the alveoli for gas-exchange. It is a circulation system 
connected in series with the systemic circulation and it receives the entire cardiac 
output [24]. The bronchial circulation, on the other hand, is part of the systemic 
circulation and a fraction of the cardiac output thus supplies the conducting airways 
with oxygen and nutrients [23]. 
   According to an alternative division of the respiratory system, three different 
regions can be defined: the extrathoracic region, the tracheobronchial region and the 
alveolar region. The extrathoracic region then refers to the respiratory tract proximal 
to the trachea (i.e. the nose, pharynx and larynx). The tracheobronchial region is also 
referred to as the ‘lower airways’, consisting of the airways that conduct air from the 
larynx to the alveolar region. Expressed differently, anatomically this region starts at 
the trachea and stops at the end of the terminal bronchioles [25].   
   The human airways show a bifurcation pattern starting at the trachea (generation 
0), which divides into the left and right main stem bronchi (generation 1), which in 
turn undergo bifurcations into additional bronchi (generation 2) [26]. The branching 
pattern continues in this manner until the last generation has been reached, which is 
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illustrated in fig. 2.1a from [11]. There are several different anatomical models for 
the lung, which differ to some extent in e.g. the total number of airway generations 
(n = 23-26) [27]. In contrast to humans, rat airways follow a monopodial 
(asymmetric) branching [22]. This different branching pattern has been an important 
factor to consider e.g. when developing realistic particle deposition models for rats. 
Models that have been constructed for describing the lung anatomy also serve to 
highlight one of the main features of the organ: its large surface area. Clearly, this 
feature is of great importance for gas-exchange. 
   The lung is considered to be a complex and heterogeneous organ [28] with distinct 
regional differences. Moving from the trachea to the alveolar region, both the type of 
epithelium and its thickness will change. In humans, the thickness of the epithelium 
decreases from 58 µm in the bronchi to 0.1-0.2 µm in the alveoli [11]. In rats, the 
bronchi epithelium thickness is 13 µm [29]. Likewise, there are also distinct 
differences in both the composition and the thickness of the lung wall [30]. The same 
principle applies for the epithelial lining fluid (ELF), which is a thin fluid layer that 
covers the epithelial surface. The ELF also becomes thinner throughout the lung; 
ranging from 8 µm in the human bronchi and gradually decreasing until reaching a 
final value of 0.07 µm in the alveoli [11]. The heterogeneity of the lung epithelium 
and the decreasing thickness of the ELF are both illustrated in fig 2.1b from [11]. 
The ELF is slightly acidic (pH 6.6) and mainly consists of water (96%), salts, 
phospholipids, protein and mucins [4]. Its composition is held to vary between 
different lung regions. Nevertheless, this information is incomplete due to the 
technical challenges associated with sampling the ELF from different regions [31]. 
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Figure 2.1 Illustration of the lung heterogeneity. a) Illustration of the bifurcation pattern in the human 
lung; starting at the trachea (generation 0), each bifurcation gives rise to a new generation. b) 
Illustration of how the thickness of the epithelial cells, which are drawn at their relative sizes, 
decreases when moving distally from the bronchi to the alveoli. The figure also demonstrates that the 
same pattern applies for the epithelial lining fluid (darker orange colour). Both figures are taken from 
[11] with permission.  
 
 2.2.3. Pharmacokinetics and pharmacodynamics 
This subsection aims to provide an overview of pharmacokinetics (PK) and 
pharmacodynamics (PD) as well as to introduce terms that are commonly used 
within the field. 
   PK can in general terms be described as “what the body does to the drug” [32]. A 
drug undergoes several different processes once it has entered the body and the PK 
of a drug is therefore often defined by its absorption, distribution, metabolism and 
excretion (ADME). If liberation (L) of the drug from its pharmaceutical form is seen 
as a separate step from absorption, the acronym LADME is used instead [33]. 
Absorption refers to the process by which unchanged drug moves from the site of 
administration (e.g. the GI-tract) to the site of measurement within the body (e.g. the 
venous blood) [34]. Absorption includes, but is not limited to, oral absorption. 
Bioavailability (F) is a term that is often used in the context of absorption. F 
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describes the extent of drug absorption and is defined as the fraction of the 
administered dose that reaches the systemic circulation in an unchanged form [35]. F 
following oral absorption can be written as 
 
habsgut fffF  .    (2.1) 
 
That is, F accounts for the fraction absorbed from the GI-tract (fabs), the fraction that 
escapes from gut (fgut) and hepatic extraction (fh). The fgut of a drug can be caused by 
luminal degradation, efflux transporters and/or gut metabolism. The fraction of 
absorbed drug that has escaped gut extraction (i.e. fabs×fgut) will initially enter the 
liver via the portal vein, where a fraction of the drug can be metabolised prior to 
reaching the systemic circulation. The hepatic extraction ratio, EH, thus accounts for 
the so-called hepatic first-pass extraction and is dependent on the extent of 
metabolism in the liver [36]. EH can also be written as 
 
hH fE 1 .     (2.2) 
 
The process by which a drug is reversibly transferred from one location to another 
within the body is referred to as distribution [37]. The rate and extent of distribution 
of a particular drug to various organs is dependent on several factors including 
binding within blood and tissue, lipid solubility and regional blood flow [35]. At 
equilibrium, the extent of distribution in the body is described by the apparent 
volume of distribution (Vd), which is calculated by 
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where Ab is the amount of drug in the body and Cp is the plasma concentration of the 
drug [34]. Expressed differently, Vd can be seen as a theoretical volume that would 
have been required to obtain the drug concentration that was measured in plasma 
given the amount of drug in the body.  
   The amount of drug in the body will decline with time as a result of drug 
elimination, which can take place via two different processes: metabolism and 
excretion. Metabolism, which describes an enzyme-catalysed conversion of a drug 
into its metabolites [35], can take place in several organs. Nevertheless, the liver has 
the highest metabolic capacity and is therefore generally the major site for 
metabolism [37]. Metabolism, or biotransformation, can be divided into two different 
phases. Phase I involves enzymatic reactions that change the parent compound by 
oxidation, reduction or hydrolysis. The resulting metabolite may or may not be 
pharmacologically active. The role of phase I is generally to create derivatives 
amenable to phase 2 biotransformation, in which the molecules undergo conjugation 
reactions. Phase 2 makes the molecule more hydrophilic and thus more easily 
excreted. Excretion describes the different processes by which a molecule or its 
metabolite is eliminated from the body. The major excreting organ is the kidney [35]. 
An essential term within the field of PK that is used for evaluating the elimination of 
drug is clearance (CL), which relates the drug concentration (C) to the rate of 
elimination (RoE) [34]: 
 
CCL  RoE .    (2.4) 
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If C refers to the plasma or blood concentration of drug, CL describes either the 
plasma or blood clearance, respectively (the concentration in these two biological 
matrices are not necessarily equal) [37]. 
   Another concept worthwhile introducing is the area under the curve (AUC), which 
is the definite integral of the plasma/blood concentration of drug as a function of 
time (C(t)) in the interval [a, b], i.e. 
 

b
a
dttCAUC )( .    (2.5) 
 
Generally, one of the two following time intervals are used: [0, 24] or [0, ∞] h. 
   PD can be described as “what the drug does to the body” [32]. More formally, in 
[38] it is defined as “the study of the biologic effects resulting from the interaction 
between drugs and biologic systems”. Hence, PK describes the drug-concentration 
time course that follows after administration of a certain dose and PD describes the 
pharmacological effect that results from a certain drug concentration.  
   Clearly, it is important to understand the link between PK and PD, which can be 
done by PK/PD-modelling. PK/PD-models aim to describe the effect-time course 
that results from administration of a certain drug dose [39]. Such models can be of 
great value both in drug discovery and drug development. Preclinically, they can, for 
instance, be used to select the most promising drug candidate to test in humans. 
PK/PD-modelling has several applications in drug development, including assisting 
in the design of clinical trials by, for instance, selecting an optimal dose and 
sampling scheme [40]. Over recent years, the discipline has progressed from using 
empirical functions to purely describe the observed data to utilising mechanism-
based PK/PD-modelling. As opposed to just describing the data, the latter aims to 
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quantitatively describe the underlying principles of the pharmacology, of the 
physiology and of the pathology. By virtue of relying on actual mechanisms, such 
models are expected to have a better predictive capability [41]. 
 
2.2.4 Systemic and local PK after inhaled drug delivery 
Figure 2.2 from [42] shows a schematic representation of the PK for an orally 
inhaled drug. In patients, inhalation devices are used to deliver the drug directly to 
the lung whilst animal studies typically rely on tidal breathing. After inhalation, a 
large fraction of the dose will deposit in the mouth and the pharynx. Given that this 
portion of the dose is not completely rinsed out of the mouth by the patient, it may be 
swallowed and reach the GI-tract. The swallowed dose will thus be treated by the 
body as an oral dose with the potential of being absorbed from the GI-tract. 
Absorbed drug that escapes first-pass metabolism in the liver will reach the systemic 
circulation in an unchanged form, potentially increasing the risk of systemic side-
effects [18]. A fraction of the delivered dose will deposit in the lung, where it will 
have to be dissolved in the ELF prior to absorption to the pulmonary/systemic 
circulation [15]. The deposited drug will also be subject to a self-cleansing 
mechanism called mucociliary clearance (MCC), which acts by transporting particles 
from the airways towards the pharynx, where they subsequently can be swallowed 
and reach the GI-tract [8]. Although not included in figure 2.2, solid drug particles 
deposited in the alveolar region may be phagocytosed by alveolar macrophages. 
However, this is a slow process that might take weeks or months to complete [43]. 
Accordingly, given that the drug is orally bioavailable, the resulting plasma PK is a 
result of parallel absorption from the lung and the GI-tract.  
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   Hence, the total amount of drug that will reach the systemic circulation after 
inhalation will be dependent on the absorption from both the GI-tract and the lung as 
well as on the ability of the lung to remove the substance. The latter includes 
clearance in terms of MCC or macrophage uptake as well as metabolic processes. 
However, the lung has low levels of metabolising enzymes. In fact, the total 
cytochrome P450s (CYP) content constitutes only 1% of the corresponding value in 
the liver. Thus, the lung is only expected to play a minor role in the metabolism 
process compared with the liver. Interestingly, the relatively low metabolic capacity 
combined with the large surface area of the lung has also lead to a widespread 
interest in using inhalation for the systemic delivery of drugs [7]. In these instances, 
the lung is seen as an entry port to the systemic circulation rather than as the target 
organ for the pharmacological effect.  
   In contrast, when the pulmonary route is used for direct treatment of disease 
localised in the lung, the focus is on improving the benefit-safety ratio by 
maximising the pulmonary and minimising the systemic unbound drug exposure 
[45]. From the description above, it becomes clear that the level of 
pharmacologically active drug in the lung will be the result of several complex and 
simultaneously occurring processes including, but not restricted to, MCC, the 
dissolution rate of solid particles (if applicable) and flux to/from the systemic 
circulation.  
   In order to minimise the systemic exposure, and thus the systemic side-effects, 
drug discovery typically aims to develop inhaled drugs with high hepatic clearances 
and low oral bioavailabilities in order to obtain rapid elimination and to avoid 
absorption from the GI-tract [5]. Nevertheless, achieving lung-selective drug 
exposure after inhalation is not a trivial task. The large surface area, good 
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vascularisation and thin alveolar epithelium offer the potential for rapid absorption 
into the systemic circulation [46]. Indeed, with the exception of intravenous (IV) 
administration, inhalation is the fastest route for systemic drug delivery of small 
molecules. This is particularly prominent for small lipophilic molecules, where the 
absorption half-life is approximately 1-2 minutes [21]. Several strategies for 
enhancing lung retention have therefore been explored, which will be described in 
section 2.2.5.4. 
 
 
Figure 2.2 Schematic representation of the fate of an orally inhaled drug from [42] with permission. 
 
2.2.4.1 Dose-response for inhaled corticosteroids 
Inhaled corticosteroids (ICS) are considered to be the most effective medication used 
for controlling asthma [47]. Indeed, the Global Initiative for Asthma (GINA) 
recommends low doses of ICS to be used as controller medication for asthma [48]. 
The clinical effect of ICS can be measured using several different outcomes 
including peak expiratory flow (PEF), use of rescue β2-agonists [47] and forced 
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expiratory volume (FEV) [49]. Meta-analyses of clinical studies investigating the 
effect(s) of ICS in asthma have shown that although ICS demonstrate a clinical 
benefit versus placebo, the dose-response curve for efficacy measurements is 
relatively flat. This is in contrast to the dose-response curve for side-effects, which 
has been reported to be steep [49,50]. However, due to paucity of data, the meta-
analysis described in [50] could not investigate the effect of dose on systemic side-
effects such as hypothalamo-pituitary axis function. The analysis instead focused on 
local side-effects related to deposition of ICS in the oropharynx. In [49] a steep dose-
response relationship was found for local side-effects and one of the included studies 
reported significantly lower cortisol levels (systemic side-effect) after a high dose of 
fluticasone propionate. References [47] and [51] also state that there is a steep dose-
response curve for systemic side-effects. Overall this implies that only a small 
clinical benefit is expected from increasing the clinical ICS doses whilst the risk of 
side-effects is considerably increased.  
 
2.2.5 Pulmonary drug disposition after inhalation 
2.2.5.1 Pulmonary drug dissolution and absorption  
Compared with other routes of administration, there is only limited information on 
the absorption of inhaled drugs. Generally, the epithelium is considered to constitute 
the main barrier for absorption from the airway lumen [11]. It is worth noting that the 
thickness of this cell barrier varies throughout the lung, starting at about 60 µm thick 
columnar epithelia in the bronchi and then decreases along the lung generations until 
reaching a final thickness of about 0.2 µm in the alveoli [4]. Due to differences both 
in thickness and blood perfusion, regional differences in absorption rates might be 
expected in different areas of the lung [15]. 
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   Drug molecules are absorbed across the epithelium both via passive and active 
transport mechanisms. The process by which a molecule moves from a point with 
higher concentration (e.g. the ELF) to a point with a lower concentration (e.g. the 
submucosa) is referred to as passive diffusion. The drug transport of lipophilic 
compounds across the cellular barriers is generally considered to rely on transcellular 
diffusion, whereas hydrophilic compounds appear to rely on paracellular diffusion 
[4]. Hydrophilic compounds can also be actively transported across cells [52] and 
over the recent years there has been an increased interest in the role of drug 
transporters in the lung [53]. Nevertheless, evaluation of the role of drug transporters 
on pulmonary drug disposition does not fall within the scope of this thesis. 
Experiments have shown that lipophilic compounds are rapidly absorbed from the 
lung (absorption half-lives ranging from seconds to a few minutes), whereas 
hydrophilic compounds are absorbed more slowly (absorption half-lives of about 1 
hour). Interestingly, the absorption half-life did not appear to be dependent on logP 
other than enabling the identification of two distinct groups in the data: hydrophilic 
(logP < 0) and lipophilic (logP > 0). Another interesting finding was that within the 
molecular weight range of 100-1000 Da there was no discernible trend of the 
pulmonary absorption rate being size-dependent [21]. 
   Before drug absorption can take place, the solid drug particles must firstly dissolve 
in the ELF. The pulmonary dissolution rate will depend on different properties of the 
drug, the formulation and the system (i.e. physiological and anatomical 
characteristics). One important property is the solubility, which will depend on e.g. 
the compound and the composition of the dissolution medium (i.e. the ELF). The 
measured solubility will therefore be different depending on the choice of dissolution 
medium. Although fluids have been specifically developed to mimic the ELF, 
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so-called simulated lung fluids, the lung has unique features that are considered 
difficult to replicate in vitro [54]. To date, development of in vitro dissolution 
methods predictive of the in vivo situation is therefore an ongoing challenge. 
Moreover, as will be discussed in depth in section 2.2.5.4, a commonly used strategy 
for enhancing lung retention is to develop poorly soluble drugs. Previous research 
aiming to predict the in vivo dissolution rate in the GI-tract based on measurements 
of the aqueous solubility have found poor in vitro-in vivo correlation for poorly 
soluble compounds [55], which emphasises the need to choose a bio-relevant 
dissolution medium for this particular compound class. 
   As mentioned in section 2.2.2, the total volume of ELF available for dissolving the 
deposited drug particles is small. Moreover, the thickness of ELF gradually decreases 
along the lung generations from 5 µm centrally [56] to 0.07 µm in the alveolar region 
[11]. This suggests that the dissolution rate might be higher centrally. Nevertheless, 
due to the complexity of the system other factors could actually lead to the opposite 
behaviour [4].  
   As pulmonary drug dissolution has been speculated to be the rate-limiting process 
for several inhaled compounds [15], there is a recognised need for further research in 
this area. 
   As mentioned in section 2.2.4, the lung has a metabolic capacity that is low relative 
to the corresponding capacity of the liver. For most inhaled compounds, pulmonary 
metabolism is therefore not expected to largely influence the extent of pulmonary 
absorption. However, the possible impact of metabolism in the target organ needs to 
be considered on a drug-specific basis. This can be exemplified by the drug 
beclomethasone dipropionate (BDP), which is rapidly metabolized by esterases in the 
lung to its active metabolite 17-beclomethasone monopropionate [57].  
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   The effect of pulmonary metabolism of different ICS has been investigated in vitro 
in human precision-cut lung slices [58]. In this experiment, lung slices were 
incubated with different ICS including FP and BDP for several hours to monitor the 
concentrations of parent compound and metabolites over time. FP was shown to be 
metabolically stable in this test system, i.e. no metabolites were found in the 
incubation medium. In contrast, the levels of BDP decreased over time and 
metabolites were detected in the medium. Hence, whilst some compounds might 
unaffected by pulmonary metabolism, this study emphasises the importance of 
considering the impact of this process on a drug-specific basis. 
 
2.2.5.2 Regional drug deposition 
After drug inhalation, the particles/droplets will deposit in different regions 
throughout the lung, which is generally referred to as the pulmonary deposition 
pattern. The optimal site for deposition is often reasoned to be dependent on the drug 
target. For instance, delivery of drug to a lung region devoid of the receptor of 
interest might result in a suboptimal response to the drug treatment [59]. As 
mentioned in the previous section, absorption rates of drug might be expected to vary 
throughout the lung [15]. Hence, different deposition patterns may be desired 
depending on the aim of the treatment and/or knowledge of the target location. It is 
therefore of interest to be able to predict the regional deposition pattern of inhaled 
particles and particle deposition modelling is used for this purpose.  
   The deposition of inhaled particles depends on several factors including: 1) the 
anatomy of the respiratory tract, 2) the respiratory physiology, and 3) the physics of 
aerosol particles. All of these factors need to be considered in mathematical 
deposition models. Due to the complexity of these factors, most models make 
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simplifying assumptions related to e.g. the structure of the respiratory tract, the 
airflow rate and the breathing pattern [60].  
   In short, an anatomical model is used to provide a geometric description of the 
airway structure. A commonly used anatomical model type is the so-called “single-
path” model. In this model type, all airways in a given airway generation have 
identical dimensions. This feature leads to identical pathways of the inhaled particles 
travelling from the nose to the alveoli. Expressed differently, all pathways can be 
represented by a single path [61]. Two important respiratory parameters used as input 
for predicting regional particle deposition are the breathing frequency (fbr), i.e. the 
number of breaths per minute, and the tidal volume (VT), i.e. the volume of air that is 
inspired in a single breath during normal breathing conditions. Both fbr and VT 
depend on the level of physical activity [61], which thus will have an impact on the 
deposition pattern. Another important parameter is the particle velocity (u), which 
will decrease distally throughout the lung. As a result of the lower velocities in the 
distal parts, particles have longer mean residence times peripherally.  
   One of the most important parameters for determining regional drug deposition is 
the aerodynamic diameter (da) of the aerosol particle [59]. The da is defined as the 
diameter of a unit density sphere that would have the same aerodynamic behaviour as 
the particle in question. The da can be calculated by 
 

 p
ga dd  ,    (2.6) 
 
where dg is the geometric diameter of the particle, ρp is the density of the particle and 
χ is a dynamic shape factor that can be used if da needs to be modified to account for 
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shape irregularity. That is, the value χ depends on the shape of the particle; e.g. χ is 
1.00 and 1.08 for spheres and cubes, respectively [62]. Expressed differently, 
particles with the same da can have different shapes and densities.  
   There are several mechanisms by which a particle can be forced to leave the stream 
of inhaled air and deposit in the airways. Three main mechanisms are: 1) inertial 
impaction, 2) gravitational sedimentation, and 3) Brownian diffusion [61]. Each of 
these mechanisms will be described below and they are graphically illustrated in 
figure 2.3, which is taken from [63]. 
   As a result of inertia, a particle may not be able to follow the air streamline when 
the curvature of the airway is changing, but it instead continues along its initial 
trajectory. The Stokes number (Stk) is a dimensionless parameter that can be used to 
characterise inertial impaction. Stk is the ratio of the particle’s relaxation time tr (the 
time it takes for a particle to reach equilibrium with a new set of forces acting on it, 
i.e. the time it takes to respond to the changes in the local flow) to the time taken to 
flow past an obstacle. Stk can therefore be seen as a measure of how rapidly a 
particle can adjust to changes in the flow field. A small Stk implies that the particle 
closely follows the streamlines while a large Stk implies that the particle takes a 
longer time to adjust to the flow distortion; i.e. it might deviate from the streamline 
and deposit due to its inertia [64]. If the characteristic length of the obstacle is set to 
the radius of the airway (Di/2), the Stk can be calculated by [65,66] 
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where Stki is Stokes number in generation i, ρ0 is the unit particle density (1 g/cm3), 
da is the aerodynamic diameter, η is the viscosity of air and Di is the diameter of the 
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airway in generation i. From eq. 2.7 it is thus evident that large particles with high 
velocities will have higher Stk and thus be more prone to inertial impaction. Hence, it 
follows that inertial impaction is most effective for large particles in the upper airway 
generations [61].  
   Deposition due to gravity is referred to as gravitational sedimentation. Deposition 
by this mechanism is e.g. dependent on the residence time in the airway (ti) and the 
gravitational settling velocity (vg), which can be calculated as  
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where ρ0 is the unit particle density (1 g/cm3) and g is the acceleration due to gravity. 
From eq. 2.8 it is clear that vg increases rapidly with particle size as it is proportional 
to the square of da. However, eq. 2.8 is only valid for larger particles unless the 
Cunningham slip correction factor (Cd) is used. Therefore, eq. 2.8 can be rewritten as 
[65,66] 
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where λ is the mean free path of air molecules. As the deposition efficiency by 
gravitational sedimentation increases with ti and vg [67], deposition by this 
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mechanism is important for larger particles in the distal lung regions where ti is 
longer. 
   The third deposition mechanism that is generally accounted for by deposition 
models is Brownian diffusion. When fine particles are suspended in air, collisions 
with the surrounding gas molecules will cause the particles to wobble randomly. This 
random motion of particles suspended in a gas is referred to as Brownian motion and 
it may cause a particle to randomly deviate from the streamline and deposit on the 
airway wall [60]. As the Brownian diffusion coefficient (Dmol) is inversely 
proportional to the particle size, this mechanism is particularly important for smaller 
particles. Dmol is calculated as [65,66] 
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where kB is the Boltzmann constant and T is the absolute temperature. Like 
gravitational sedimentation, a prolonged ti increases the probability of deposition by 
this mechanism. Brownian diffusion is thus the predominant deposition mechanism 
for smaller particles in the alveolar region [61]. 
   Several different analytical equations have been published for calculating the 
deposition probability by each of these three mechanisms in cylindrical airways [61]. 
As can be understood from the description of each mechanism above, the probability 
of particle deposition by each mechanism will vary over the different lung 
generations. The resulting deposition probability of a particle in generation i (Pi) is 
given by [68] 
 
28 
 
)1)(1)(1(1 ,,, idisiimi DEDEDEP  ,   (2.12) 
 
where DEim,i, DEd,i and DEs,i are the probabilities of particle deposition by inertial 
impaction, Brownian diffusion and gravitational sedimentation, respectively. When 
eq. 2.12 is combined with the inhaled air volume passing through each generation i 
as well as the fraction of particles already deposited in the preceding lung 
generations, the particle deposition in generation i (DEi) can be calculated during the 
inhalation phase. The value of DEi can be calculated for each of the three stages of a 
breath: inhalation (DEi
in), breath-holding (DEi
b) and exhalation (DEi
ex) [66]. The 
total deposition (DEi
tot) during a breath is subsequently given by 
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Some models developed for rats exclude the breath-holding phase since this interval 
is short compared to the breathing-phase [65]. Generally, the particle deposition is 
reported for larger lung regions rather than an individual lung generation. The 
deposition in a lung region (DEregion) between region j and k is then defined as 
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The resulting deposition fraction in a certain region (DFregion) is subsequently 
obtained by dividing the amount of deposited drug in a predefined region (eq. 2.14) 
by the amount inhaled. 
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   Several computational models have been developed for predicting regional drug 
deposition both in humans [61] and rodents [65,66,69,70]. 
 
Figure 2.3 Drug deposition mechanisms. Drug can deposit in the respiratory tract by different 
mechanisms including inertial impaction, gravitational sedimentation and Brownian diffusion. The 
figure is taken from [63]. 
 
2.2.5.3 Mucociliary clearance and macrophage clearance  
Since the primary physiological function of the lung is gas exchange, it follows that 
this organ must be in constant contact with the external environment and it will thus 
be exposed to inhaled particles such as dust and bacteria. As a result, several innate 
defence mechanisms have evolved to protect the body from potential threats that 
might enter the body via the airways [71]. One of the most important defence 
mechanisms is the mucociliary clearance (MCC), which acts by transporting particles 
from the airways toward the pharynx, where they subsequently may be swallowed 
and reach the GI-tract [8]. Interestingly, the velocity of MCC has been shown to be 
independent of particle properties such as size, shape and charge [72]. Obviously, 
this clearance mechanism will also be effective for inhaled drugs. As ciliated cells 
are responsible for clearing particles from the airways, inhaled drugs will be 
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subjected to MCC in the ciliated parts of the airways (unless the particles are readily 
dissolved) [73]. Consequently, MCC can reduce the pulmonary bioavailability after 
inhalation and this effect is expected to be more pronounced for slowly dissolving 
drugs.  
   MCC is primarily associated with the tracheobronchial region [74], however, there 
is another innate defence mechanism in the peripheral parts of the lung. Solid drug 
particles deposited in the alveolar region may be phagocytosed by alveolar 
macrophages. Nevertheless, this is a slow process that might take weeks or months to 
complete [43]. It is hypothesised that some of these macrophages might migrate to 
the ciliated terminal bronchioles, where they are subsequently cleared from the lung 
via MCC [74]. 
 
2.2.5.4 Strategies for enhancing lung retention 
Regardless of route of administration, it is crucial to develop drugs with appropriate 
effect duration. Clearly, there are no general rules defining either the desired level or 
the duration of effect of a drug, but these need to be evaluated on a case-by-case 
basis for each drug target and disease. Nevertheless, it is often desirable to have an 
efficacious response throughout the entire dose interval. Once-daily is generally the 
preferred dosing regimen since this is convenient for the patient. As a result, it is 
important to design locally acting inhaled drugs such that sufficiently high 
concentrations can be obtained throughout the entire dosing interval . As previously 
described in section 2.2.4, depending on drug properties, inhaled drugs might be 
rapidly absorbed to the systemic circulation. Achieving a sustained lung exposure is 
therefore not a trivial task and several different strategies have been explored for 
enhancing lung retention of inhaled drugs.  
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   One commonly used strategy to prolong the pulmonary residence time is to 
develop drugs with a low solubility in order to reduce the dissolution rate. Indeed, a 
low aqueous solubility has been demonstrated to give a prolonged lung retention 
preclinically . Two poorly soluble inhaled compounds are fluticasone propionate 
(FP) and BDP. Clinical data have shown that the average pulmonary absorption time 
of FP (5-7 h) is considerably longer compared with more soluble ICS such as 
budesonide and triamcinolone acetonide (2.9 and 1 h, respectively) [11]. The 
prolonged absorption time has been suggested to be caused by the slow dissolution of 
FP [75]. Moreover, the absorption across membranes is a rapid process for lipophilic 
ICS, which further strengthens the hypothesis of dissolution rate-limited absorption 
[76]. This approach is thus well-known for yielding high lung concentrations as well 
as a prolonged lung retention. Even so, there are potential caveats with this strategy. 
One important factor to bear in mind when considering using this approach is that 
undissolved drug cannot elicit a pharmacological response. Moreover, solid drug 
particles will be removed by MCC . Hence, this is a strategy that elucidates the 
importance of understanding the complex interplay between different pulmonary 
processes; more research is needed to understand what compound- and formulation-
specific properties are required for this strategy to be advantageous. 
   Another approach that is commonly used to obtain lung retention is to chemically 
design the inhaled compounds to be bases. Cooper et al. [7] showed that the ion class 
strongly influences lung retention. A comprehensive data set was generated 
preclinically, where the amount of drug remaining in the lung was monitored after 
intratracheal instillation of dissolved compounds belonging to different ion classes. 
The researchers noted that the compounds could be broadly grouped by ion class: 1) 
neutral, acidic and zwitterionic compounds tended to have a generally short 
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pulmonary half-life (t½,lung), 2) basic compounds had an intermediate t½,lung, and 3) di-
bases had a long t½,lung. One potential explanation for this phenomenon is lysosomal 
trapping. The working hypothesis is that basic compounds are sequestered in 
lysosomes, i.e. this organelle can be seen as a subcellular drug reservoir which then 
acts like a slowly eluting pool. Lysosomal trapping has been demonstrated to take 
place in vitro in lung slices [77]. However, to the best of my knowledge, the kinetics 
of this process has not yet been characterised in the literature.    
   The lung retention of the ICS budesonide is held to rely on a completely different 
mechanism. Reversible fatty acid esterification of the molecule has been found to 
take place intracellularly, which results in an intracellular reservoir of inactive drug.  
The ester, budesonide-oleate, will then be hydrolysed back to its active form as the 
intracellular concentration of free budesonide decreases. The ester is thus suggested 
to act like an intracellular depot of budesonide, which would prolong lung retention 
of the molecule. This reasoning may be supported by the following observations: 1) 
the esterification is a rapid process, 2) a large fraction of the molecules (70-80%) was 
found to be in the esterified form in the central airways after intratracheal 
administration of the compound [78], and 3) preclinical PK-studies have shown that 
similar tissue concentrations of budesonide-oleate and budesonide are obtained after 
IV-administration and inhalation of the parent compound [79].  
   Another approach that has been speculated to drive lung- and effect duration is a 
slow dissociation rate from the receptor. Some inhaled drugs are held to have this 
property, e.g. in vitro experiments have shown a slow drug-receptor dissociation rate 
for FP. Högger and Rohdewald state that the long half-life of the drug-receptor 
complex might provide a scientific rationale for the dosing interval of FP. However, 
they also emphasise that in vitro dissociation rates are not necessarily translatable to 
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the in vivo situation [80]. Nevertheless, in order to use this strategy it is crucial to 
understand if sufficiently high unbound concentrations can be obtained at the lung 
target site prior to the drug is being absorbed to the systemic circulation and/or 
cleared from the lung. 
   To summarise, several different strategies can be used for enhancing lung retention 
of inhaled drugs. From the literature review it is also clear that a more thorough 
mechanistic understanding is desirable to enable informed decisions about the choice 
of strategy.   
 
2.2.6 Preclinical inhalation studies 
2.2.6.1 Inhalation pharmacokinetic studies in drug discovery  
In drug discovery, several different methodologies can be employed for studying 
pulmonary drug delivery. These can roughly be divided into two different categories: 
exposure methods and direct dosing methods. 
   Exposure methods rely on creating a controlled atmosphere of drug exposure. 
Depending on how the test animals are exposed to the drug atmosphere, such 
systems fall into different subcategories of whole-body exposure, nose-only 
exposure, head-only exposure and specialised exposure methods. In this section, the 
first two categories will be introduced.  
   In whole-body exposure, the test animal is placed in a chamber with a controlled 
atmosphere of drug exposure. The methodology thus resembles environmental or 
work-place exposure of potentially toxic vapours. The animals can be housed either 
individually or in groups [81]. This methodology is straightforward from an 
experimental perspective. Nevertheless, results from such studies might be difficult 
to interpret since the entire animal is exposed to drug, which inevitably will lead to 
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contamination of the fur. This has the potential to confound the results in two 
different ways. Firstly, in conjunction with blood sampling, there is a risk of the 
samples being contaminated by drug from the fur. Secondly,  as a result of the animal 
cleaning process, the test subjects are likely to swallow compound from the 
contaminated fur. The latter might cause substantial oral absorption of the drug. In 
drug discovery, nose-only exposure studies are therefore generally favoured . In 
contrast to whole-body exposure, such systems are designed to minimise fur- and 
skin exposure of drug by only exposing the nose to the drug atmosphere. This can be 
obtained by keeping each animal in a separate tube, which has an adjustable back 
restraint preventing the animal from backing out. The tube is open at one end to a 
chamber containing aerosolised compound. Thus, the opening has been designed 
such that only the nose will protrude into the chamber. Nose-only exposure systems 
are well suited for rodents, such as the rat, since they are obligate nasal breathers. 
Furthermore, in comparison with whole-body exposure systems, a lower amount of 
compound is required for conducting an inhalation study [81]. Perhaps the biggest 
challenge associated with exposure methods in general is  that the lung deposited 
dose (LDD) cannot be directly measured, but instead needs to be estimated, which 
will be discussed in detail in section 2.2.6.2.  
   In contrast to exposure methods, direct dosing via intratracheal (IT) instillation 
offers the advantage of delivering a known amount of compound directly into the 
lung. Moreover, much less compound is needed for such studies, making it attractive 
for early drug discovery projects. IT-instillation is generally performed by inserting a 
catheter into the trachea of an anesthetised animal. A small volume of the test 
compound, either as solution or suspension, is subsequently injected through the 
catheter into the lungs [81]. Clearly, there are distinct differences between exposure 
35 
 
methods and instillation. Whereas exposure methods provide a natural route of entry 
to the lung, IT-instillation is an invasive delivery method. One of the most important 
disparities between these two methods is the distribution of particles. As opposed to 
exposure methods, which produce a relatively homogenous distribution of particles 
throughout the lung, IT-instillation tends to result in a denser distribution centrally 
compared to the peripheral regions as the drug is injected specifically at the site 
where the opening of the catheter resides (i.e. in the central region). These regional 
differences can have an impact on e.g. doses to certain cells and lung regions as well 
as on the degree and site of systemic absorption.  Another important aspect to bear in 
mind is that IT-instillation bypasses deposition in the upper respiratory tract, i.e. 
above the site of drug delivery. Moreover, prior to delivering a drug via the IT route, 
it is important to carefully consider the choice of the instillation volume as well as 
the vehicle used to solubilise or suspend the compound. A too large instillate volume 
can potentially cause a too rapid mechanical clearance from the lung due to 
coughing, which clearly would have an impact on the pulmonary PK. It is also 
important to ensure that the vehicle does not have an influence on either the PD or 
the PK [82].  
   Regardless of the experimental methodology used to study pulmonary drug 
delivery in a preclinical setting destructive sampling is a necessity in order to obtain 
measurements of lung concentrations. That is, the animal is euthanized in 
conjunction with sampling and only one sample is obtained from each test subject. 
Expressed differently, n animals are needed to create a concentration-time profile of 
n observations. Interindividual variability in PK-parameters is thus expected to be 
seen in such profiles. Equally important, variability in the delivered dose is expected 
from inhalation PK studies that utilise exposure methods. Cooper et al. suggest that a 
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majority of the variability seen in such PK-studies can be attributed to interindividual 
variability in the inhaled dose rather than in the PK parameters [7]. 
 
2.2.6.2 Dose estimation 
As opposed to e.g. oral and intravenous drug delivery where the given dose is easily 
controlled, dose estimation after inhalation is very complex. The same degree of 
control can essentially be achieved in a preclinical setting if the drug is directly 
instilled in the lung via the trachea (direct dosing methods). However, as mentioned 
in the previous subsection, techniques such as IT-instillation generally generate a less 
homogenous dose distribution throughout the lung.  
   In order to achieve a more uniform distribution in a preclinical setting, drugs can 
be inhaled from a chamber that contains a cloud of material (exposure methods). The 
total inhaled dose (ID) is defined as the total amount of drug that is inhaled by the 
animal, whereas the lung deposited dose (LDD) is defined as the actual amount of 
drug that is deposited in the lung. ID and LDD are calculated accordingly: 
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where C is the concentration of substance in the air (mg/L), RMV is the respiratory 
minute volume (L/min), D is the duration of exposure (min), BW is the body weight 
(kg) and DF is the deposition fraction of the particles [83]. As can be seen from eqs. 
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2.15-2.16, several assumptions must be made in order to estimate LDD such as a 
consistent breathing pattern throughout the dosing period.  
   From eqs. 2.15-2.16 it is also clear that C is a key value for calculation of LDD. To 
enable calculation of C, a filter is included in the inhalation system setup. 
Air/compound is extracted to the filter at a predefined flow rate throughout the 
duration of exposure, D. The amount of drug collected on the filter (mfilter) is 
subsequently quantified using, for instance, liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) and C is then calculated as  
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where fr is the filter flow rate [7]. 
   It is well-known that different aerodynamic diameters have different deposition 
probabilities in different lung regions, i.e. DF will be dependent on the particle size 
distribution. Prior to preclinical inhalation studies, this distribution is generally 
characterised using a cascade impactor, which provides a discrete aerodynamic 
particle size distribution. By using this discrete distribution and the DF 
corresponding to each particle size range, the total DF can be calculated for the batch 
used in a particular study. In the absence of such data, a default value of DF of 10% 
is generally used for deposition in rodent lungs [7]. 10% is also the conservative DF 
used for inhalation rodent studies by the Food and Drug Administration (FDA) [84]. 
An alternative approach to determining LDD is to quantify the amount of drug in the 
lung at the end of the exposure period. Under certain circumstances this method may 
represent LDD. However, the following criteria need to be met: 1) the inhalation 
period is short, 2) the pulmonary absorption that takes place from the start of the 
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exposure until the sampling of the lung is negligible, and 3) potential pulmonary 
metabolism of the parent compound is negligible. If any of these criteria are not met, 
then there is a substantial risk of underestimating LDD . Given that several 
compounds are rapidly absorbed to the systemic circulation [21], this method is 
inappropriate for numerous inhaled drugs. An alternative approach is to determine 
the area under the curve (AUC) in blood/plasma following inhalation. By comparing 
the AUC generated after inhalation of an unknown LDD with an AUC from a known 
dose, e.g. obtained from IV-dosing, it is possible to calculate LDD. Nevertheless, this 
approach also has its limitations. Firstly, if a poorly soluble drug is delivered, then 
the drug is likely to be transported away from the lung by MCC, which would lead to 
a reduction in the AUC relative to IV-delivery of the same dose. Secondly, drug 
absorption from the GI-tract would increase the AUC after inhaled drug delivery 
leading to overestimation of LDD. Thirdly, it is essential to assume a negligible first-
pass pulmonary extraction . Consequently, much prior information of the PK of the 
drug candidate is needed to confidently rely on this approach. 
   To summarise, dose estimation is not straightforward after inhalation and the 
method used for estimating LDD should be chosen with care based on prior 
knowledge of the drug. 
 
2.2.6.3 Exposure measurements 
This subsection aims to provide an overview of the different exposure measurements 
that are often collected in preclinical inhalation PK-studies. This text also aims to 
underline potential limitations/challenges associated with the different 
measurements.  
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   The PK-properties of inhaled compounds are routinely investigated by 
measurements of total lung concentrations (Clung) and plasma concentrations (Cp). It 
is worth mentioning that measurements of Cp generally put high demands on the 
analytical sensitivity due to low Cp-values . This can primarily be attributed to two 
features: 1) inhalation doses are typically low, and 2) inhaled drug candidates tend to 
have a high clearance. For this reason, it can be very challenging to properly 
characterise the systemic PK after inhalation. 
   After inhalation, appearance of drug in plasma is a downstream event that follows 
after pulmonary absorption [2]. The Cp-profile is thus expected to inherently contain 
information on the pulmonary absorption, the events preceding the absorption as well 
as on the systemic PK.  
   It is generally accepted that the unbound drug concentration at the target site drives 
the pharmacological effect, a theory that often is referred to as ‘the free drug 
hypothesis’ [85]. For systemically acting drugs, the unbound plasma concentrations 
are usually assumed to reflect the free target site concentration. However, since the 
appearance of drug in the systemic circulation is the result of pulmonary absorption, 
unbound concentrations in plasma cannot be assumed to reflect the free target site 
concentration in the lung [2]. This constitutes a challenge since unbound plasma 
concentrations usually form the basis for establishing PK/PD-relationships.  
   As previously mentioned, it is possible to measure Clung in a preclinical setting. To 
obtain such measurements, lungs are collected by destructive sampling at several 
time points after IT-instillation or exposure inhalation. In most studies, the entire 
lung is dissected and homogenised. Drug concentrations are subsequently measured 
in lung tissue homogenates, providing a time profile of Clung where the organ is 
erroneously reflected as one anatomical entity. Moreover, the homogenisation 
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process also severely distorts the data interpretation by disrupting the normal 
compartmentalisation (e.g. lysosomal trapping) and by dissolving solid drug particles 
[6]. Indeed, the establishment of PK/PD-relationships based on total lung 
concentrations is known to be more challenging for poorly soluble compounds . 
Great caution should thus be exercised when interpreting such data, especially for the 
latter compound class.   
   As opposed to measurements of the fraction unbound in plasma (fu), it is 
challenging from a technical point of view to measure the fraction unbound in lung 
tissue (fu,lung) . Perhaps even more important, the information obtained from 
measuring the fraction unbound in a heterogeneous organ, such as the lung, should 
not be used in the same manner as fu since it is unlikely that one value would be 
reflective of the entire organ. Expressed differently, fu,lung cannot be used to convert a 
measured total organ concentration (i.e. Clung) into one unbound lung target site 
concentration. Nevertheless, two different in vitro methodologies have previously 
been employed for measuring the unbound fraction in lung homogenate (fu,h): 
equilibrium dialysis and ultra-filtration. It is well-known that measurements obtained 
from these two methods potentially are confounded due to the necessity to 
homogenise the lung tissue, which disrupts the normal compartmentalisation of the 
cells and thereby can release drug that was entrapped in lysosomes and/or other 
endosomal compartments [77,84]. This experimental caveat needs to be taken into 
account when interpreting data and it is particularly prominent for basic compounds. 
Since lysosomes are acidic organelles, basic compounds are expected to be trapped 
in these cellular compartments due to a higher proportion of the molecules being 
charged in the acidic environment of the lysosome (pH 4-5) as compared to the 
cytosol (pH 7.4). Furthermore, the lung is a lysosome-rich tissue [86] and lysosomal 
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trapping might therefore be even more pronounced in this tissue. To overcome this 
potential experimental caveat, a lung slice methodology was developed, by virtue of 
using freshly prepared rat lung slices, the compartmentalisation of the lung tissue is 
kept intact. This can therefore be considered as a better in vitro system for studying 
the extent of lung tissue distribution. The lung slice methodology provides 
measurements of the unbound lung volume of distribution (Vu,lung). If Vu,lung and 1/fu,h 
differ from unity, the deviation is likely to be caused by the investigated substance 
being trapped in lysosomes and/or displaying carrier-mediated transport. Indeed, a 
systematic deviation from unity has been demonstrated for several basic compounds 
[77].  
   A procedure called bronchoalveolar lavage (BAL) is occasionally also used for 
preclinical PK-investigations to estimate the drug concentration in the epithelial 
lining fluid (ELF). This technique does not allow for direct measurements of ELF 
alone, but it is retrieved indirectly by repeated instillation of sterile saline. That is, 
technically the saline is diluted by an unknown volume of ELF. Thus a meaningful 
quantification of the drug concentration in this fluid would require determination of 
the volume of ELF obtained by BAL [84]. As urea diffuses freely throughout the 
body, the concentration of urea is expected to be the same in plasma and ELF. By 
using this knowledge, simultaneous measurements of urea in both fluids enables 
calculation of the dilution factor. However, diffusion of urea into the BAL fluid 
during the instillation has shown to confound this calculation in a time-dependent 
matter. It has therefore been suggested that the volume of ELF obtained from using 
this correction method should be referred to as an apparent volume of ELF [87]. 
Consequently, such measurements should also be interpreted with care. 
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   Hence, there are several limitations with the different exposure measurements 
currently used to characterise the PK and PK/PD of inhaled drugs. Clearly, under 
many circumstances the utility of using the described exposure measurements for 
establishing PK/PD-relationships for locally acting inhaled drugs can be questioned. 
This problem is also reflected by the sparse scientific literature within the area of 
inhaled drugs, where the focus instead is typically on systemic effects driven by 
systemic exposure [88,89,90]. A few studies quantitatively link the pulmonary PK to 
the local effect by relating ELF concentrations to minimum inhibitory concentrations 
of antibiotics. This is, however, not following topical, but systemic, administration 
[91,92]. Interestingly, a PK/PD-analysis by Hochhaus et al. suggested that cardiac 
side-effects, but not the local pulmonary effects, could be described by the plasma 
PK after inhalation. The analysis instead implied that the free concentrations of drug 
were higher at the target site in the lung as compared to the plasma thus indicating a 
lung-selective drug exposure [93].  
   To conclude, the lack of exposure measurements that are relevant from a PK/PD 
perspective significantly hampers basic PK/PD understanding for locally acting 
inhaled drugs. Besides, due to the heterogeneous nature of the lung, the unbound 
concentration cannot be expected to be homogenous throughout the entire organ. 
Further research within this field is thus an important avenue for drug discovery as 
well as drug development. 
 
2.3 Modelling 
2.3.1 Empirical compartmental modelling (PK)  
In the field of pharmacokinetics, empirical compartmental models are often used to 
describe the concentration time-profiles that follow after drug administration. In 
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short, a compartmental model consists of a finite number of subunits that are called 
compartments. Each of these compartments is assumed to consist of homogenous 
and well-mixed material. These compartments can interact with each other via the 
flow of material from one compartment to another. Furthermore, they can also 
interact with the external environment. Linear, time-invariant compartmental models 
are often used in the field of pharmacokinetics. The term ‘time-invariant’ means that 
the parameters of the system do not change over time [94]. The general form of such 
a system with n compartments is given by: 
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where xi is the amount of drug in compartment i (i ∈ {1, ..., n}), kji is the rate 
constant from compartment j to compartment i, kij is the rate constant from 
compartment i to compartment j, ki0 is the elimination rate constant from 
compartment i to the external environment (i.e. the outflow from the system) and 
ui(t) is the input to compartment i [95]. In general, elimination is assumed to take 
place directly and exclusively from the central compartment [96]. That is, if the 
central compartment is referred to as compartment 1, ki0 = 0 for i > 1. Furthermore, 
the input is often limited to the central compartment, i.e. ui(t) = 0 for i > 1. Eq. 2.18 
is represented conceptually by the diagram in fig. 2.4. 
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Figure 2.4 Two compartments of a compartmental system as described by eq. 2.18. 
 
   PK-studies will generally provide measurements of drug concentration and not the 
amount of drug. The introduction of an additional parameter is therefore required: the 
volume of distribution V. Given that the measurements are assumed to reflect drug 
concentrations in the central compartment, the model output y that will be compared 
with the observations is as follows: 
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y  .     (2.19) 
 
   In pharmacokinetics, an empirical compartmental model rarely has more than 3 
compartments (n ≤ 3). The following terminology will henceforth be used for 
pharmacokinetic compartmental models: 1-compartment model (n = 1), 2-
compartment model (n = 2) and so on. The physiological interpretation of e.g. a 2-
compartment model is that drug distributes between a central compartment (i = 1) 
and a peripheral compartment (i = 2), where the latter consists of tissues into which 
drug distributes more slowly. It is worth mentioning that the choice of n is normally 
45 
 
dependent on the available data. That is, the number of compartments is chosen to fit 
the concentration-time data of a particular drug [96]. 
   Due to the simplicity of the 2-compartment model, it is suitable for illustrating two 
different parameterisation options: 1) micro-constants (k10, k12, k21 and V1), and 2) 
physiological parameters (CL, V1, CLd and V2). Both options are graphically 
illustrated by fig. 2.5:  
 
 
Figure 2.5 A 2-compartment model parameterised using a) micro-constants (k10, k12, k21 and V1), and 
b) physiological parameters (CL, V1, CLd and V2). 
 
   It can be argued that the advantage of the latter parameterisation option (fig. 2.5b) 
is that the parameters have a physiological meaning. Clearly, CL corresponds to 
clearance, which was described in section 2.2.3. V1 and V2 represent the volumes of 
the central and peripheral compartments, respectively, CLd corresponds to the 
intercompartmental distribution between plasma and tissue, which might comprise 
e.g. perfusion, diffusion, active transport and partitioning [97]. In this thesis, the 
physiological parameterisation has been used.  
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2.3.2 Physiologically based PK models 
Within drug discovery, there is generally much information gathered about 
individual drug candidates. In order to guide PK decisions physicochemical, in vitro 
and/or structural properties are characterised. In addition, at later stages, emphasis is 
put on studying in vivo PK of the compounds. Empirical compartmental models are 
often used for analysing in vivo studies as described in the previous section. These 
models are indeed very useful for many purposes, including characterisation of in 
vivo PK and guidance of future study design. However, by virtue of being empirical, 
these models cannot accommodate prior information on either the compound or the 
physiology. This feature restricts their ability to predict the PK for compounds with 
slightly different properties or to use such models for extrapolation to different 
physiological conditions [55]. Hence, although much information is available only a 
small fraction is used in the model development.  
   As opposed to the empirical compartmental models, physiologically-based 
pharmacokinetic (PBPK) models aim to integrate the current knowledge of 
physiological processes with physicochemical properties and/or other available 
information about the drug candidate in order to simulate complex biological 
processes. The level of detail is dependent on several factors, including nature and 
knowledge of the process(es) studied and the level of complexity needed reach a 
predictive capability. Hence, these models aim to provide a mechanistic 
understanding of the system by mathematically describing the relevant processes and 
integrating prior information on the drug. This approach carries advantages and there 
are several examples of when they have been used to provide new insights into 
important biological processes [98]. As observed PK-profiles are the result of several 
underlying processes, they can be said to carry subtle information on different 
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mechanisms driving the PK. Any discrepancies between the predicted and observed 
outcomes may therefore be informative as they can provide insights into mechanisms 
that have not been accounted for by the model. As such, PBPK models can be used 
for hypothesis generation, to design experiments aimed at supporting/rejecting the 
hypothesis and to answer key questions in drug discovery and development projects 
[99].   
   Traditionally, PBPK models have been said to consist of a structural model and 
two distinctive groups of input parameters: 1) system-specific input parameters, such 
as blood flows and organ volumes that are specific for the investigated species, and 
2) drug-specific input parameters, such as permeability, clearance and binding 
kinetics parameters that are unique for each investigated drug. The structural model 
comprises a compartmental representation of organs and tissues connected by the 
blood flow [100], where each compartment is represented by a discrete tissue volume 
perfused uniformly by its specific blood flow [101]. A schematic representation of a 
typical whole body PBPK model is shown in figure 2.6.  
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Figure 2.6 A schematic representation of a typical whole-body physiologically based pharmacokinetic 
(PBPK) model adapted from [102]. 
For compartment i, the rate of change of quantity within the organ is described as 
[103] 
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where Vi is the tissue volume, Ci is the drug tissue concentration, Qi is the blood flow 
to the tissue, CA is the arterial drug concentration, R is the blood/plasma ratio and Kp,i 
is the tissue-plasma partition coefficient.  
   The drug distribution into a tissue can be described as either perfusion rate-limited 
(eq. 2.20) or permeability rate-limited. The former tends to apply for small lipophilic 
compounds for which the tissue barrier does not present a barrier for diffusion. 
Hence, the blood flow to the tissue becomes the rate-limiting step for the distribution 
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process. In contrast, permeability rate-limited distribution might be feasible for 
describing the distribution of large polar molecules where permeability across the 
cell membrane constitutes the rate-limiting step [104].   
   A group of important drug-specific input parameters for the distribution is the 
Kp-values, defining the ratio of drug concentration between tissue and plasma at 
equilibrium. Previously, Kp-values were obtained by time-consuming animal studies 
where in vivo steady-state tissue and plasma drug concentration data were collected. 
Today there are several in silico methodologies for prediction of the tissue to 
unbound plasma partition coefficients (Kp,u-values) in the literature that are derived 
from a mechanistic understanding of the tissue composition as well as the 
physicochemical properties of the compound. The methodology suggested by [105] 
has been found to have good predictive capabilities [106]. In short, this method 
utilises a mechanistic equation that incorporates drug dissolution in tissue water and 
partitioning into neutral lipids and neutral phospholipids. For acids, neutrals and very 
weak bases it also takes binding to extracellular proteins into account. Compound-
specific input parameters for this equation are unbound fraction in plasma (fu), the 
partition coefficient of unionised drug (P) and, if applicable, pKa [105]. Thus, Kp,u is 
predicted by 
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where fEW, fIW, fNL and fNP are fractional tissue volumes for extracellular water, 
intracellular water, neutral lipids and neutral phospholipids, respectively. The ratio 
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[PR]T/[PR]P refers to the tissue to plasma ratio of albumin or lipoprotein (albumin is 
used for acids and very weak bases, whereas lipoprotein is used for neutral 
compounds). The definitions of X and Y depend on the compound class as described 
in [105], e.g. for neutral compounds both equal 1 due to the lack of ionisation. 
   A compartment can represent a part of an organ, an organ or several organs lumped 
together. They are generally described as homogenous, well-stirred compartments. 
For tissues described by permeability rate-limited distribution, the tissue is often 
subdivided into two well-stirred spaces [107]. As the complexity of the model 
increases with the number of compartments, only compartments critical for 
characterising the system should be included [98]. Consequently, there are several 
examples in the literature of reduced models where tissues with similar perfusion 
rates have been lumped together in order to reduce this number and the overall 
complexity of the model [108,109]. 
   For the inhaled route of administration, a third group of input parameters should be 
added: formulation-specific input parameters, such as the particle size distribution. 
This parameter is of importance for describing the input signal to the system (the 
deposited dose), which is more complex than other routes of administration. 
 
2.3.3 Structural identifiability and parameter estimation 
This section aims to provide a short overview of parameter estimation and structural 
identifiability. Briefly, parameter estimation aims to, given a model structure and 
some sampled experimental data, find a set of model parameters θ which is thought 
to have generated the data. This is usually done by minimising (or maximising) a 
cost function (sometimes referred to as an objective function), which quantifies how 
well the model and the set of parameters θ fit the sampled data.  
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   In this section, we will only consider cases where the optimisation process relies on 
finding the minimum of a cost function. Clearly, the cost function best suited for the 
optimisation will depend on the nature of the problem investigated. A commonly 
used cost function is the sum of squared errors, a so called least squares approach. 
This approach is performed as follows: consider the observation function 
 
),( ty ,     (2.22) 
 
which depends on time t and a set of parameters θ. An experiment is conducted, 
providing a sampled data vector (experimental data) yˆ at n time points, which we 
hope to describe using the model y(t,θ). According to the least squares approach, the 
best parameter estimates are defined as those which minimise the sum of the squared 
differences between the model output y(t,θ) and the observations yˆ , i.e. 
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This is commonly known as ordinary least squares. The differences between the 
model output y(t,θ) and the observations yˆ are referred to as the residuals. Ordinary 
least squares assumes that all observations are equally reliable and thus should be 
treated equally.  However, if the standard deviation σi of the experimental error is not 
expected to be constant but instead e.g. is proportional to the magnitude of each 
observation iyˆ  and the data span over several orders of magnitudes, this assumption 
might not be valid. Weighted least squares can then be applied by multiplying each 
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residual by a weight proportional to the inverse of the standard deviation wi = 1/σi to 
form: 
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In the case of the standard deviation σi being proportional to the magnitude of the 
sampled data, it is natural to use the inverse sampled data as weights. This could be 
done by using either the sampled data yˆ , or if the model is deemed more reliable, the 
model output y(t,θ) in which case: 
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Given that the function y(t,θ) is nonlinear, nonlinear regression is used to find the set 
of parameters θ that minimises the cost function. In contrast to linear regression, 
where the unique solution can be found by solving a set of linear equations, nonlinear 
regression requires more advanced search methods. An optimisation algorithm, e.g. a 
gradient descent algorithm, is used to find the minimum of the cost function. In this 
context another important difference between linear and nonlinear models should be 
highlighted. A gradient descent method will follow the gradient of the cost function 
to a point where small changes to the set of parameters θ no longer improve the cost. 
Such a point is known as a local minimum. The cost function of a general nonlinear 
model might have several local minima, and the gradient descent method will follow 
the gradient from an initial set of parameter estimates and find one of these. Hence, it 
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will be unknown if it is the “best”, global minimum. The linear model on the other 
hand will only have one minimum, which is then the global minimum.    
   Importantly, for parameter estimates to be meaningful, the aim of parameter 
estimation needs to be extended: the aim is to find a set of uniquely identifiable 
parameters θ that minimises (or maximises) an appropriately chosen cost function. 
From this revised aim, it is clear that structural identifiability is a prerequisite for 
parameter estimation. Briefly, a model is said to be structurally identifiable if it is 
possible to uniquely determine all model parameters under ideal circumstances with 
an error-free, continuous set of observations [110,111]. In case of a non-identifiable 
model, several combinations of parameters will produce identical input-output 
behaviours. Hence, whilst a non-identifiable model might well describe the data, the 
parameter values estimated from such model should be interpreted very cautiously.   
 
2.3.4 Sensitivity analysis 
A sensitivity analysis can be used to quantify how “sensitive” the output of a system 
is to changes in e.g. parameter values, initial conditions or inputs [112]. Such 
analyses can be useful for several reasons. One important application is to understand 
which parameters are the most influential on the outcome/response of the system. 
Such information can be useful per se to gain a better understanding of the input-
output behaviour of the system. Moreover, if it is possible to minimise the 
uncertainty of one/some of the input parameters, information from a sensitivity 
analysis can be useful for prioritising which input parameter(s) to choose in order to 
reduce the uncertainty of the output the most [113]. It can also be useful for optimal 
experimental design by e.g. identifying sampling times that would generate 
informative data, which is crucial for parameter estimation accuracy.  
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   When implementing larger simulation models, a sensitivity analysis can also be an 
important part of the model verification process; by detecting unexpected input-
output behaviours, potential bugs in the model code can be detected. Another 
possible application is model simplification, which can be done by identifying, and 
subsequently possibly removing, redundant parameters that do not have any effect on 
the output.  
   In this section, the focus will be on so-called local sensitivity analysis techniques of 
systems that can be written on the following general form as in [112]: 
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where y is an n-dimensional vector of state variables, θ is a p-dimensional vector of 
parameters and the independent variable is time, t. 
   The sensitivity of a state variable, yi, to a parameter, θj, can be expressed by the 
following sensitivity function [112]: 
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If the analytical solution of eq. 2.26 is known, its partial derivatives (eq. 2.27) may 
also be solved analytically. However, this is rarely the case and numerical methods 
are therefore generally used to approximate the sensitivity function (eq. 2.27). By a 
local sensitivity analysis, it is implied that eq. 2.27 is evaluated around one fixed 
value of the parameter θj. These methods utilise the so-called one-at-a-time (OAT) 
techniques, meaning that the parameters are varied one at a time while the other 
parameters are kept at their baseline (nominal) values. One commonly used 
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technique is the so-called finite difference method, which approximates the partial 
derivative defined in eq. 2.27. Eq. 2.27 can also be defined accordingly (forward 
difference considered) [112]: 
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As can be seen from the definition above, eq. 2.28 is only valid if an infinitesimal 
small perturbation of the parameter θj is considered; i.e. Δθj → 0. This has important 
implications for the finite difference method, which is implemented as follows [112]: 
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Hence, to ensure that eq. 2.29 is equivalent to the former equation (eq. 2.28), it is 
required that Δθj is small. The factor by which the nominal parameter value is 
multiplied is generally referred to as the perturbation factor ξ. Theoretically, eq. 2.28 
will only be equivalent to eq. 2.29 if ξ approaches 0. Nevertheless, numerically this 
can never be achieved as the limited precision of the calculations would then give 
rise to numerical inaccuracies. ξ should thus be chosen to be as small as possible 
while still maintaining numerical accuracy [112]. 
   For interpretation purposes, it is generally more convenient to investigate the 
normalised sensitivity. One approach that for instance is used in Berkeley 
Madonna™ is [114]:  
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2.4 Summary 
Chapter 2 provides a summary of the relevant and necessary theoretical background 
that was used in this thesis for designing, performing and interpreting experiments as 
well as to develop and apply mathematical models. The latter category includes 
modelling of the in vivo binding kinetics of two corticosteroids and the development 
of a mechanistic in silico model for predicting the systemic PK, the local tissue 
concentrations as well as the resulting receptor occupancy after inhalation. 
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Chapter 3 Development of an in vivo receptor occupancy 
methodology 
 
 
3.1 Introduction 
One of the main findings of the literature review was that researchers investigating 
pharmacokinetics via the inhaled route face the tough challenge of not being able to 
directly measure unbound drug concentrations locally in the lung tissue. 
Furthermore, the appearance of drug in the blood is a downstream event that follows 
from absorption of inhaled drug from the lung [2]. As a result, the unbound drug 
concentration in the blood cannot be assumed to reflect the unbound drug 
concentration at the target site in the lung . Clearly, this constitutes a challenge for 
the understanding of PK/PD-relationships for locally acting inhaled drugs. As 
receptor occupancy is driven by the unbound drug concentration at the target site, 
such measurements would clarify the PK- and PK/PD-evaluation of locally acting 
inhaled drugs and provide a quantitative estimate of target engagement in the target 
organ. Receptor occupancy methodologies amenable to targets of inhaled drugs, such 
as the glucocorticoid receptor (GR), are therefore desired.  
   Inhaled corticosteroids have been stated to constitute the cornerstone of asthma 
treatment [115]. The pharmacological effect of this compound class is mediated by 
binding to the cytoplasmic GR, which forms a dimer and translocates to the nucleus, 
where it either binds to sites on the DNA called glucocorticoid responsive elements 
(transactivation) or interacts with transcription factors (transrepression) [116]. 
Hence, it was proposed at an early stage that receptor-binding properties could be 
important in order to link the PK to the PD for this compound class [117]. Indeed, 
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more recently PK/PD-relationships for receptor/gene-mediated effects of 
intravenously administered corticosteroids were described in the liver [118]. 
   Estimates of drug occupancy are typically obtained by assessing the number of free 
binding sites using a tracer ligand that, when administered at a sufficiently low dose, 
binds with high affinity and specificity to the target of interest. A tracer for the GR 
amenable to in vivo occupancy studies has not been previously reported, although 
numerous attempts have been made to develop positron emission tomography (PET) 
radiotracers for this receptor [119]. Receptor occupancy of the GR has been 
measured in the rat using ex vivo binding assays where the tracer is incubated with 
the tissue sample after collection from the animal [120,121]. Receptor occupancy 
profiles generated from this methodology were shown to be similar after intravenous 
(IV) and intratracheal instillation of an aqueous solution of triamcinolone acetonide 
[120].  
   While in vitro and ex vivo binding assays rely on radiolabelled tracer ligands, tracer 
analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS) offers 
advantages including simultaneous determination of occupancy and drug 
concentration. Furthermore, tracer quantification with LC-MS/MS is made without 
interference of metabolites [122], a feature that is of particular interest for in vivo 
receptor occupancy studies where the tracer is administered to the animal. 
   Based on the properties of several inhaled drugs, it can be reasoned that a fully in 
vivo based receptor occupancy methodology would carry advantages over ex vivo 
binding assays for the study of inhalation drugs. This reasoning is primarily based on 
the anticipated risk of additional particle dissolution and thus subsequent formation 
of drug-receptor complexes post-sacrifice during the processing steps of tissues, 
which could lead to overestimation of pulmonary occupancy if the tracer is added ex 
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vivo. As several inhaled corticosteroids are poorly soluble compounds, and hence are 
retained in a solid state in the lung for a considerable time period after inhalation, the 
advantage of in vivo tracer administration is perhaps even more pronounced for this 
drug class and route of administration. Moreover, the reliability of ex vivo binding 
assays has been questioned since dissociation of drug from receptors during 
incubations could lead to underestimation of occupancy [123,124].  
   One objective of this PhD thesis was therefore to complete the ongoing 
development of an in vivo receptor occupancy methodology for an inhaled target (the 
GR). 
   Identification of tracer molecules is perhaps the most challenging step and this 
often constitutes a bottle-neck in the development of receptor occupancy 
methodologies for new targets. Successful tracers have been shown to have a high 
target-bound fraction (ftb). A mathematical model, which describes ftb as a function of 
the unbound target site concentration (Cu) has been proposed by Fridén et al. [125]:  
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where Vu,brain is a measurement of the nonspecific binding in brain tissue, Kd denotes 
the affinity of the tracer to the target and Bmax denotes the target density in the brain. 
Although this model was initially developed for brain targets, it is applicable for all 
tissues. Tracer molecules are typically given at low doses with resultingly low Cu. If 
Cu << Kd, eq. 3.1 simplifies accordingly to give: 
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Hence, given that successful tracer molecules have been shown to have high ftb [125], 
eq. 3.2 points at three important properties for functioning tracer molecules: 1) a high 
affinity of the tracer to the target (affinity=1/Kd), 2) a low degree of nonspecific 
binding (Vu,brain), and 3) a high expression of the target (Bmax). Needless to say, the 
third property should already be considered when choosing the target of interest. If 
Bmax is considered to be sufficiently high, the choice of potential tracer candidates to 
take forward to experimental evaluation should be based on the two first properties. 
According to eq. 3.2, molecules with a low product of Kd and Vu,brain (or the 
corresponding measurement for the tissue of interest) should thus be favoured. An 
additional important property, which is not covered by eq. 3.2, is a high bioanalytical 
sensitivity to enable quantification of low tracer concentrations. 
   This chapter will describe the development of a novel in vivo receptor occupancy 
methodology for the GR, which was accepted for publication in the Journal of 
Pharmacology and Experimental Therapeutics [126]. 
 
3.2 Tracer identification and development of an in vivo protocol 
The following subsection describes the sequence of steps taken for developing an in 
vivo receptor occupancy methodology for an inhaled target with respect to the tracer 
identification in vitro as well as the in vivo protocol development. 
   The experiments described in sections ‘3.2.1.2 Tracer identification in vitro’ and 
‘3.2.1.4 Evaluation of tracer dose’ were performed during my master’s thesis. The 
experiment described in section ‘3.2.1.5 Evaluation of nonspecific binding’ was done 
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whilst employed at AstraZeneca R&D Gothenburg. In contrast to the data collection 
described in the aforementioned three sections, which was done prior to the PhD 
studies, modelling of the data generated from experiments described in sections 
‘3.2.1.4 Evaluation of tracer dose’ and ‘3.2.1.5 Evaluation of nonspecific binding’ 
was performed as part of this PhD project. 
   The author was responsible for the design and the execution of all studies. All 
studies but one were carried out by the author alone: during the in vivo part of the 
PK-study assistance was received from Dr Markus Fridén at AstraZeneca R&D 
Gothenburg. 
 
3.2.1 Methods 
3.2.1.1 Chemicals and animals 
Chemicals. Bovine serum albumin fraction v was purchased from Roche (Penzberg, 
Germany), KCl, MgSO4, HEPES, NaHCO3, NaOH, glucose, N,N-
dimethylacetamide, dexamethasone, 5,5-diethyl-1,3-diphenyl-2-iminobarbituric acid 
and polyethylene glycol 400 were obtained from Sigma-Aldrich (St. Louis, MO, 
USA). NaCl, CaCl2, KH2PO4 and ascorbic acid were purchased from Merck 
(Darmstadt, Germany). Fluticasone propionate, R-budesonide, compound 1 (fig. 
3.1a), and compound 2 (fig. 3.1b) were synthesised by chemists at AstraZeneca R&D 
Gothenburg. Compound 1 and 2 were discovered as part of a collaboration between 
AstraZeneca and Bayer HealthCare in the field of selective glucocorticoid receptor 
modulators. Chemicals were of analytical grade and all solvents of HPLC grade. 
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Figure 3.1 Chemical structures for a) compound 1 (EC50 = 0.153 nM, logD7.4 = 2.5), and b) 
compound 2 (EC50 = 0.476 nM, logD7.4 = 2.9) 
 
Animals. Male Wistar Han rats (Harlan, Horst, the Netherlands) weighing 275 to 
325 g were used for the in vitro and the in vivo studies. The animals were group-
housed at 18-22 ºC under a 12:12 h light/dark cycle with free access to food and 
water for at least five days prior to the experiments. The studies were approved by 
the Animals Ethics Committee of Gothenburg (234-2011, 190-2010 and 71-2013). 
Studies were carried out in accordance with the Guide for the Care and Use of 
Laboratory Animals as adopted and promulgated by the US National Institutes of 
Health. 
 
3.2.1.2 Tracer identification in vitro  
AstraZeneca’s internal chemical library has numerous of molecules that bind to GR 
and thus could be tested as potential tracer candidates. Experimental evaluation of all 
compounds would thus not be feasible. A rational approach was applied in order to 
narrow down the search space of molecules to enable identification of molecules 
with a higher probability of success. As described in section 3.1, compounds with a 
1
2
a) 
b) 
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low product of Kd and Vu,brain (or the corresponding measurement describing the 
nonspecific binding in the tissue of interest) are more likely to be successful tracer 
molecules. Needless to say, the added value of making this search is highly 
dependent on the choice of criteria. The database contains results from numerous 
tests, it is thus important to identify a test that gives information about the properties 
(i.e. Kd and nonspecific binding). Furthermore, to minimise exclusion of promising 
compounds, a commonly used test must be chosen such that several compounds have 
been evaluated with this particular test. 
     A high lipophilicity is known to be associated with a high degree of nonspecific 
binding; lipophilicity, as expressed by logD7.4, was therefore chosen to represent the 
nonspecific binding. The in vitro potency (EC50) from a reporter gene assay system 
determining the transrepression activity [127] was used as a surrogate for the 
dissociation constant (Kd). Compounds were ranked by their differences between –
 log(EC50) and logD7.4 as a large difference indicates a compound with a high 
potency and a low degree of nonspecific binding in tissue; i.e. a combination 
predicted to give a high value for ftb according to eq. 3.2, which has been shown to be 
an important property for successful tracer molecules [125].    
   Based on this criterion a first selection of compounds was made and these were 
evaluated for the degree of nonspecific binding in slices of agarose-inflated rat lungs 
using a methodology described in [77]. Two compounds with low measured values 
of EC50 and low degree of nonspecific binding were subsequently identified from 
this selection. To experimentally determine ftb for these compounds in vitro, lung 
slices were incubated at subnanomolar concentrations of the potential tracer either in 
the absence (n = 3 to 6) or presence of excess of R-budesonide (100 nM, n = 3 to 6).  
Lung slice concentrations of the tracer candidate from incubations with excess R-
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budesonide corresponded to the nonspecific binding (Cslice,nonspec) and the 
concentrations from incubations containing only the tracer candidate gave the total 
binding (Cslice,total). ftb was calculated using equation 3.3, given by  
 
totalslice
nonspecslicetotalslice
tb
C
CC
f
,
,, 
  ,  (3.3) 
 
and these values, as well as the analytical sensitivity, were subsequently used for 
ranking of the compounds. A more detailed description of the evaluation of tracer 
candidates in vitro is provided in the master’s thesis written by the author [128]. 
 
3.2.1.3 Studies for in vivo protocol development  
In general terms, in vivo receptor occupancy is measured by tracer administration, 
usually via the intravenous route, and subsequent quantification of tracer 
concentration in the tissue(s) of interest. Receptor occupancy is reflected by the 
difference between tissue tracer concentrations in treated animals and drug-naïve 
control animals.  
   As was mentioned in section 3.1, successful tracers have been shown to have a 
high ftb-value. From eq. 3.1, it can be seen that a low Cu of tracer is key to obtaining 
a high value for ftb. A low tracer dose is therefore used to achieve this goal as well as 
to ensure that the tracer only binds to a small portion of the available binding sites. 
Hence, this is important to certify that the measured tissue tracer concentration will 
be sensitive to changes in occupancy by the drug. 
   The maximum concentration of tracer is derived from drug-naïve control animals 
and is denoted by Ccontrol, which represents the sum of the nonspecific (Cnonspec) and 
the maximum specific binding of tracer (i.e. the receptor-bound concentration, 
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Cspec,max) and corresponds to 0% occupancy (i.e. all receptors are available to the 
tracer). Cnonspec thus has to be taken into account to enable estimation of the level of 
specific tracer binding to derive the occupancy by drug from the tracer concentration 
measured in animals pre-treated with test compound (Ctest). A second group of 
animals is therefore dedicated to determination of Cnonspec. These animals are pre-
treated with a high dose of another ligand, with the purpose of occupying all 
receptors of interest, prior to the tracer administration. Hence, the lower tissue 
concentration of tracer measured in these animals is only reflective of Cnonspec and is 
assigned to a value of 100% occupancy. To summarise, three different groups of 
animals are included in in vivo receptor occupancy methodologies: 1) drug-naïve 
control animals (Ccontrol), 2) animals dedicated to determination of the nonspecific 
binding (Cnonspec), and 3) animals treated with test compound (Ctest). The measured 
tissue concentrations of tracer in the drug-naïve control animals and the treated 
animals can be described accordingly: 
 
max,specnonspeccontrol CCC      (3.4) 
)1(max, ROCCC specnonspectest     (3.5) 
 
   An appropriate time period, a so-called post-tracer survival interval, is needed after 
tracer administration for the tracer to bind the receptor and for the nonspecific 
binding to decrease so that a high ratio of total-to-nonspecific binding is achieved 
[129].  
   Consequently, once a promising tracer candidate has been identified, several tracer 
doses, and sometimes also post-tracer survival intervals, are tested in order to 
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develop experimental procedures that yield a high ratio of total-to-nonspecific 
binding. 
 
3.2.1.4 Evaluation of tracer dose  
Three dose levels of the tracer candidate compound 1 were assessed (40, 400 and 
4000 nmol/kg, respectively). Henceforth, compound 1 will be referred to as the 
tracer. At each dose level the animals were divided into two groups in order to 
investigate if Ccontrol was distinguishable from Cnonspec. A post-tracer survival interval 
of 30 minutes was tested since it has proven successful for several in vivo receptor 
occupancy methodologies [130,131]. For determination of tissue concentrations of 
tracer, the animals were injected via the tail vein with their group specific dose of 
tracer (n = 3). Animals dedicated to determination of Cnonspec were pre-treated with a 
high IV-dose of compound 2 via the tail vein 30 minutes prior to the tracer 
administration (compound 2, 5.0 µmol/kg, n = 2, n = 3 and n = 2 for the 40, 400 and 
4000 nmol/kg dose groups, respectively). A high dose of compound 2 was used as 
pre-treatment since it is a highly potent compound (transrepression EC50 = 0.476 nM) 
with a long half-life in blood, and was thus expected to give a high occupancy over a 
long time period. This study was complemented with an additional dose level (4 
nmol/kg, n = 3) using an identical protocol except that the animals dedicated to the 
determination of Cnonspec were pre-treated with dexamethasone (20 mg/kg, n = 3). 
The vehicle used for all three compounds was N,N-dimethylacetamide, polyethylene 
glycol 400 and water (1:1:1, w/w/w). Thirty minutes after administration of the tracer 
candidate, a blood sample was taken and the lung was dissected for concentration 
determination.  
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3.2.1.5 Evaluation of nonspecific binding  
To confirm that only nonspecifically-bound tracer remained after pre-treatment with 
compound 2, Cnonspec was measured after pre-treatment with dexamethasone (20 
mg/kg, n = 3). Dexamethasone was injected via the tail vein 30 minutes prior to IV-
administration of tracer (40 nmol/kg). Thirty minutes after the tracer administration, 
a terminal blood sample was collected and the lung was dissected for concentration 
determination.   
 
3.2.1.6 PK-study 
The plasma PK of a low tracer dose (30 nmol/kg) was investigated over the first 30 
minutes after IV-administration of the tracer, i.e. over the so called post-tracer 
survival interval. This experiment thus aimed to characterise the PK over this time 
period. As in vivo receptor occupancy methodologies benefit from low tracer doses 
and the bioanalytical sensitivity allowed for using a slightly lower tracer dose than 
the one used in section 3.2.1.5, a tracer dose of 30 nmol/kg was selected.    All 
animals (n = 8) were anaesthetised by inhalation of isoflurane shortly before the 
tracer administration. A heparinised catheter was inserted in arteria femoralis, the 
tracer was subsequently injected via the tail vein (30 nmol/kg). Blood samples (100-
150 µL/sample) were then repeatedly collected directly in Microvette® 300 LH tubes 
(Sarstedt, Nürnbrecht, Germany) from the arterial catheter at the following time 
points: 2, 5, 10, 15, 20, 25 and 30 min. The animals were maintained under 
inhalation anaesthesia during the entire study and were then euthanized in 
conjunction with the last sample by cutting the abdominal aorta.  
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3.2.1.7 Evaluation of tracer function in other organs 
To investigate the functionality of the tracer in various organs, Ccontrol and Cnonspec 
were compared in several organs. Animals dedicated to measurements of Cnonspec 
were pre-treated intravenously with dexamethasone (20 mg/kg, n = 5) prior to tracer 
administration, whereas animals dedicated to measurements of Ccontrol did not receive 
any pre-treatment (n = 5). Dexamethasone was injected via the tail vein 30 minutes 
prior to IV-administration of tracer (30 nmol/kg). All animals were sacrificed 30 
minutes after tracer administration, a terminal blood sample was collected and organs 
(lung, liver, brain, kidney and spleen) were dissected for concentration 
determination. 
 
3.2.1.8 General procedures and final protocol for in vivo receptor occupancy 
measurements  
The tracer, compound 1, was given intravenously via the tail vein (30 nmol/kg). 
Animals dedicated to determination of Cnonspec had been pre-treated intravenously 
with dexamethasone (20 mg/kg) 30 minutes prior to the tracer administration. In 
contrast, animals set aside for determination of Ccontrol did not receive any pre-
treatment. Animals were anaesthetised by inhalation of isoflurane during the 
administration(s) and were then allowed to wake up. Anaesthesia during tail vein 
administrations was made a standard procedure since the tail is sensitive. In 
conjunction with the termination, the rats were anesthetised once more by inhalation 
of isoflurane. The fur was rinsed with 70% ethanol and laparotomy was conducted. 
Heparin (2000 IU) was injected into vena cava, a terminal blood sample was 
collected (3-4 mL) in a heparinised tube from the abdominal aorta and the rat was 
subsequently euthanized by cutting the abdominal aorta. The terminal blood sample 
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was taken 30 minutes after the tracer administration. The diaphragm was then 
removed and the apex was incised along its transverse axis. The pulmonary 
circulation was perfused by room-tempered bovine serum albumin solution (40 mL, 
2.5% bovine serum albumin) via the pulmonary artery in order to clear the tissue of 
blood. The heart and lung were removed from the thorax en bloc. The trachea was 
dissected from the lung and a predefined section of the spleen (~200 mg) was 
dissected. The lung and spleen samples were weighed and stored separately in tissue 
tubes and Eppendorf tubes respectively at - 20 ºC until sample handling and analysis, 
a detailed description of these procedures is provided in section 3.2.1.10. Receptor 
occupancy was then calculated for each animal (eq. 3.6, section 3.2.1.9). 
 
3.2.1.9 Calculation of receptor occupancy  
Receptor occupancy calculations are made for each animal using a previously 
established method [130,131,132,133] described below: 
 

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
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nonspec
test
t
C
C
Ratio      (3.7) 
and 
nonspec
control
c
C
C
Ratio  .    (3.8) 
 
Ratiot refers to the ratio of total tracer concentration in tissue from animals treated 
with test compound (Ctest) divided by the mean value of Cnonspec obtained from the 
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group of animals pre-treated with a high dose of another ligand. Ratioc represents the 
ratio of Ccontrol to Cnonspec, where Ccontrol is the mean value of the total tissue 
concentration of tracer obtained from a drug-naïve control group. Accordingly, when 
Ratiot is equal to Ratioc this corresponds to an occupancy of 0% and when the Ratiot 
is 1 (i.e. the tracer concentration in the treated animal is equal to Cnonspec) to an 
occupancy of 100%.  
    
3.2.1.10 Analytical procedures 
Sample handling. The blood samples were collected in heparinised tubes which 
were centrifuged for 10 minutes at 4000g (Rotanta 46R, Hettich, Germany). The 
plasma samples were subsequently transferred to Eppendorf tubes and stored at -20 
ºC until analysis. 
   The tissue tubes containing lung samples were separately flash-frozen in liquid 
nitrogen and then immediately placed into Covaris CryoPrep™ (Covaris Inc., 
Woburn, Massachusetts, USA) for pulverisation. This freeze-fracture-procedure was 
repeated until pulverisation was judged as being sufficient, generally three times. The 
pulverised samples were then transferred to separate glass tubes and Ringer-buffer 
was added to each lung sample (4.0 mL). Covaris E210 and SonoLab software 
v.4.2.0 (intensity 10.0, cycles 1000, treatment time 180 s, bath degree 40 °C) were 
used for dissolution of the samples. 
   Predefined parts of the liver, brain, spleen and kidney were weighed in Eppendorf 
tubes and homogenised in 3 volumes of distilled water (w/v) with an ultrasonic 
probe. The samples were stored at -20 ºC until analysis. 
   Analytical methods. Concentrations of tracer and FP in tissues and plasma were 
quantified using reversed phase LC-MS/MS with the electrospray ionization source 
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set in positive mode. The LC-system used was LC Agilent 1200 Series gradient 
pump (Agilent Technologies, Waldbronn, Germany), a CTC autosampler (CTC 
Analytics, Zwingen, Switzerland), a HALO C18 column (30×2.1 mm, 2.7 µm, 
Advancedmaterialtechnology) and an Agilent 6460 detector (Santa Clara, CA, USA). 
Gradient elution over 1.5 minutes time with acetonitrile and 0.2% formic acid and a 
flow rate of 0.7 mL/min was performed. 
   Protein precipitation was used for all samples except lung homogenates. A defined 
volume (50 µL) of each sample was added in triplicate to a NUNC 96-deepwell plate 
(Nalge Nunc International, Rochester, NY) and was then protein precipitated by 
addition of cold acetonitrile containing 0.2% formic acid and 100 nM of 5,5-diethyl-
1,3-diphenyl-2-iminobarbituric acid as internal standard (200 µL) to each sample. 
After two minutes of mixing with a VWR VX-2500 Multi-Tube Vortexer (VWR 
International west Chester, Pennsylvania, USA) and 20 minutes of centrifugation at 
4000 rpm at 4 ºC (Centrifuge 5810 R Eppendorf, Hamburg, Germany) the 
supernatants (75 µL) were transferred to a new plate, where each sample was diluted 
by addition of 0.2% formic acid (75 µL). The diluted samples were then injected (20 
µL) to the HPLC system.  
   Liquid-liquid extraction was performed before analysis of the lung homogenates. A 
certain volume (50 µL) of each sample was added in triplicate to glass vials to which 
a carbonate buffer pH 10 (50 mM Na2CO3, 50 mM NaHCO3) containing 100 nM of 
5,5-diethyl-1,3-diphenyl-2-iminobarbituric acid as internal standard was added (50 
µL). Each sample was extracted with methyl-tertbutyl ether (MTBE, 600 µL). After 
sealing the vials with silicon cover, the vials were shaken horizontally for 5 minutes 
(150 min-1, Edmund Bühler Swip, POCD Scientific, Artarmon, Australia), followed 
by 15 minutes of mixing with a VWR VX-2500 Multi-Tube Vortexer (speed 5, 
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VWR International west Chester, Pennsylvania, USA). A defined volume of the 
upper organic layer (450 µL) was then transferred to glass vials, which were 
vaporised to dryness with a Techne Sample Concentrator (Techne Incorporated, 
Staffordshire, UK) during approximately 20 minutes. Samples were reconstituted in 
33% acetonitrile and 0.2% formic acid in water (150 µL) and placed in an ultrasonic 
bath (5210 Branson, Gemini, Apeldoorn, the Netherlands) for 10 minutes. Except 
from the sample preparation technique of the lung homogenates, the analytical 
procedure was identical to the one applied for the other samples.  
   The compounds were quantified using Mass Hunter Workstation Software for 
Quantitative Analysis (Agilent Technologies Inc., Santa Clara, CA, USA). A 
standard curve was created for each sample type: plasma, lung, spleen, liver, brain 
and kidney. The standard curve samples contained a biological matrix, not to be 
confused with the mathematical term, (blank plasma, blank lung homogenate, blank 
spleen homogenate, blank liver homogenate, blank brain homogenate and blank 
kidney homogenate, respectively) in a 1:9 volume ratio in order to match the 
samples. The highest point of the standard curve was always followed by two 
injections of blank matrix in order to clean the system and avoid possible 
contamination. The LLOQ of the tracer was 0.10 nM in all investigated matrices 
except for the brain homogenate, which had a LLOQ of 0.35 nM. The LLOQ of FP 
was 1.4, 2.1 and 8.6 nM in lung homogenate, spleen homogenate and plasma, 
respectively.   Corticosterone plasma levels were analysed using an ELISA-kit 
(ab108821, Abcam, Cambridge, UK). 
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3.2.1.11 Statistical analysis 
Statistical comparisons between two groups were made using a two-tailed, unpaired 
Student’s t-test. The level of significance was set at p ≤ 0.05. Data are presented as 
mean ± standard deviation and precision of the estimated parameters is presented as 
standard errors.  
 
3.2.1.12 Modelling of tissue concentrations of tracer  
The four different tracer doses were evaluated by a modelling approach where the 
tissue concentration of tracer was assumed to consist of two parts: 1) linear 
nonspecific binding determined by the plasma tracer concentration (Cp) and a 
partitioning constant for nonspecific binding (Kp,ns), and 2) nonlinear binding to the 
target determined by Cp, the dissociation constant (Kd) and the receptor density 
(Bmax), given by: 
 
pd
p
nsppcontrol
CK
CB
KCC


max
,    (3.9) 
and 
nsppnonspec KCC , .    (3.10) 
 
The model was implemented in MATLAB R2013a (Mathworks Inc., Natick, MA, 
USA) with fitting performed using nonlinear least squares (lsqnonlin) and iterative 
reweighting using predicted data. The default optimisation algorithm of ‘lsqnonlin’ 
was used (the trust region-reflective algorithm). In case of several local minima 
within the expected parameter space, an exhaustive search was conducted in 
MATLAB to ensure that the optimization algorithm had not converged to a local 
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minimum. The sum of squares was evaluated at 4503 combinations of parameter 
values, where Bmax varied between 0.1 and 40 nM, Kp,ns varied between 0.1 and 10 
and Kd varied between 0.1 and 30 nM.  
   A sensitivity analysis was performed to investigate how the function responds to 
small perturbations of the parameters over a broad range of Cp (0.1-10000 nM). Only 
the function describing Ccontrol (eq. 3.9) was considered since Cnonspec (eq. 3.10) is a 
component of that function. The sensitivities were generated by considering the 
partial derivatives of the output Y with respect to each parameter xi and these were 
calculated keeping all other parameters fixed at their assigned values (x0), i.e. 
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The partial derivatives were solved analytically to give: 
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3.2.2 Results 
3.2.2.1 Tracer identification in vitro  
Fifteen GR binders were selected from AstraZeneca’s internal chemical library on 
the basis of having large numerical differences between the values of –log(EC50) and 
logD7.4. Based on the measured nonspecific binding in lung slices and the analytical 
sensitivity a refined selection of two compounds was made. The chemical structures 
of compounds 1 and 2 are shown in figure 3.1. Incubation of lung slices in the 
absence and presence of excess of R-budesonide resulted in statistically significant 
differences between Cslice,total and Cslice,nonspec for both compounds. ftb was calculated 
to be 0.56 ± 0.071 and 0.48 ± 0.069 for compound 1 and 2, respectively. ftb and 
analytical sensitivity were subsequently used for ranking. Based on these criteria, 
compound 1 was identified as the most promising tracer candidate.  
 
3.2.2.2 Evaluation of tracer dose 
As illustrated in figure 3.2, which shows Ccontrol and Cnonspec for each tracer dose, 
there was a separation between Ccontrol and Cnonspec at the second lowest dose level 
(40 nmol/kg). Ccontrol was 9.2 ± 2.1 nM and Cnonspec was 3.8 ± 0.32 nM, resulting in a 
Ccontrol/Cnonspec ratio of 2.4, corresponding to a value for ftb of 0.59. The ratio between 
Ccontrol and Cnonspec decreased with ascending tracer doses (2.4, 1.5 and 1.3 for 40, 
400 and 4000 nmol/kg, respectively). Cnonspec was below the lower limit of 
quantification (LLOQ) at the lowest dose level (4 nmol/kg) and therefore the ratio 
could not be calculated. Cnonspec was proportional to Cp and thus they were found to 
be highly correlated (r2 = 0.99). 
   The dependence of Ccontrol and Cnonspec on Cp was captured by the model. Parameter 
estimates and standard errors for the model are presented in table 3.1. The 
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correlations between the estimated parameters are presented in table 3.2. The 
correlation between Bmax and Kd was found to be reasonably high (0.886). Whilst 
Kp,ns had a high parameter precision, the confidence intervals for Bmax and Kd  were 
somewhat wider. Thus, some caution should be exercised when interpreting these 
two parameter estimates. 
   In the exhaustive search, the minimum cost function was found at the following 
parameter values: Kp,ns = 0.761, Bmax = 21.2 nM and Kd = 10.4 nM. The same 
minimum was thus found when using nonlinear least squares (the trust region-
reflective algorithm as the optimisation algorithm) and the exhaustive search 
algorithm, which confirms that the global minimum had been found within the 
investigated parameter space.  
   A partial derivative based sensitivity analysis was performed as described in 
section 3.2.1.12 and the results are presented in figure 3.3a-c. The plot of 
∂Ccontrol/∂Kd as a function of Cp (fig. 3.3a) indicates that samples from the two 
intermediate dose groups (40 and 400 nmol/kg) were informative with respect to Kd. 
In contrast, at the Cp resulting from the highest and the lowest dose group (4000 and 
4 nmol/kg, respectively), a change in Kd only had a minor effect on the output. As 
can be seen from eq. 3.14 and fig. 3.3b, the influence of Bmax on the output becomes 
more pronounced with increasing Cp until Cp >> Kd when the maximum value of 
∂Ccontrol/∂Bmax has been reached (i.e. ∂Ccontrol/∂Bmax tends towards 1 as Cp >> Kd). Eq. 
3.15 shows that ∂Ccontrol/∂Kp,ns equals Cp (fig. 3.3c), i.e. the higher Cp the more 
pronounced is the effect of Kp,ns on the output. 
   By using the developed model and its final parameter estimates, the ratio 
Ccontrol/Cnonspec could be simulated for a range of Cp-values of tracer. According to the 
simulations, the ratio consistently increased with lower Cp-levels of tracer (fig. 3.4). 
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A ratio of 3 was judged to be a sufficiently high ratio, which occurred when Cp < 3.5 
nM. As the Cp-data used for constructing this model had been collected 30 min after 
IV-administration, the 2-compartment model that had been parameterised to describe 
the PK of the tracer (section 3.2.2.4) could be used to evaluate what intravenous dose 
that would yield a Cp of 3.5 nM at t = 30 min. It was found that this situation 
corresponded to a tracer dose of approximately 55 nmol/kg or less. These model 
predictions combined with information about the analytical sensitivity could then be 
used for identifying an appropriate tracer dose. The lowest tracer dose that could be 
reliably quantified by LC-MS/MS was chosen (30 nmol/kg). 
 
Table 3.1 Parameter estimates from modelling of tissue concentrations of tracer, which was assumed 
to consist of two parts: 1) linear nonspecific binding determined by the plasma tracer concentration 
(Cp) and a partitioning constant for nonspecific binding (Kp,ns), and 2) non-linear binding to the target 
determined by Cp, the dissociation constant (Kd) and the receptor density (Bmax). 
Parameter Estimate 
Kp,ns 0.76 ± 0.021  
Bmax (nM) 21 ± 8.1  
Kd (nM) 10 ± 6.2
a) 
a) Kd is estimated from total Cp, if corrected for plasma protein binding Kd is 0.21 ± 0.12 nM. 
Precision of the estimates is expressed as standard errors. The root mean square error for this fit was 1.2 nM. 
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Figure 3.2 Evaluation of total (white circles) and nonspecific (black diamonds) lung concentration of 
tracer after IV-administration of four different tracer doses (4, 40, 400 and 4000 nmol/kg) to rats. 
Animals dedicated to determination of nonspecific binding were pre-treated with a glucocorticoid 
receptor binder 30 minutes before tracer administration. 
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Figure 3.3 A sensitivity analysis was performed by considering the partial derivatives (eqs. 3.12-3.14, 
blue lines) of the output Ccontrol (eq. 3.9) with respect to each of the estimated parameters: a) the 
dissociation rate constant (Kd), b) the receptor density (Bmax), and c) the partitioning constant for 
nonspecific binding (Kp,ns). The plasma concentrations (Cp) at which observations were made are 
illustrated by open circles. 
 
 
Figure 3.4 Model simulations of the ratio between total (Ccontrol) and nonspecific (Cnonspec) lung 
concentration of tracer as a function of plasma concentration (Cp). 
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Table 3.2 Estimated correlation matrix of the parameter estimates. 
  Kp,ns Bmax Kd  
Kp,ns 1 -0.487 -0.396 
Bmax -0.487 1 0.886 
Kd  -0.396 0.886 1 
 
 
3.2.2.3 Evaluation of nonspecific binding  
The same degree of nonspecific binding remained when dexamethasone replaced 
compound 2 as the pre-treatment drug; i.e. Cnonspec/Cp was of the same magnitude 
(0.76 ± 0.12 and 0.69 ± 0.11 after pre-treatment with dexamethasone and compound 
2, respectively). As in section 3.2.1.4, Cnonspec was proportional to Cp (r
2 = 0.99). 
 
3.2.2.4 PK-study 
A 2-compartment model with a multiplicative error model was used to describe the 
plasma PK of the tracer. A graphical illustration of the model (fig. 2.5b) is included 
in section 2.3.1. The model was implemented in Phoenix™ WinNonlin® 6.3.0 
(Pharsight, Sunnyvale, CA). The compartmental model equations are given by 
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2
2  CtCtCCl
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V .  (3.16) 
 
where D is the dose, C1 is the concentration in the central compartment, CL is the 
clearance, V1 is the volume of the central compartment, C2 is the concentration in the 
peripheral compartment, CL2 is the intercompartmental clearance and V2 is the 
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volume of the peripheral compartment. The observations and the model fit are shown 
in figure 3.5a. The estimates and the precision of the parameters are summarised in 
table 3.3. As can be seen in fig. 3.5b, the weighted residuals were randomly 
distributed around zero when a multiplicative error model was used. 
 
 
Figure 3.5 Characterisation of the plasma pharmacokinetics (PK) of the tracer. a) The plasma 
concentration (Cp) after IV-administration of the tracer (30 nmol/kg, n = 8). A 2-compartment model 
was used to describe the plasma PK (solid line). b) Weighted residuals plotted against the predicted 
Cp. 
Table 3.3 Parameter estimates from PK-modelling of tracer. 
Parameter Estimate 
V1 (L/kg) 0.19 ± 0.037 
V2 (L/kg) 0.56 ± 0.075  
CL (L/h/kg) 4.8 ± 0.30 
CL 2 (L/h/kg) 3.1 ± 0.43  
Precision of the estimates is expressed as standard errors. 
 
3.3.2.5 Evaluation of tracer function in other organs  
There were statistically significant differences between Ccontrol and Cnonspec in the 
lung, liver, spleen and kidney (table 3.4). The difference was especially pronounced 
in the lung and in the spleen (p < 0.001).  All brain samples were below the LLOQ. 
The ratio of Ccontrol/Cnonspec in the spleen was found to be higher than the 
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corresponding ratio in the other investigated organs and the spleen was thus selected 
to be used as a reference organ for the systemic exposure.  
 
Table 3.4 Total and nonspecific tracer concentrations (Ccontrol and Cnonspec, respectively) measured in 
lung, liver, spleen, kidney and brain. Cnonspec is measured in animals pre-treated intravenously with 
dexamethasone (20 mg/kg, n = 5) and Ccontrol is obtained from drug-naïve control animals (n = 5). 
Asterisks denote statistical significance between Ccontrol and Cnonspec. 
  Ccontrol (nM) Cnonspec (nM) 
Lung 10 ± 1.4 2.8 ± 0.53*** 
Liver 1.4 ± 0.41 0.77 ± 0.20* 
Spleen 16 ± 1.6 2.8 ± 0.44*** 
Kidney 20 ± 4.4 14 ± 3.4* 
Brain <LLOQ <LLOQ 
LLOQ: Lower limit of quantification; *Significant at the 0.05 probability level **Significant at the 0.01 
probability level ***Significant at the 0.001 probability level 
 
3.3 Application of the methodology 
In order to evaluate the developed methodology, the well-established drug 
fluticasone propionate (FP), which is known to be a selective high-affinity GR 
agonist [134], was used to assess the ability of the method to: 1) establish a dose-
receptor occupancy relationship, and 2) study the time course of receptor occupancy. 
The intravenous route of administration was favoured versus other routes since it 
provides the lowest possible interindividual variability in lung tissue exposure. 
   The author was responsible for the design and the execution of both studies 
described in section 3.3.1. The dose-receptor occupancy study was done by the 
author alone. For the in vivo work of the time profile study, the author was assisted 
by Susanne Arlbrandt and Dr Britt-Marie Fihn at AstraZeneca R&D Gothenburg. 
Both studies were conducted during the PhD studies. 
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3.3.1 Method 
3.3.1.1 Dose-receptor occupancy relationship  
The dose-receptor occupancy relationship for FP was assessed by measuring GR 
occupancy 1.5 hours after IV-administration of three escalating doses of FP: 20 
nmol/kg (n = 4), 150 nmol/kg (n = 6) and 750 nmol/kg (n = 6). Prior to both the 
administration of FP and tracer, plasma samples were taken for measurements of 
corticosterone in order to investigate if the endogenous ligand was a potential source 
of variability. To allow for interindividual differences in plasma corticosterone, the 
IV-administrations of FP were spread out over the time course of a day (8 a.m. – 7 
p.m.). One group of animals was pre-treated with dexamethasone via the IV-route 
(20 mg/kg) 30 minutes prior to tracer administration (n = 6), whereas the animals 
dedicated to determination of the maximum tissue tracer concentration did not 
receive any pre-treatment (n = 8). Receptor occupancy was calculated for each 
animal treated with FP according to eq. 3.6 (section 3.2.1.9).  
 
3.3.1.2 Receptor occupancy time profile  
The time course of receptor occupancy was studied after IV-administration of FP (90 
nmol/kg). As detailed in section 4.2.1, the choice of the IV-dose was based on the 
ED50 of FP in a preclinical PD-model. Tracer was administered intravenously at the 
following time points after drug administration: 0.5, 1, 2, 4, 7, 24 and 48 hours (3 
animals/time point). Receptor occupancy was calculated for each animal according to 
eq. 3.6 (section 3.2.1.9). 
 
 
 
84 
 
3.3.1.3 Statistical analysis 
   One-way analysis of variance (ANOVA). A one-way analysis of variance 
(ANOVA) was used to determine whether there was a statistically significant 
difference between any of the mean values of the five different groups in the dose-
receptor occupancy study.  
   An ANOVA compares the mean values of a dependent variable between different 
groups that are categorised by an independent variable. In this case the dependent 
variable is the tracer concentration in the lung or in the spleen and the independent 
variable is the group (i.e. the three FP-dose groups, the group of animals pre-treated 
with dexamethasone and the group of drug-naïve control animals). That is, an 
ANOVA tests the following null hypothesis (H0) 
 
nH   ...: 210 ,    (3.17) 
 
where µi is the mean value of group i and n is the total number of groups. H0 is 
violated if there is a statistically significant difference between at least two of the 
group means. Three assumptions should be met in order to make an ANOVA: 1) the 
dependent variable should have a normal distribution within each group, 2) the data 
should have equal variances in each group, and 3) the observations should be 
independent. This statistical test is known to be robust against modest violations of 
the normality assumption. The second assumption regarding homogeneity of 
variances can be tested using Levene’s Test [135]. 
   Importantly, an ANOVA does not give any information on which specific groups 
are statistically significantly different from each other. A significant result should 
therefore be followed up by a post-hoc test in order to find where the difference(s) 
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exist. If the assumption regarding equal variances is met, Tukey’s honestly 
significant difference test can be used [135]. 
    One-way ANOVA using MATLAB. The data were initially tested for equality of 
variances using Levene’s test, which tests the null-hypothesis that the variances are 
equal. The null-hypothesis was considered to be violated if p ≤ 0.05, this level of 
significance applies to all statistical tests in this section. A MATLAB-script for 
Levene’s test was obtained from [136]. Provided that the null-hypothesis was not 
violated, an ANOVA was carried out. 
   An ANOVA was conducted in MATLAB using the command ‘anova1’ for both 
lung and spleen tracer concentrations. Provided that the null-hypothesis was rejected, 
a post-hoc test was performed using the command ‘multcompare’ with the 
information in the ‘stats’ structure as input. The ‘stats’ structure had been obtained 
from the ANOVA-analysis and it contained the information needed for a post-hoc 
analysis. Tukey’s honestly significant difference test was selected. 
 
3.3.1.4 Modelling of the dose-receptor occupancy relationship  
A nonlinear Emax-model with a baseline (eq. 3.18) was used to describe the dose-
receptor occupancy relationship, using  
 







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50
max, 1
EDD
D
CCC specnonspeci   (3.18) 
   
where Ci is the tissue tracer concentration in animal i, Cnonspec is the nonspecific 
binding, Cspec,max is the maximum specific binding, D is the dose and ED50 is the dose 
which gives 50% occupancy at 1.5 hours. A high dose (10000 nmol/kg) was assigned 
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to the animals pre-treated with dexamethasone (n = 6) and D was set to 0 for drug-
naïve control animals (n = 8). 
   An exhaustive-search algorithm was used to obtain initial estimates for Cnonspec, 
Cspec,max and ED50 for the subsequent parameter estimation. This was done by 
evaluating the sum of squares at 1503 combinations of parameter values for both data 
from the lung and the spleen. For the lung, Cnonspec varied between 0 and 6 nM, 
Cspec,max varied between 2 and 12 nM and ED50 varied between 10 and 60 nmol/kg. 
For the spleen, Cnonspec varied between 0 and 6 nM, Cspec,max varied between 2 and 14 
nM and ED50 varied between 20 and 80 nmol/kg. 
   The parameter estimation was implemented in MATLAB R2013a using nonlinear 
least squares (lsqnonlin), which minimised the difference between the measured and 
the predicted Ci. The default optimisation algorithm of ‘lsqnonlin’ was used (trust 
region-reflective algorithm). Ccontrol for drug-naïve control animals was then 
calculated as follows 
 
nonspecspeccontrol CCC  max,  .   (3.19) 
 
   A sensitivity analysis was performed to investigate how the function responds to 
changes in the parameters over a broad dose range (0.1-1000 nmol/kg). The 
sensitivities were generated by considering the partial derivatives of the output Ci 
with respect to each parameter xi and these were calculated whilst keeping all other 
parameters fixed at their assigned values (x0) as described by eq. 3.11 (section 
3.2.1.12). That is, the following partial derivatives were generated: 
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The analysis was implemented using the MATLAB symbolic math toolbox. 
 
3.3.2 Results 
3.3.2.1 Dose-receptor occupancy relationship 
A dose-dependent decrease in tracer concentrations was observed in the lung and the 
spleen, which is illustrated in figures 3.6a and 3.6b, respectively. An ANOVA was 
used to determine whether there was a statistically significant difference between any 
of the mean values for the five different groups. The statistical analysis resulted in a 
rejection of the null-hypothesis for both measured tissue concentrations of tracer 
(F(4,25) = 75.52, p = 1.38×10-13 and F(4,25) = 107.42, p = 2.29×10-15 for the lung 
and the spleen tracer concentrations, respectively).  
   The results of the two post-hoc tests of all possible pairings of the groups are 
summarised in tables 3.5 and 3.6. Table 3.5 contains the results of the analysis in 
which the lung tracer concentration was the dependent variable, whereas the analysis 
of the spleen tracer concentration is presented in table 3.6.  
   Table 3.5 shows that the mean values of the lung tracer concentration in the control 
group and the lowest dose group (20 nmol/kg, FP) were statistically significantly 
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different from the mean values for all other groups. It also shows that the differences 
between the mean values of all dose groups were statistically significant. The 
difference between the mean values of the highest dose group (750 nmol/kg, FP) and 
the group pre-treated with dexamethasone was not statistically significant, neither 
was the difference between the intermediate dose group (150 nmol/kg) and the group 
pre-treated with dexamethasone. 
   As can be seen in table 3.6, the post-hoc test for the spleen tracer concentrations 
shows that differences in group mean values were statistically significant for all 
combinations except for the highest dose group (750 nmol/kg, FP) and the group pre-
treated with dexamethasone. 
 
Table 3.5 Post-hoc test for the lung tracer concentrations. 
 Control 20 nmol/kg 150 
nmol/kg 
750 
nmol/kg 
Dex 
Control NA p ≤ 0.05 p ≤ 0.05 p ≤ 0.05 p ≤ 0.05 
20 nmol/kg p ≤ 0.05 NA p ≤ 0.05 p ≤ 0.05 p ≤ 0.05 
150 
nmol/kg 
p ≤ 0.05 p ≤ 0.05 NA p ≤ 0.05 X 
750 
nmol/kg 
p ≤ 0.05 p ≤ 0.05 p ≤ 0.05 NA X 
Dex p ≤ 0.05 p ≤ 0.05 X X NA 
The level of significance was set at p ≤ 0.05. X indicates that the difference between two mean values 
was not statistically significant. 
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Table 3.6 Post-hoc test for the spleen tracer concentrations. 
 Control 20 nmol/kg 150 
nmol/kg 
750 
nmol/kg 
Dex 
Control NA p ≤ 0.05 p ≤ 0.05 p ≤ 0.05 p ≤ 0.05 
20 nmol/kg p ≤ 0.05 NA p ≤ 0.05 p ≤ 0.05 p ≤ 0.05 
150 
nmol/kg 
p ≤ 0.05 p ≤ 0.05 NA p ≤ 0.05 p ≤ 0.05 
750 
nmol/kg 
p ≤ 0.05 p ≤ 0.05 p ≤ 0.05 NA X 
Dex p ≤ 0.05 p ≤ 0.05 p ≤ 0.05 X NA 
The level of significance was set at p ≤ 0.05. X indicates that the difference between two mean values 
was not statistically significant. 
 
   A dose-receptor occupancy relationship was thus observed after IV-administration 
of FP (fig. 3.7). As can be seen in fig. 3.7, IV-administration resulted in receptor 
occupancies of similar magnitude in both investigated organs. An Emax-model with a 
baseline captured how tissue concentrations of tracer depend on the dose of FP. 
Parameter estimates and standard errors obtained from the model are presented in 
table 3.7. ED50 was estimated to be 47 ± 8.6 nmol/kg. Concentration data from the 
lung and the spleen were initially modelled separately. When the data sets were 
modelled separately, they gave overlapping 95% confidence intervals of ED50 (34 
[13-52] and 53 [27-79] nmol/kg for the lung and the spleen, respectively). Since the 
models provided overlapping 95% confidence intervals for ED50 and no difference in 
ED50 is expected for these two organs after IV-dosing, co-modelling of both data sets 
was instead applied in order to achieve a more reliable estimate of ED50. As can be 
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seen in the correlation matrix (table 3.8), none of the estimated parameters were 
found to be highly correlated. 
   As can be seen from eqs. 3.19-3.21, the partial derivatives with respect to Cnonspec 
and Cspec,max are identical for concentration data from the spleen and the lung, 
whereas ∂Ci/∂ED50 will have different magnitudes for the two organs as Cspec,max is 
included in the numerator (eq. 3.21). The sensitivity analysis showed that 
∂Ci/∂Cnonspec is constant and all observations thus provided similar information for 
this parameter regardless of FP dose (fig. 3.8a). This is expected as Cnonspec should be 
unaffected by receptor occupancy and thus also unaffected by the dose of the test 
compound. In contrast, the function was most sensitive to Cspec,max as the dose 
approached 0 (fig. 3.8b), which is also in line with the expectations as the specific 
binding decreases with increasing doses of test compound and drug-naïve animals 
should thus be most informative with respect to this parameter. ∂Ci/∂ED50 had a bell-
shaped curve and the function was most sensitive to changes in ED50 in the proximity 
to ED50 (fig. 3.8c-d). For all parameters, the sensitivity analysis showed that 
observations had been made in informative regions of the dose range.  
   Although the measurements of corticosterone, both before the administration of FP 
(27-330 µg/L) and tracer (25-260 µg/L), varied between the animals, no relationship 
between corticosterone and estimated receptor occupancy was observed in the treated 
animals. This is shown in a representative graph (fig. 3.9). 
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Figure 3.6 Tissue tracer concentration in a) the lung, and b) the spleen after IV-administration of three 
escalating doses of fluticasone propionate to rats (20, 150 and 750 nmol/kg). Drug-naïve control 
animals as well as animals pre-treated with dexamethasone (20 mg/kg) were also in the study to 
account for maximum and nonspecific tracer concentration, respectively. The solid line represents the 
model fit (eq. 3.17). Asterisks denote statistical significance between treated animals and drug-naïve 
control animals (n = 8), which are also included in the graph. *Significant at the 0.05 probability level 
**Significant at the 0.01 probability level ***Significant at the 0.001 probability level 
 
 
Figure 3.7 Dose-receptor occupancy relationship: receptor occupancy in the lung (black triangles) and 
the spleen (white circles) measured 1.5 hours after IV-administration of escalating doses of fluticasone 
propionate to rats (20, 150 and 750 nmol/kg).  
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Table 3.7 Parameter estimates from the modelling of the dose-receptor occupancy relationship, in 
which the tracer concentration was described with a nonlinear Emax-model with a baseline. 
Parameter Estimate 
Cnonspec,lung (nM) 2.2 ± 0.28 
Cspec,max,lung (nM) 6.4 ± 0.44 
Cnonspec,spleen (nM) 2.6 ± 0.30 
Cspec,max,spleen (nM) 9.6 ± 0.44 
ED50 (nmol/kg) 47 ± 8.6 
Precision of the estimates is expressed as standard errors. The root mean square error for this fit was 0.99 nM. 
 
 
Figure 3.8 A sensitivity analysis was performed by considering the partial derivatives of the output Ci 
with respect to: a) Cnonspec, b) Cspec,max, c) ED50 (using parameter estimates specific for the lung) and d) 
ED50 (using parameter estimates specific for the spleen). 
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Table 3.8 Estimated correlation matrix of the parameter estimates 
  Cspec,max,spleen  ED50 Cnonspec,spleen  Cspec,max,lung  Cnonspec,lung  
Cspec,max,spleen  1 0.0751 -0.657 0.00380 -0.0270 
ED50 0.0751 1 -0.498 0.0503 -0.359 
Cnonspec,spleen  -0.657 -0.498 1 -0.0251 0.179 
Cspec,max,lung  0.00380 0.0503 -0.0251 1 -0.686 
Cnonspec,lung  -0.0270 -0.359 0.179 -0.686 1 
 
 
Figure 3.9 Corticosterone and receptor occupancy: receptor occupancy in the lung 1.5 hours after IV-
administration of three different doses of fluticasone propionate: 20 nmol/kg (diamonds), 150 nmol/kg 
(circles) and 750 nmol/kg (triangles), respectively. No relationship was observed between receptor 
occupancy and plasma corticosterone measurements made before the IV-administration of tracer. 
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3.3.2.2 Receptor occupancy time profile  
As can be seen in figure 3.10, a high initial receptor occupancy was observed, which 
was followed by a time-dependent decline between 0.5 and 7 h. Receptor occupancy 
in the spleen had returned to baseline within seven hours after dosing, whereas there 
still remained some drug occupancy in the lung. The occupancy profiles initially 
followed each other closely, while the occupancy was estimated to be slightly higher 
in the lung at t = 4 and 7 h after IV-administration of FP.  
 
Figure 3.10 Time course of receptor occupancy in the lung (triangles) and the spleen (circles) after 
intravenous administration of fluticasone propionate to rats (90 nmol/kg). 
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3.3.2.3 Concentration-receptor occupancy relationship in the spleen 
When data from both studies (sections 3.3.2.1 and 3.3.2.2) were used, a relationship 
between occupancy in the spleen and the spleen concentration of FP was observed 
(fig. 3.11). Since the analytical sensitivity for FP in the lung tissue was not equally 
good, the corresponding graph could not be created for the lung. 
 
 
Figure 3.11 A relationship between receptor occupancy in the spleen and spleen concentrations of 
fluticasone propionate (Cspleen,FP) was observed. Each data point corresponds to the receptor 
occupancy of an individual animal and data were taken from two different studies where FP was 
administered as an IV-bolus. In the first study, occupancy was measured 1.5 hours after IV-
administration of different doses of FP: 150 nmol/kg (diamonds) and 750 nmol/kg (triangles), 
respectively. In the second study, the time course of occupancy was studied after administration of 90 
nmol/kg (circles). All animals from the two studies where Cspleen,FP > LLOQ  are included in the graph.   
 
3.4 Discussion 
This chapter presents the development of the first methodology that is capable of 
simultaneous measurements of both pulmonary and systemic in vivo occupancy of 
GR. It is novel both in terms of measuring GR occupancy strictly in vivo and by the 
analytical technique used for tracer quantification (LC-MS/MS). 
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   Identifying a tracer molecule is a prerequisite for developing a receptor occupancy 
methodology for a new target and this is indeed recognised as a challenging task. As 
highlighted in section 3.2.1.2, AstraZeneca’s internal library contains numerous 
compounds with affinity for the GR, which thus theoretically could be considered as 
potential tracer candidates. However, it would not be feasible to experimentally 
evaluate each candidate and a rational approach was thus needed to narrow down the 
search space and select compounds with a higher probability of success as GR 
tracers. Potential tracer candidates were therefore selected based on molecular and 
pharmacological properties as suggested by Fridén et al. [125]. This strategy proved 
to be successful and one of these compounds, which had demonstrated a high ftb in 
vitro and a sufficiently high analytical sensitivity, was brought forward to in vivo 
evaluation. The in vivo studies showed that it was a successful tracer for the GR in 
lung tissue as an appropriate ratio of Ccontrol/Cnonspec was obtained at a low tracer dose 
(30 nmol/kg, IV). As expected, this ratio was demonstrated to decrease with higher 
tracer doses since the relative contribution of Cnonspec increases with higher tracer 
exposure (fig. 3.2). This behaviour was captured by a model, which described the 
receptor- and nonspecifically-bound tracer concentrations as a function of Cp (eqs. 
3.9-3.10). Simulations of this model evaluated at its final parameter estimates 
showed that the ratio Ccontrol/Cnonspec consistently increased with lower Cp-levels of 
tracer (fig. 3.4). Thus, an appropriate tracer dose should be low while still ensuring 
that the resulting tissue tracer concentrations exceed the LLOQ. By combining PK-
model predictions with information about the analytical sensitivity, a low tracer dose 
that could be reliably quantified by LC-MS/MS was selected (30 nmol/kg). A post-
tracer survival interval of 30 minutes was tested since it is commonly used in other 
preclinical in vivo receptor occupancy methodologies [130,131]. As it proved to give 
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an appropriate ratio of total-to-nonspecific binding, this post-tracer survival interval 
was chosen. It was also shown that normal variation of corticosterone plasma 
concentrations had no relevant impact on the estimates of occupancy after drug 
administration (fig. 3.9).  
   There is no tissue devoid of GR that can be used as a reference region to estimate 
nonspecific tissue binding for the tracer. Instead the nonspecifically-bound tracer 
concentration must be estimated in separate animals. As expected, it was shown that 
Cnonspec was proportional to Cp. The partitioning constant for nonspecific binding 
(Kp,ns) was of the same magnitude when high doses of two structurally different GR 
binders, a steroid and a selective non-steroidal GR agonist respectively, were used as 
pre-treatment. Based on these results the tested IV-dose of dexamethasone (20 
mg/kg) was considered an appropriate pre-treatment for measurements of Cnonspec.  
   The possibility of extending the methodology by including a reference organ for 
the systemic exposure after inhalation was explored by evaluating the functionality 
of the GR-tracer in several organs. The ratio of total-to-nonspecific tracer 
concentrations was found to be considerably higher in the spleen as compared to the 
other tested organs (including the lung). From a methodological point of view, a 
higher ratio of total-to-nonspecific tracer concentration allows for more reliable 
receptor occupancy measurements. Accordingly, the experimental methodology 
provides slightly more accurate measurements of receptor occupancy in the spleen. 
Furthermore, the spleen is known to be a highly perfused organ, which is a desired 
property of a reference organ for systemic exposure. Due to the rapid perfusion, a 
fast equilibrium between the unbound drug concentrations in plasma and tissue can 
be expected (given a perfusion rate-limited drug distribution). This property also 
contributed to the choice of reference organ. 
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   Once the experimental procedures had been established, the developed 
methodology was evaluated by assessing its ability to establish a dose-receptor 
occupancy relationship and to study the time course of receptor occupancy. 
Fluticasone propionate was selected as test compound based on its pharmacological 
properties; a high selectivity and high affinity for the GR [134].  
   As expected from a dose-receptor occupancy evaluation, a dose-dependent 
decrease in tracer concentrations was observed both in the lung and the spleen (fig. 
3.6a-b). This behaviour was captured by a model and the ED50 was estimated to be 
47 nmol/kg. A partial derivative based sensitivity analysis suggested that informative 
doses had been used in the study. In summary, the methodology proved capable of 
demonstrating a dose-receptor occupancy relationship.  
   GR occupancy had previously not been determined after IV-administration of FP. 
Nevertheless, based on its high potency the highest dose level (750 nmol/kg) was 
expected to give a high occupancy. In fact, complete occupancy was observed in 
both organs. It should not be possible to exceed 100% occupancy but as Cnonspec is 
obtained from a separate group of animals, interindividual variability can explain 
why some estimates were slightly higher than 100%. Measurements of occupancy 
were therefore made in treatment groups of 4-6 animals to reduce the impact of 
interindividual variability.  
   The time course of receptor occupancy was captured in the lung and the spleen 
after IV-dosing of FP (90 nmol/kg). A high initial occupancy was followed by a 
relatively rapid decline, where the occupancy had returned to 0% in the spleen within 
7 hours after dosing (fig. 3.10). This is in line with the behaviour observed after IV-
administration of another corticosteroid, triamcinolone acetonide, where the level of 
free receptors was found to return to baseline within six hours using an ex vivo 
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binding assay [120]. The estimated occupancy 24 hours after dosing was higher than 
after 7 hours and is most likely not reflective of the drug-receptor interaction. Rather, 
this observation may reflect the dynamics of the GR with a drug-induced down-
regulation of the receptor population, which has been demonstrated to take place 
after GR agonist exposure both in vitro and in vivo [137]. Either way, the estimated 
occupancy can be viewed as a reflection of free binding sites. 
   One of the advantages of utilising LC-MS/MS for tracer quantification is that such 
methodologies also allow for simultaneous quantification of drug concentrations in 
the same sample. Hence, total organ concentrations of FP had been measured in the 
spleen and the lung in both studies. When the results from these two studies were 
combined, a relationship between GR occupancy in the spleen and total spleen 
concentrations appeared (fig. 3.11). Interestingly, a plateau of occupancy (100%) 
was reached at a total tissue concentration of 40 nM, which is in close proximity to 
the measured GR density in the spleen (31 nM) [138]. It is also noted that the rise in 
occupancy below 40 nM showed a linear behaviour, these two indices suggest that a 
large fraction of the tissue concentration constitutes of receptor-bound rather than 
nonspecifically-bound drug; i.e. the results point towards FP having a high ftb in the 
spleen. As the analytical sensitivity of FP was not equally good in lung homogenates, 
it could not be investigated whether the same relationship was present in the lung 
(several samples were below the LLOQ).  
   By applying this methodology, a dose-receptor occupancy relationship was 
established and the time course of occupancy was captured after IV-administration of 
FP, a well-known GR agonist. This gives confidence in the methodology, which 
henceforth can be used as a tool to increase the fundamental understanding of 
inhalation PK and PK/PD by studying receptor occupancy after inhalation of GR 
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modulators. In chapter 4, the developed methodology will be used for this very 
purpose. 
 
3.5 Summary 
Chapter 3 presents the development and the subsequent evaluation of an in vivo 
receptor occupancy methodology for an inhaled target: the GR. The developed 
methodology is novel both in terms of being fully in vivo-based and by utilising LC-
MS/MS for tracer quantification. 
   A refined selection of potential tracer candidates was made based on molecular and 
pharmacological properties as suggested by Fridén et al. [125]. One of these 
compounds, which had a demonstrated high ftb in vitro and a sufficiently high 
analytical sensitivity, was brought forward for in vivo evaluation. The in vivo studies 
showed that it was a successful tracer for the GR in lung tissue as an appropriate 
ratio of Ccontrol/Cnonspec was obtained at a low tracer dose (30 nmol/kg, IV) after a 
post-tracer survival interval of 30 minutes. The possibility of simultaneously 
estimating receptor occupancy in a reference organ for the systemic exposure was 
explored by evaluating the functionality of the selected tracer molecule in other 
organs as judged by the ratio of Ccontrol/Cnonspec. Based on this criterion and the high 
splenic perfusion rate, the spleen was considered to be an appropriate reference 
organ.  
   Once the experimental in vivo protocol had been finalised, the developed 
methodology was evaluated by assessing its ability to establish a dose-receptor 
occupancy relationship and to characterise a time course of receptor occupancy. Both 
studies used a selective, high-affinity GR agonist as test compound (FP). As 
expected from a dose-receptor occupancy evaluation utilising the IV-route, a dose-
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dependent decrease in tracer concentrations was observed (fig. 3.6a-b) and the 
occupancies were of similar magnitude in both organs (fig. 3.7). Hence, the 
methodology proved capable of demonstrating a dose-receptor occupancy 
relationship after IV-administration. The dose-dependency was described by a 
mathematical model and the ED50 was estimated to be 47 nmol/kg. A partial 
derivative based sensitivity analysis suggested that informative doses had been 
selected for the study. In the time course study, the highest receptor occupancy 
observation was made at the first time point (t = 30 min). The peak was followed by 
a relatively rapid decline and the receptor occupancy had returned to 0% in the 
spleen within 7 hours after dosing (fig. 3.10).  
   Besides being a selective and high-affinity GR-agonist, FP has interesting 
properties from an inhalation PK perspective. These properties will be discussed in 
more detail in chapter 4, in which the developed methodology is used for studying 
receptor occupancy after nose-only exposure of this compound. 
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Chapter 4 Temporal relationship between target site exposure and 
receptor occupancy 
 
4.1 Introduction 
As highlighted in chapter 3, contemporary experimental methodologies do not allow 
for direct measurements of unbound drug concentrations locally in the lung tissue. 
Since receptor occupancy is driven by the unbound drug concentration at the target 
site, such measurements would clarify the PK- and PK/PD-evaluation of locally 
acting inhaled drugs. The in vivo receptor occupancy methodology, the development 
of which was described in chapter 3, could thus be used for this purpose. Fluticasone 
propionate (FP) was selected as a test compound for various reasons. Firstly, it is a 
well-established drug that is broadly used in the clinic, for example for the treatment 
of asthma [48]. Secondly, it is a highly selective and potent glucocorticoid receptor 
(GR) agonist [79]. Thirdly, its lung retention is held to rely on its low solubility and 
thus slow dissolution rate [4]. Although a low solubility is a commonly used strategy 
for achieving lung retention after inhalation, more in-depth knowledge is needed to 
better understand potential benefits and limitations of this strategy. As measurements 
of total lung concentrations (Clung) after inhalation does not distinguish between solid 
and dissolved drug, preclinical inhalation studies of poorly soluble compounds are 
held to be exceedingly difficult to interpret. Furthermore, the complex interplay 
between e.g. dissolution, mucociliary clearance and permeation into lung tissue 
makes the interpretation even more challenging. The third property is thus clearly the 
most interesting one from an inhalation PK perspective. When switching focus from 
the pulmonary to the systemic PK, it becomes clear that FP, and several other inhaled 
corticosteroids, has properties strategically chosen to minimise the systemic exposure 
following inhalation: a high clearance and a low oral bioavailability [18]. In 
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summary, characterisation of the receptor occupancy of FP after nose-only exposure 
has the potential to yield interesting information about inhalation PK. 
   In contrast to drug delivery via the inhaled route, the unbound plasma 
concentration (Cu) is generally assumed to reflect the target site concentration after 
IV-administration of drug. This is based on the assumption that unbound drug freely 
distributes between blood and tissues, hence at equilibrium the Cu and the unbound 
drug concentration in tissues (CuT) will be the same (the ‘free drug hypothesis’). 
Assuming that the drug of interest has a perfusion rate-limited drug distribution, i.e. 
membranes do not present a barrier to distribution but the rate determining step is the 
blood flow to the tissue, the tissue distribution half-life (t½,distr) can be calculated 
from the distribution rate constant kT accordingly [139]:  
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where Qi is the flow to tissue i, Cvein is the venous concentration of drug, Vi is the 
volume of tissue i and Kp is the tissue-to-plasma partition coefficient. Parameters 
specific for the spleen were used to investigate whether it would be feasible to 
assume that measurements of Cu would be representative of the unbound drug 
concentration in the spleen. By setting Qspleen to 1.485 L/h/kg (cardiac output, QCO = 
20.77 L/h/kg [140] and the spleen receives 7.15% of QCO [141]), Vspleen to 2 mL/kg 
[142] and Kp to e.g. 2.5, eq. 4.2 gives a t½,distr of 8.4 s. Hence, the Cu can be assumed 
to be reflective of the unbound drug concentration in the spleen. This has interesting 
implications; given that receptor occupancy is measured in the spleen, the more 
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easily accessible Cu can be used to mathematically describe the relationship between 
target site exposure and receptor occupancy after IV-administration. Expressed 
differently, such studies would enable characterisation of the in vivo binding kinetics 
by estimating the association rate constant (Kon) and the dissociation rate constant 
(Koff). The binding kinetics of several GR agonists have previously been 
characterised in in vitro systems. However, data generated from an in vitro system 
are not necessarily translatable to the in vivo situation. In fact, results from previous 
work have indicated that this might be the case. In an in vitro system, the Koff of the 
corticosteroid triamcinolone acetonide was experimentally determined to be 5.5×10-4 
min-1, which corresponds to a dissociation half-life of 21 h [143]. In contrast, when 
an ex vivo binding assay was used to monitor receptor occupancy following an IV-
dose of triamcinolone acetonide to rats (22 µg), the level of free receptors initially 
declined rapidly after dosing, but was then found to return to baseline already within 
six hours after dosing [120]. Hence, studies with triamcinolone acetonide as a model 
drug suggest a disconnection between the in vitro and the in vivo situation with 
respect to the dissociation half-life. To gain further understanding of inhaled 
corticosteroids, it would thus be interesting to characterise the in vivo binding 
kinetics for this compound class. Ultimately, if estimates of Kon and Koff subsequently 
could be incorporated into a mechanistic in silico model used for predicting the local 
tissue concentrations after inhalation, measurements of receptor occupancy after 
inhalation would provide the first opportunity for validating such predictions. 
   This chapter will describe the experiments and the mathematical modelling used to 
characterise the in vivo binding kinetics after IV-administration of FP and 
budesonide. It also comprises the experiments used for studying the inhalation PK as 
well as the receptor occupancy after nose-only exposure of FP. 
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4.2 Receptor occupancy studies after IV-administration  
The time course of receptor occupancy was studied after IV-administration of FP and 
budesonide. The experimental details and the results from the study with FP are 
described in sections 3.3.1.2 and 3.3.2.2, respectively, whereas the budesonide study 
is described in this subsection. 
 
4.2.1 Choice of IV-dose 
As the IV-studies aimed to characterise the binding kinetics of the two compounds, it 
was essential to choose a dose that would significantly perturb the system and 
thereby enable receptor occupancy measurements over an extended time period. It 
was reasoned that data from preclinical PD-studies could be used to find an 
appropriate dose. Since both compounds are usually administered via the inhaled 
route, previous research at AstraZeneca has focused on characterising the compounds 
after inhalation. Due to a lack of efficacy data after IV-administration, inhalation PD-
studies were used to guide the dose setting. Both compounds had been investigated 
in an animal model that is used internally at AstraZeneca to evaluate the local 
pulmonary effects as well as the systemic side-effects of glucocorticoid receptor 
(GR) binders in rats. This animal model is e.g. described in [144]. In these studies, 
the effect is studied for several different lung deposited doses (LDD). This enables 
estimation of ED50, i.e. the LDD giving 50% efficacy. Since the intention was to 
perturb the system such that the receptors would be occupied several hours after drug 
administration, it was reasoned that the IV-dose should be several-fold higher than 
the ED50 to increase the chances of achieving this goal. Clearly, the IV-dose cannot 
be too high as that might jeopardise the well-being of the animals. The IV-dose was 
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therefore set to be 7.5 times ED50, which corresponded to 90 and 167 nmol/kg for FP 
and budesonide, respectively. 
 
4.2.2 IV-study, budesonide 
The author was responsible for designing, coordinating, performing as well as 
analysing the receptor occupancy IV-studies. Three additional researchers from 
AstraZeneca R&D Gothenburg assisted the author with the in vivo aspects of the 
budesonide study: Dr. Britt-Marie Fihn, Kajsa Claesson and Louise Hammarberg. 
   Animals. Male Wistar Han rats (Harlan, Horst, the Netherlands) weighing 260 to 
300 g were used for the IV-study with budesonide. The animals were group-housed 
at 18-22 ºC under a 12:12 h light/dark cycle with free access to food and water for at 
least five days prior to the experiments. The studies were approved by the Animals 
Ethics Committee of Gothenburg (71-2013).  
   Study protocol. The animals were anaesthetised by inhalation of isoflurane during 
both drug- and tracer administration. Budesonide was administered via the tail vein 
(167 nmol/kg) and the animals were then allowed to wake up. Tracer was 
subsequently administered via the tail vein at the following time points after drug 
administration: 0.5, 1, 2, 4, 7, 24 and 48 h (3 animals/time point). Animals dedicated 
to determination of Cnonspec had been pre-treated with an IV-dose of dexamethasone 
(20 mg/kg) 30 minutes prior to the tracer administration (n = 6). In contrast, animals 
set aside for determination of Ccontrol did not receive any pre-treatment prior to tracer 
administration (n = 7). A detailed experimental protocol for the in vivo receptor 
occupancy methodology as well as the sample handling is provided in section 
3.2.1.8. 
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4.2.3 Analytical procedures  
The sample handling as well as the analytical procedures used for the GR-tracer are 
described in detail in section 3.2.1.10.  
 
4.2.4 Results 
As can be seen in fig. 4.1, the receptor occupancy in the lung (ROlung) and the spleen 
(ROspleen) were of similar magnitudes after IV-administration of budesonide. The 
receptor occupancy was initially high and then rapidly returned to baseline within 4 
hours after dosing.  
   One animal, which was dosed with tracer at t = 4 h (where t = 0 h assigns the time 
point of drug administration), was excluded from the study since the apex was not 
incised along its transverse axis prior to perfusion of the lung. Due to this 
experimental error, water assembled in the lung causing the lung weight to increase 
by more than 100%. It was therefore judged as inappropriate to include 
measurements from this animal.  
   The data generated in this study was subsequently used for characterising the in 
vivo binding kinetics by mathematical modelling, which is described in section 4.4. 
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Figure 4.1 Glucocorticoid receptor (GR) occupancy was measured in the lung (blue circles) and the 
spleen (red circles) after IV-administration of budesonide (167 nmol/kg) to rats. 
 
4.3 Pharmacokinetic studies 
To enable modelling of the in vivo binding kinetics, the plasma pharmacokinetics 
(PK) of FP and budesonide were characterised using the same IV-doses as in the 
receptor occupancy studies. As the experimental data showed that dRO/dt was high 
during the initial part of the study, emphasis was placed on characterising the initial 
part of the plasma PK-profile by designing a study with frequent sampling at early 
time points. 
   FP is known to be challenging from a bioanalytical perspective and in the previous 
LC-MS/MS analyses the analytical sensitivity in plasma was recognised as very poor 
with a lower limit of quantification (LLOQ) above 5 nM. An improved analytical 
methodology was therefore set up in collaboration with Dr. Anders Lundqvist at 
AstraZeneca R&D Gothenburg. Due to the poor analytical sensitivity with the 
previously employed LC-MS/MS methodology, several plasma samples were still 
judged to be at high risk of falling below the LLOQ after an IV-dose of 90 nmol/kg. 
Hence, to ensure that it would be possible to quantify the plasma concentrations of 
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FP over several hours following drug administration an additional higher dose level 
was included in the PK-study (1000 nmol/kg). 
 
4.3.1 Preparation of dose solutions 
FP and budesonide were prepared as nanosuspensions at AstraZeneca’s R&D facility 
in Gothenburg by Sara Johansson and Annica Jarke according to the following two 
experimental protocols. In this study, nanosuspensions were favoured over the 
previously used vehicle with N,N-dimethylacetamide, polyethylene glycol 400 and 
water (1:1:1, w/w/w) due to newly discovered issues with possible animal discomfort 
during the tail-vein administration.  
   Fluticasone propionate. Glass-ware and utensils were cleaned with 70% ethanol. 
20 mL of the vehicle (Polyvinylpyrrolidone K30/SDS, 0.2%/0.25 mM) was prepared 
by mixing polyvinylpyrrolidone K30 (1 mL), 50 mM SDS (0.1 mL) and purified 
water (18.9 mL). A stock solution of 33.33 mM in DMA (stock A) was prepared by 
dissolving FP (4.05 mg) in DMA (243 µL). Subsequently, a second stock solution of 
3 mM (stock B) was prepared by diluting stock A (33.33 mM, 18 µL) with DMA 
(182 µL). 
   The nanosuspension for the higher dose level was prepared by precipitating stock 
A (33.33 mM, 60 µL) in vehicle (1940 µL), resulting in a final concentration of 1.0 
mM.   The nanosuspension for the lower dose level was prepared by precipitating 
stock B (3 mM, 60 µL) in vehicle (1940 µL), resulting in a final concentration of 90 
µM. Hence, the concentrations of both nanosuspensions were prepared such that the 
dose volume should be 1 mL/kg. The particle size was determined by fibre-optic 
detection and quasi-electric light-scattering (FOQELS); 371.7 and 297.8 nm for the 
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1.0 mM and 90 µM nanosuspensions, respectively. Both suspensions were stored in 
room temperature under stirring until dosing. 
   Budesonide. The vial and the magnetic stirrer were cleaned using 70% ethanol. 
Budesonide was weighed (57 mg) and vehicle (2% Pluronics F127, 510 µL) was 
added to the substance. The slurry was put on stirring over-night. The milling vessel 
was cleaned with 70% ethanol prior to the start of wet milling (4×30 min at 700 rpm 
with 15 minutes intermission). A washing step with 5% filtered mannitol was then 
applied (filtered through a 22 µm filter). The process resulted in a final particle size 
of 186 nm. The suspension was diluted with 5% filtered mannitol providing a final 
concentration of 167 µM so that the dose volume should be 1 mL/kg. The suspension 
was stored in room temperature until dosing. 
 
4.3.2 In life pharmacokinetic study  
The surgeries and the PK-study were performed at AstraZeneca R&D Gothenburg. 
The surgeries were performed by Marie Johansson and Gina Hyberg. The PK-study 
was led, designed and coordinated by the author, who also actively took part in the 
experimental study. Three additional researchers assisted the author in the 
experimental parts of the PK-study: Dr. Britt-Marie Fihn, Marie Johansson and Gina 
Hyberg. 
   Animals. Male Wistar Han rats (Harlan, Horst, the Netherlands) weighing 290 to 
350 g were used for the PK-study. The animals were group-housed at 18-22ºC under 
a 12:12 h light/dark cycle with free access to food and water for at least five days 
prior to the experiments.  The studies were approved by the Animals Ethics 
Committee of Gothenburg (71-2013).  
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   Study protocol. Jugular vein catheterisation was performed on 11 rats to enable 
repeated blood sampling.  The surgery was followed by four days of recovery before 
the start of the PK-study. On the day of the study, the functionality of the vein 
catheters was tested both by injecting saline solution and by taking a blood sample. 
Three catheters did not pass the test and those animals were therefore not included in 
the study, leaving eight animals for the PK-study. A nanosuspension of the drug was 
administered as an IV-bolus (1 mL/kg) to the three different dose groups 
accordingly: 1) 167 nmol/kg budesonide (n = 3), 2) 90 nmol/kg FP (n = 2), and 3) 
1000 nmol/kg FP (n = 3). Blood samples were repeatedly collected from the catheter 
over 8 hours following drug administration (t = 1, 3, 5, 10, 15, 30, 60, 120, 240 and 
480 min). An additional time point was included for budesonide at t = 24 h. No 
sample was taken for FP at t = 24 h as the drug concentration was expected to be 
below the LLOQ. The animals were euthanized by injection of pentobarbital (200 
mg/kg) after the last blood collection. 
   Sample handling. The blood samples were collected in heparinised tubes which 
were centrifuged for 10 minutes at 4000g (Rotanta 46R, Hettich, Germany). The 
plasma samples were subsequently transferred to Eppendorf tubes and stored at -
20ºC until analysis. 
 
4.3.3 Analytical procedures 
The plasma samples were analysed at AstraZeneca R&D Gothenburg by Dr. Anders 
Lundqvist according to the following experimental protocols, which were written in 
collaboration with Dr. Lundqvist. Both the analytical methodology for FP and 
budesonide provided an improved analytical sensitivity, i.e. a lower LLOQ, as 
compared to the previously used methodologies. The improved methodologies 
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provided a LLOQ in plasma of 0.04 and 0.10 nM for FP and budesonide, 
respectively. 
 
4.3.3.1 Analytical procedures for fluticasone propionate 
Sample preparation. A Solid Phase Extraction (SPE) procedure was used for 
preparation of the FP plasma samples. Briefly, aliquots of 100 µL plasma samples 
were pipetted to a 96-well plate and 125 µL Zinc sulphate (0.2 M) was added to each 
well. The plate was sealed and vortexed for 1 minute and then centrifuged for 5 min 
at 4000 rpm. The supernatants (200 µL) were loaded on an Bond Elute C18 SPE 
plate (Agilent Technologies Inc., Wilmington, DE, USA), preconditioned with 200 
µL acetonitrile, methanol and water, respectively and a vacuum was then applied. 
The wells were washed with 200 µL water and then 200 µL of 20% methanol water 
solution. FP was eluted from the plate by 300 µL of 90% acetonitrile water solution 
and evaporated to dryness under nitrogen flow. The extracts were reconstituted with 
125 µL of 40% acetonitrile water solution prior analysis by LC-MS/MS. 
   LC-MS/MS conditions. Separation was carried out on a Kinetex C18, 2.6 µm, 
50×2.1 mm column (Phenomenex, CA, USA) at 45 °C, connected to a LC-20 AD 
binary pump (Shimadzu Scientific Instruments, MD, USA) delivering a flow rate of 
0.4 mL/min. Mobile phases A and B consisted of 0.02% ammonium hydroxide in 
water and 50% acetonitrile in methanol, respectively. Gradient elution was applied 
using a linear gradient of 35-95% mobile phase B from 0.2 to 1.5 minutes, held at 
95% for 1 minute and returned to initial conditions in one step. Sample storage and 
injection was performed by a CTC PAL HTC-xt autosampler (CTC Analytics, 
Zwingen, Switzerland) keeping the samples conditioned at 12 °C. The mass 
spectrometric detection was carried out by a Sciex API 5000 triple quadrupole 
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(Applied Biosystems, MDS Sciex, Toronto, Canada) operating under positive ESI in 
SRM mode. The m/z transition for FP was 501.2 > 293.2. Instrument control, data 
acquisition and data evaluation were performed using Analyst 1.6.  
 
4.3.3.2 Analytical procedures for budesonide 
Sample preparation. A liquid liquid extraction (LLE) procedure was used for 
preparation of budesonide plasma samples. Briefly, aliquots of 50 µL plasma 
samples were pipetted to glass tubes placed in a 96-well plate followed by addition 
of 50 µL carbonate buffer, pH 10. Methyl-tertbutyl ether (MTBE, 600 µL) was 
added to create a two phase condition. The plate was sealed and shaken for 20 
minutes and then centrifuged for 5 min at 2000 rpm. The upper organic layer (550 
µL) was transferred to a new set of glass tubes and evaporated to dryness under 
streaming nitrogen. The extracts were reconstituted with 150 µL of 50% acetonitrile 
water solution prior analysis by LC-MS/MS. 
   LC-MS/MS conditions. Separation was carried out on a Kinetex C18, 2.6 µm, 
50×2.1 mm column (Phenomenex, CA, USA) at 45 °C, connected to a LC-20 AD 
binary pump (Shimadzu Scientific Instruments, MD, USA) delivering a flow rate of 
0.5 mL/min. Mobile phases A and B consisted of 10 mM ammunium acetate/0.2% 
acetic acid and methanol/0.2% acetic acid, respectively. Gradient elution was applied 
using a linear gradient of 45-97% mobile phase B from 0.1 to 1.0 minutes, held at 
97% for 0.7 minute and returned to initial conditions in 0.3 min. Sample storage and 
injection (10 µL) was performed by a CTC PAL HTC-xt autosampler (CTC 
Analytics, Zwingen, Switzerland) keeping the samples conditioned at 12°C. The 
mass spectrometric detection was carried out by a Sciex API 5000 triple quadrupole 
(Applied Biosystems, MDS Sciex, Toronto, Canada) operating under negative ESI in 
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SRM mode. The m/z transition for the acetate adduct of budesonide was 489.4 > 
357.2. Instrument control, data acquisition and data evaluation were performed using 
Analyst 1.6. 
 
4.3.4 Modelling of plasma pharmacokinetics 
All plasma samples were above the LLOQ except for the samples collected at the last 
time point in the budesonide PK-study (t = 24 h). The LLOQ for budesonide and FP 
were 0.1 nM and 0.04 nM, respectively. 
   A 3-compartment model with a multiplicative error model was used to describe the 
plasma PK after IV-administration of FP (90 nmol/kg, n = 2) and budesonide (167 
nmol/kg, n = 3). This model has been proven to be structurally identifiable [94]. An 
additive error model was also tested. A naïve-pooled data approach was used, i.e. the 
observations were treated as if they came from one individual. The models were 
implemented in Phoenix™ WinNonlin® 6.3.0 (Pharsight, Sunnyvale, CA), which 
minimised the exact negative log-likelihood using a quasi-Newton algorithm. The 
compartmental model equations describing the process were given by 
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The model is graphically illustrated by figure 4.2. The plasma profiles and the model 
fits are shown in figure 4.3a-b and the estimated PK-parameters are presented in 
table 4.1. The correlation matrices for the parameter estimates are presented in tables 
4.2 and 4.3 for FP and budesonide, respectively. Plots of weighted residuals resulting 
from using either multiplicative or additive error models are shown in fig. 4.4a-d. As 
can be seen in fig. 4.4a, the weighted residuals were randomly distributed around 
zero when a multiplicative error model was used for FP. A small trend was noted in 
the residuals at two time points for budesonide when a multiplicative error model 
was used (fig. 4.4c). However, they were judged to provide a sufficiently good 
description of the data.  In contrast, the weighted residuals systematically increased 
with increasing values of the predicted plasma concentration when an additive error 
model was used (fig. 4.4b and 4.4d). Expressed differently, a fan-shaped pattern 
appeared in the residual plot, which indicated that an additive error model was 
inappropriate to use for both data sets.   
 
Table 4.1 Estimated pharmacokinetic parameters for fluticasone propionate (FP) and budesonide 
(mean ± SE) 
Parameter  FP Budesonide 
V1 (L/kg) 0.63 ± 0.16 0.49 ± 0.13 
V2 (L/kg) 9.0 ± 3.5 1.3 ± 0.78  
V3 (L/kg) 2.8 ± 1.0 0.44 ± 0.10  
CL1 (L/h/kg) 11 ± 1.0 3.0 ± 0.19  
CL2 (L/h/kg) 2.1 ± 0.63 0.15 ± 0.035 
CL3 (L/h/kg) 5.8 ±1.6 4.3 ± 1.8  
Abbreviations: V1=volume of distribution in the central compartment; V2=volume of distribution in the slowly 
equilibrating compartment; V3=volume of distribution in the rapidly equilibrating compartment; CL1=clearance; 
CL2=slow distribution clearance; CL3=rapid distribution clearance 
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Figure 4.2 Graphical illustration of a 3-compartment model. 
 
 
Figure 4.3 Plasma concentration (Cp) after intravenous (IV) administration of a) fluticasone 
propionate to rats (90 nmol/kg, n = 2), and b) Cp after IV-administration of budesonide to rats (167 
nmol/kg, n = 3). Observed data are indicated by circles and the model fit by a solid line. 
 
Table 4.2 Estimated correlation matrix for the parameters obtained from modelling of the 
pharmacokinetics of fluticasone propionate. 
 
V1 V2 V3 CL CL2 CL3 
V1 1 0.41 0.55 0.82 0.45 0.71 
V2 0.41 1 0.57 0.23 0.036 0.52 
V3 0.55 0.57 1 0.35 -0.28 0.80 
CL 0.82 0.23 0.35 1 0.62 0.62 
CL2 0.45 0.036 -0.28 0.62 1 0.13 
CL3 0.71 0.52 0.80 0.62 0.13 1 
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Table 4.3 Estimated correlation matrix for the parameters obtained from modelling of the 
pharmacokinetics of budesonide. 
 
V1 V2 V3 CL CL2 CL3 
V1 1 0.11 -0.75 0.50 0.27 -0.63 
V2 0.11 1 0.038 0.053 0.89 -0.06 
V3 -0.75 0.038 1 0.061 0.043 0.72 
CL 0.50 0.05 0.061 1 0.39 -0.19 
CL2 0.27 0.89 0.043 0.39 1 -0.12 
CL3 -0.63 -0.06 0.72 -0.19 -0.12 1 
 
 
Figure 4.4 Weighted residuals plotted against the predicted plasma concentration using different error 
models: a) multiplicative error model, fluticasone propionate (FP), b) additive error model, FP, c) 
multiplicative error model, budesonide, and d) additive error model, budesonide. 
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4.4 Modelling of binding kinetics 
4.4.1 Characterisation of binding kinetics  
As described in section 4.3.4, a 3-compartment model with a multiplicative error 
model was used to describe the plasma PK after IV-administration of FP (90 
nmol/kg) and budesonide (167 nmol/kg). The compartmental model equations were 
given by eqs. 4.3-4.5 and the estimated PK-parameters were presented in table 4.1. 
The unbound drug concentration in plasma (Cu) was calculated from eq. 4.6, where fu 
is the fraction unbound in plasma and C1 is the drug concentration in the central 
compartment given below: 
 
)()( 1 tCftC uu  .    (4.6) 
 
The receptor density (Bmax) in the spleen has previously been measured and found to 
be 31.5 nM [138]. The concentration of the receptor-drug complex (RD) could 
therefore be calculated from the spleen GR occupancy data, which were favoured for 
modelling purposes as this organ had a higher ratio of total-to-nonspecific tracer 
binding and thus allowed for more accurate occupancy estimations [126].  
   For both compounds a high initial occupancy was observed after IV-
administration, which then returned to baseline within 7 and 4 h after dosing for FP 
and budesonide, respectively. The estimated occupancy at 24 h after dosing of FP 
was higher than after 7 h, which, most likely, is not reflective of the drug-receptor 
interaction. Rather, the observation may reflect the dynamics of the glucocorticoid 
receptor with a drug-induced downregulation of the receptor population, which has 
been demonstrated to take place after administration of GR agonists both in vitro and 
in vivo [137]. Receptor occupancy data from 0 < t ≤ 7 and 0 < t ≤ 4 h were therefore 
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used for parameter estimation for FP and budesonide, respectively. Within these two 
time intervals, two receptor occupancy observations had been calculated as negative 
(-4.0 and -5.3%). Negative receptor occupancy is not possible from a theoretical 
point of view; however, since the maximum tracer concentration is obtained from a 
separate group of animals, interindividual variability can explain why these two 
estimates were slightly lower than 0%. As the receptor occupancy cannot be lower 
than 0%, these two values were set to zero in the modelling data set. 
   The binding kinetics was described accordingly: 
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where Kd is the dissociation constant, Kon is the association rate constant and Koff is 
the dissociation rate constant. As opposed to the PK model, an additive error model 
was used for the binding kinetics. 
   Both the PK- and the binding kinetics models were implemented in Phoenix™ 
WinNonlin® 6.3.0 (Pharsight, Sunnyvale, CA). “The Naïve pooled engine” was 
used, i.e. the observations were treated as if they came from one individual. This 
engine minimises the exact negative log-likelihood by using a quasi-Newton 
algorithm. The default ODE-solver was used for the PK-model (matrix exponential). 
A stiff ODE-solver was used for the binding kinetics model. The estimated binding 
kinetics parameters are presented in table 4.4. The observations and the 
corresponding model fit are shown in figure 4.5a and 4.5b for FP and budesonide, 
respectively.  
120 
 
   The estimated correlation matrices for FP and budesonide are presented in table 4.5 
and 4.6, respectively. A negative correlation between Koff and Kd was found (-0.76 
and -0.74 for FP and budesonide, respectively). The optimisation was restarted 
several times with different sets of initial estimates to check whether it converged to 
the same estimates. The optimisation algorithm was found to converge to same 
solution when a broad range of initial estimates were used. 
   An exhaustive search was subsequently performed in MATLAB to ensure that the 
global minimum had been found within the expected parameter space. The sum of 
squares was evaluated at 360000 combinations of parameter values. For FP, Kon 
varied between 1 and 100 L/nmol/h and Koff varied between 0.05 and 5 h
-1. For 
budesonide, Kon varied between 0.1 and 100 L/nmol/h and Koff varied between 0.05 
and 10 h-1. The parameter values were selected from a logarithmic scale to ensure 
that the search was not biased to the large regions. 
   In the exhaustive search for FP, the lowest cost function was found at 33.8 
L/nmol/h and 0.510 h-1 for Kon and Koff, respectively. For budesonide, the lowest cost 
function was found at 1.13 L/nmol/h and 1.31 h-1 for Kon and Koff, respectively. 
Hence, the exhaustive search showed that the global minimum had been found for 
both compounds within the defined parameter space. The two exhaustive searches 
are graphically illustrated in figures 4.6a and 4.6b. 
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Figure 4.5 Concentration of receptor-drug complex in the spleen (RDspleen) after intravenous (IV) 
administration of a) fluticasone propionate (90 nmol/kg, n = 3/time point) and b) budesonide (167 
nmol/kg, n = 3/time point). Observed data are indicated by circles and the model fit by a solid line. 
 
Figure 4.6 An exhaustive search was performed for a) fluticasone propionate, and b) budesonide by 
evaluating the cost function (the sum of squares) at 360000 different combinations of parameter 
values. These two exhaustive searches confirmed that the global minimum had been found within the 
expected parameter space. 
 
Table 4.4 Estimated binding kinetics parameters for fluticasone propionate (FP) and budesonide 
(mean ± SE) 
Parameter  FP Budesonide 
Kd (nM) 0.015 ± 0.0045 1.2 ± 0.34 
Koff (h
-1) 0.51 ± 0.17 1.3 ± 0.39 
Kon (L/nmol/h) 34 ± 20 1.12 ± 0.62 
Abbreviations: Kd = dissociation constant; Koff = dissociation rate constant; Kon = association rate constant 
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Table 4.5 Estimated correlation matrix for the parameters estimates obtained from modelling of the 
binding kinetics of fluticasone propionate. 
  Kd Koff 
Kd 1 -0.76 
Koff -0.76 1 
 
Table 4.6 Estimated correlation matrix for the parameters estimates obtained from modelling of the 
binding kinetics of budesonide. 
  Kd Koff 
Kd 1 -0.74 
Koff -0.74 1 
 
4.4.2 Sensitivity analysis 
A sensitivity analysis was performed by considering the partial derivatives of the 
output RD with respect to each estimated binding kinetics parameter pi. That is, each 
partial derivative was evaluated at the final parameter estimate. Phoenix™ 
WinNonlin® 6.3.0 computed a numerical approximation of the partial derivatives 
accordingly 
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where pi is Kd or Koff (Kon was a secondary parameter) and Δ is the increment 
multiplied by the final parameter estimate (Δ = 0.00001). That is, all other 
parameters but pi were kept at their nominal values in the calculations. 
   The plots showing ∂RD/∂Kd over time (figs. 4.7a and 4.7c for FP and budesonide, 
respectively) indicate that small changes in Kd would have a profound effect on RD 
directly after IV-dosing, i.e. this is an effect that coincides with the peak in the drug 
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plasma concentration. This was especially pronounced for FP. In general, with the 
exception of a small bump, this parameter became less influential over time. Hence, 
the sensitivity analysis shows that observations made at early time points had the 
largest influence on the estimation of Kd. From a mathematical point of view, if the 
studies were to be repeated they would benefit from a sampling scheme with more 
frequent sampling at early time points, given that the purpose was to obtain a good 
estimate of Kd. Nevertheless, in general the sampling scheme used was informative 
with respect to Kd. However, at the last time point included in the modelling data set 
of budesonide (t = 4 h), the analysis showed that Kd only had a minor effect on the 
output RD. 
   Figures 4.7b and 4.7d show the ∂RD/∂Koff over time for FP and budesonide, 
respectively. Again, the analysis shows that the output RD was sensitive to small 
changes in the investigated parameter (Koff) directly after dosing. ∂RD/∂Koff had the 
same behaviour for both compounds and it changed sign from positive to negative 
over the investigated time course. For FP, RD was very sensitive to changes in Koff at 
approximately t = 3 h, whereas the output would have been less sensitive to changes 
in the parameter at later time points. For budesonide, the corresponding nadir 
occurred at approximately t = 1.8 h. 
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Figure 4.7 Sensitivity analysis was performed by considering the partial derivatives of the output RD 
with respect to the estimated binding kinetics parameters Kd and Koff. This was done for both the study 
comprising fluticasone propionate (FP) and budesonide. 
 
4.5 Receptor occupancy studies after nose-only exposure 
The time course of receptor occupancy after nose-only exposure was studied for FP. 
The experimental details as well as the results are included in this subsection. 
 
4.5.1 Nose-only exposure studies 
In the inhalation studies, the rats were nose-only exposed to dry powder of FP. In 
nose-only exposure studies, each rat is restrained in a separate tube that is open at 
one end to a chamber containing aerosolised compound [145]. The inhalation system 
was controlled and operated by Anders Wigenborg, AstraZeneca R&D Gothenburg. 
Otherwise, the author (Elin Boger) was responsible for designing, coordinating, 
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performing as well as analysing the studies. The bioanalysis with respect to FP in the 
plasma samples was done by Dr. Anders Lundqvist. Three additional researchers 
from AstraZeneca R&D assisted the author in the in vivo parts of the studies: Dr 
Markus Fridén, Dr Britt-Marie Fihn and Susanne Arlbrandt. The subsection 
describing the inhalation system is written in collaboration with Anders Wigenborg.  
   Animals. Male Wistar Han rats (Harlan, Horst, the Netherlands) weighing 250 to 
375 g were used for the inhalation studies. The animals were group-housed at 18-
22ºC under a 12:12 h light/dark cycle with free access to food and water for at least 
five days prior to the experiments.  The studies were approved by the Animals Ethics 
Committee of Gothenburg (71-2013). 
   Study protocol. The time course of receptor occupancy was studied after nose-
only exposure of FP. The inhalation study was performed twice using the same 
experimental setup. The two studies are henceforth referred to as study 1 and study 2. 
   The following precautions were taken to reduce the stress for the animals: 1) all 
animals were accustomed to nose-only exposure, including the restrainer tubes, prior 
to the study, 2) they were accustomed to human contact prior to the study, 3) the 
animals were weighed the day before the study, and 4) they were carefully moved to 
the laboratory several hours before the start of the study. 
   The GR occupancy after nose-only exposure was investigated over 48 hours (t = 1, 
2, 4, 7, 24 and 48 h, n = 3 and n = 4 per time point in study 1 and 2, respectively) 
with additional PK-measurements at earlier time points (t = 45 and 75 min, n = 2 per 
time point). The maximum tracer concentration was obtained from drug-naïve 
control animals and the nonspecific tracer concentration from animals that had been 
pre-treated intravenously with dexamethasone (n = 6, 20 mg/kg) 30 min prior to 
tracer administration. The drug-naïve control animals from the two studies were 
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pooled (n = 14). In conjunction with euthanization, a terminal blood sample was 
taken from the abdominal aorta and organs (lung and spleen) were collected for 
quantification of the GR-tracer and drug concentrations. 
   Details concerning receptor occupancy calculations, the inhalation system, dose 
estimation and bioanalytical procedures are described under their respective 
headings. 
   Calculation of receptor occupancy and propagation of error. Receptor 
occupancy was calculated by the ratio method (eq. 4.10) [130,131,132,133] which 
includes three different measurements: 1) the tissue tracer concentration obtained 
from treated animals (T), 2) the nonspecific tracer concentration obtained from 
animals pre-treated with a high IV-dose of dexamethasone (N), and 3) the maximum 
tracer concentration obtained from drug-naïve control animals (C). Propagation of 
error was used to account for the effect of the uncertainty of each experimental 
measurement on the calculated receptor occupancy, i.e. 
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By inserting eqs. 4.11 and 4.12 into 4.10, the function can be simplified accordingly 
to yield: 
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The simplified equation is used for calculation of partial derivatives with respect to 
each measurement (eqs. 4.15-4.17), which then can be inserted into the formula for 
propagation of error assuming independent variables (eq. 4.14), so that 
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   Inhalation system. FP was formulated as a micronized dry powder and was 
compressed to a pellet, from which a dry particle aerosol could subsequently be 
produced using a Wright Dust Feeder mechanism (L. Adams Ltd, London, UK). 
   The inhalation system used for nose-only exposure studies can be considered to 
consist of two basic parts: an airflow and a dosing tower with a dry powder 
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generator. The airflow can further be described as two separate flows: 1) an airflow 
into the dosing tower, through the generator, and 2) a flow out of the dosing system. 
   The incoming air is mixed with the dry powder in a generator prior to entering into 
the tower, and therefore acts as both a carrier for the active compound and provides 
fresh air for the animals to breathe. The outflow of air/compound runs through the 
animal breathing ports and the bottom of the tower, where the excess is extracted. 
The driving force for this is provided by a vacuum with a slightly lower flow than the 
incoming air. 
   The dosing tower usually consists of two concentric cylinders. The outer cylinder 
is in direct contact with the animals through the dosing openings, communicating 
with the inner cylinder that serves as a container for compound/air mixture. Since the 
flow of air into the tower and the amount of substance generated is known, the 
concentration in the inner cylinder of the tower can be calculated. The concentration 
of delivered compound is measured online while dosing, using an aerosol monitor 
(Casella Microdust-Pro-Aerosol-Monitoring, Bedford, UK) connected to a computer 
with a software specifically developed for controlling inhalation dosing (MIVIS, 
developed by Flexura AB, Sweden). MIVIS is one of the systems used to regulate 
the dosing rate. This also means that the rate of the generation of powder and/or the 
duration of dosing can be changed during the study if deemed necessary. 
   Some losses occur due to coating of the internal walls of the tower and for particles 
with high kinetic energy, by impacting with the base of the tower. In either case, 
these particles will not be inhaled by the animals. The actual concentration of the 
compound in the aerosol and an estimate of the amount delivered to each animal can 
be calculated by sampling at one of the animal ports. Air/compound is extracted to a 
filter at a pre-defined flow during the time of dosing using a vacuum and the 
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compound is collected onto a filter for later analysis. This procedure ensures that the 
amount of drug on the filter reflects the concentration of compound exposed to the 
animals. The equations used for estimating the lung deposited dose are provided in 
the next section. 
   Estimation of the lung deposited dose. A filter was included in the Wright Dust 
Feeder during dosing to enable estimation of LDD for each study according to eq. 
4.18. A detailed description is provided in . The LDD is determined by: 
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where RMV is the respiratory minute volume (eq. 4.19), BW is the mean body weight 
(0.344 and 0.270 kg in FP study 1 and FP study 2, respectively), D is the duration of 
exposure (7.25 and 8.64 min in FP study 1 and 2, respectively), DF is the deposition 
factor (eq. 4.20) and CC is the chamber concentration of drug (eq. 4.21), where 
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where fi is the mass fraction of particles of size class i where i ∈ {1, …, 8}, fp,i and fc,i 
are the fractions of peripheral and central deposition for particles of size class i 
130 
 
extracted from [65] (aerodynamic diameter considered), mfilter is the amount of drug 
on the filter and fr is the filter flow rate (0.25 L/min).  
   The particle size distribution was determined using a 7-stage Mercer cascade 
impactor (model 02 110, In-tox Products, USA). In short, a cascade impactor has 
several impactors with decreasing cut-off sizes in series. As each stage has its own 
removable collection plate, the amount of compound collected at each stage can 
subsequently be determined either by gravimetric analysis or by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) analysis. The impactor 
used in these studies provided a discrete particle size distribution with eight different 
particle sizes. LC-MS/MS analysis was employed for quantifying the amount of 
compound collected at each stage and the same analytical method was also used for 
quantification of mfilter. Analytical details are provided in section 3.2.1.10 and the 
sample handling is described in section 4.5.2. The particle size distribution is 
presented in table 4.7. Using this particle size distribution and eq. 5.6, the lung 
deposition fraction was calculated to be 10.3%, which is close to the deposition 
fraction used by the FDA for rat inhalation studies (10%) [84]. 
   The LDD was estimated to be 12.8 and 9.75 nmol/kg in study 1 and 2, respectively. 
Since identical experimental procedures were applied and the drug concentrations in 
lung and plasma were indistinguishable between the two studies (figs. 4.8a and 4.8b), 
it was reasoned that the same LDD had been delivered. The average value of the two 
estimated LDD values was therefore used (11.3 nmol/kg), which was judged to be a 
reasonable estimate of LDD given the average amount of drug recovered in the lungs 
collected at the earliest time points (6.5 ± 1.8 nmol/kg for 45 ≤ t ≤ 75 min). 
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Figure 4.8 a) Total lung concentrations (Clung) and b) plasma concentrations (Cp) after inhalation of 
fluticasone propionate (FP) in study 1 (white circles) and study 2 (black circles). 
 
4.5.2 Analytical procedures 
The analytical procedures used for quantifying FP and the GR-tracer in lung 
homogenates, spleen homogenates and plasma have been described in detail 
previously in section 3.2.1.10. The analytical procedures used for quantifying FP in 
plasma was described in section 4.3.3.1. 
   Sample preparation and analytical procedures connected to the filter analysis. 
To enable estimation of the LDD, the amount of drug collected by a filter (mfilter) 
during the inhalation period needed to be quantified. The filter was placed in a jar of 
appropriate size immediately after inhalation. On the day of analysis, ethanol (4 mL) 
was added to the filter and the jar was placed in an ultrasonic bath (5210 Branson; 
Gemini, Apeldoorn, The Netherlands) for 20 minutes. Dimethyl sulfoxide (4 mL) 
was then added to the sample to ensure that all of the substance was dissolved. A 
certain volume of the resulting solution (1 mL) was filtered through 0.2 µm 
Acrodisc® syringe filter (Pall Corporation, Ann Arbor, Mich.) to remove filter 
particles prior to further treatment. The filtered solution was diluted by a factor of 35 
by transferring a predetermined volume (20 µL) to a vial containing 40% acetonitrile 
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and 0.2% formic acid in water (680 µL). The resulting solution was added in 
triplicate to a NUNC 96-deep well plate (Nalge Nunc International, Rochester, NY). 
The samples were then injected (20 µL) to a high-performance liquid 
chromatography system, a detailed description of the bioanalysis is provided in 
section 3.2.1.10.  
   Except for the filtering step, the same sample handling procedure was applied to 
the samples collected from the 7-stage Mercer cascade impactor. The impactor 
samples were diluted by a factor of 15 by transferring a predetermined volume (50 
µL) to a vial containing 40% acetonitrile and 0.2% formic acid in water (700 µL). 
The amount of drug collected at each stage and the corresponding mass fraction were 
subsequently calculated. The result is presented in table 4.7 below: 
 
Table 4.7 Characterisation of particle size distribution of fluticasone propionate. The table shows the 
amount of drug and the corresponding mass fraction collected at each stage by a 7-stage Mercer 
cascade impactor. 
Stage 
 
Geometric 
midpoint 
(µm) 
Amount 
(µg) 
Mass 
fraction 
1 6.0 3.63 0.17 
2 3.9 6.29 0.30 
3 2.4 5.45 0.26 
4 1.5 3.68 0.18 
5 0.92 1.53 0.073 
6 0.59 0.190 0.0091 
7 0.39 0.0678 0.0032 
8 0.20 0.0729 0.0035 
   
 
  
Total  20.9 1  
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4.5.3 Results 
As can be seen in fig. 4.9, the ROlung was generally slightly higher than ROspleen after 
nose-only exposure of FP. The highest receptor occupancy observation was not made 
at the first time point, but the measured occupancy peak occurred at t = 4 h. The 
receptor occupancy had returned to 0% at t = 48 h. 
   The drug concentration was quantified in plasma, lung homogenates and spleen 
homogenates from the inhalation studies. The drug concentration-time profiles are 
shown individually for each of the biological matrices in fig. 4.10a-c. All three 
profiles are shown in fig. 4.10d. All samples collected at t = 24 and 48 h were below 
the LLOQ. Furthermore, all spleen homogenates samples from t = 8 h were below 
the LLOQ.  
    
 
Figure 4.9 Glucocorticoid receptor (GR) occupancy in the lung (blue circles) and the spleen (red 
circles) after nose-only exposure of fluticasone propionate, n = 7 per time point, lung deposited dose = 
11.3 nmol/kg. 
134 
 
 
Figure 4.10 Drug concentration profiles after nose-only exposure after nose-only exposure of 
fluticasone propionate (FP). Drug concentrations were quantified in lung homogenates (Clung, blue 
circles), spleen homogenates (Cspleen, red circles) and blood plasma (Cp, green circles). The lung 
deposited dose was 11.3 nmol/kg. Destructive sampling was applied, i.e. the animals were sacrificed 
in conjunction with the sampling. 
 
4.6 Discussion 
The studies aimed at characterising the receptor occupancy following IV-dosing of 
FP and budesonide were found to give results similar to those previously reported 
after IV-administration of another corticosteroid (triamcinolone acetonide) [120]: a 
high initial receptor occupancy, which then returned to baseline within 4-7 hours 
after dosing (4, 4 and 7 h for triamcinolone acetonide, budesonide and FP, 
respectively). As with triamcinolone acetonide, these results would not have been 
expected based on the binding kinetics parameters previously reported from in vitro 
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experiments with dissociation half-lives of 21 h [143], 10 h [80] and 4.6 h [146] for 
triamcinolone acetonide, FP and budesonide, respectively. These results, combined 
with earlier research [120], thus suggest a disconnection between the in vitro system 
used for studying binding kinetics and the in vivo situation. However, the cited in 
vitro experiments were conducted at temperatures that were low relative to the 
rodent’s body temperature, which could explain the deviation between the in vitro 
and the in vivo situation.  
   As pointed out in section 4.4.1, the estimated receptor occupancy 24 hours after 
IV-dosing of FP was higher than after 7 hours, which is most likely not reflective of 
the drug-receptor interaction. Rather, the observation may reflect the dynamics of the 
GR with a drug-induced down-regulation of the receptor population, which has been 
demonstrated to take place after GR agonist exposure both in vitro and in vivo [137]. 
Furthermore, observations from earlier time points revealed that the receptor 
occupancy had returned to baseline within 7 hours after the IV-injection. The 
observations made at 24 and 48 h after dosing were therefore not included in the data 
set for parameter estimation. Similarly, since receptor occupancy had returned to 
baseline within 4 hours after dosing of budesonide, observations made at t > 4 h were 
not judged to provide any information on the binding kinetics and were thus not used 
for parameter estimation purposes. 
   Based on the receptor occupancy profiles obtained from the IV-studies, it can be 
concluded that the chosen doses were sufficiently high to significantly perturb the 
system and thus enable receptor occupancy measurements over several hours. Hence, 
mathematical modelling could subsequently be applied to estimate the in vivo 
binding kinetics parameters (Kon and Koff), where an exhaustive search confirmed that 
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the minimum had been found by the optimisation algorithm (within the expected 
parameter space as defined in section 4.4.1).  
   The PK-data from the nose-only exposure studies (fig. 4.10) followed a pattern 
expected from a poorly soluble inhaled drug: a large amount of drug remained in the 
lung over several hours after inhalation whereas only low drug levels could be 
detected in plasma. Furthermore, the plasma profile was flat as compared to the 
corresponding profile resulting from IV-dosing, which indicates a slow absorption of 
drug to the systemic circulation. This PK-behaviour can thus potentially be explained 
by a dissolution rate-limited absorption. 
   The measured receptor occupancy peak occurred at t = 4 h, which possibly, at least 
partly, could be explained by a slow dissolution process. The receptor occupancy 
was generally slightly higher in the lung than in the reference organ for systemic 
exposure (the spleen) after nose-only exposure (fig. 4.9). It is worth noting that the 
low degree of lung-selectivity reflected by receptor occupancy measurements was 
consistent with data from a preclinical PD-model, in which the local and systemic 
effects are studied after nose-only exposure of GR modulators. In short, as described 
by Källström et al. [147] this PD-model relies on inducing pulmonary inflammation 
by Sephadex, which will be reflected by an increased lung weight. The local effect of 
the test compound is subsequently determined by lung weight changes, whereas the 
systemic effect is determined by quantifying thymic involution. Interestingly, FP was 
found to have a therapeutic ratio of approximately 1 in this PD-model [148].  
   In chapter 5, the estimates of Kon and Koff will be incorporated into a mechanistic in 
silico model developed for predicting the systemic PK, the local tissue 
concentrations as well as the resulting receptor occupancy after inhalation. In 
contrast to traditional PK/PD-models, this model will not rely on a top-down 
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approach where an appropriate model structure (empirical or mechanistic) is chosen 
and the included parameters are optimised to minimise an objective function (e.g. the 
deviation between predicted and observed data as described by the sum of squares). 
Instead, the model structure will be based on the current understanding of pulmonary 
drug disposition as well as on the rodent physiology and the input parameters will be 
obtained from experimental data and literature sources. By subsequently comparing 
model predictions from this systems model to observed data, the current 
understanding of the system can be evaluated. For the first time, receptor occupancy 
observations from an inhalation study will be used for validating predictions of the 
local, and not only the systemic, exposure following topical administration. Any 
discrepancy can be informative with respect to the existing knowledge of underlying 
mechanisms and assumptions. If proven to be predictive, the model can be used to 
e.g. generate hypotheses, explore scenarios that currently cannot be tested 
experimentally and to provide a framework for a facilitated translation from animal 
to human. 
 
4.7 Summary 
This chapter presented a sequence of research activities undertaken for characterising 
the in vivo binding kinetics of the two GR agonists FP and budesonide. The two 
drugs were given at sufficiently high IV-doses to perturb the system such that 
receptor occupancy could be monitored over several hours (fig. 4.5a-b). For the first 
time, the binding kinetics parameters for these two substances could be estimated 
based on in vivo data. Parameter estimation was performed in Phoenix™. An 
exhaustive search algorithm implemented in MATLAB subsequently confirmed that 
the minimum objective function had been found by the optimisation algorithm 
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(within the expected parameter space). The receptor occupancy and the PK were 
studied after nose-only exposure of FP (11.3 nmol/kg, LDD). The PK-data showed 
high levels of unabsorbed drug in the lung following inhalation with low resulting 
plasma levels. The receptor occupancy was generally slightly higher in the lung than 
in the reference organ for systemic exposure (the spleen) and the data suggested a 
late occupancy peak at approximately 4 h after dosing. 
   The estimates of the binding kinetics parameters Kon and Koff will be used as drug-
specific input parameters for a mechanistic in silico model in chapter 5 that was 
developed as part of this thesis. The receptor occupancy measurements as well as the 
PK from the nose-only exposure studies will be used for model validation purposes. 
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Chapter 5 A mechanistic inhalation PBPK model for prediction of 
local and systemic PK and receptor occupancy 
 
5.1 Introduction 
Even though inhalation is an attractive route of administration that has been 
employed for more than 2000 years [1], inhalation pharmacokinetics is still 
recognised as a challenging research area. As discussed in depth in chapters 3 and 4, 
the challenges are partly related to the difficulties of getting relevant exposure 
measurements. Furthermore, pulmonary drug disposition of inhaled drugs is known 
to be a complex interplay between numerous processes including e.g. regional drug 
deposition, particle dissolution and mucociliary clearance (MCC). Additional 
complexity comes from the heterogeneous nature of the organ with distinct 
differences between the tracheobronchial and the alveolar regions [11]. Lung 
targeting by inhalation in terms of the free target site concentration and the resulting 
local receptor occupancy is therefore notoriously difficult to predict.  
   While some of the aforementioned processes have been thoroughly characterised 
on an individual basis, a step-change in the understanding of inhalation 
pharmacokinetics could be gained if we also understood the interplay between these 
different processes in a physiological context. Significant progress towards achieving 
this goal can be made by developing a physiologically-based pharmacokinetic 
(PBPK) model, which places emphasis on lung disposition for inhaled drugs by 
mathematically describing these fundamental processes. However, such a 
mechanistic model predictive of local tissue concentrations combined with 
measurements such as receptor occupancy for validation is currently lacking. The 
recently generated data on local and systemic receptor occupancy after inhalation of 
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fluticasone propionate (FP) in combination with the estimates of its binding kinetics 
parameters (Kon and Koff) thus provide an opportunity to validate such predictions. 
Furthermore, data on drug concentrations in different biological matrices will also be 
available for model validation.  
   Expressed differently, a new mathematical framework can be built by formulating 
mathematical descriptions of the system based on the current understanding of 
pulmonary drug disposition and rodent physiology. Once the model structure is in 
place, it can be evaluated by using drug- and formulation-specific parameters, 
obtained from experimental data or literature sources, as input parameters. In this 
context, it is worth mentioning that the approach used to evaluate this model type, 
i.e. a systems model, is different from the approach used to evaluate standard 
PK/PD-models. Since systems models are built based on the current understanding of 
a system, any discrepancy between model predictions and observations can be 
informative with respect to the existing knowledge of underlying mechanisms and 
assumptions [149]. That is, a discrepancy may for example be due to a mechanism 
that is unaccounted for by the model structure or not fully understood.  
   If the model is proven to be predictive, it can be used to generate hypotheses and 
explore scenarios that have not been tested experimentally. Another useful feature of 
PBPK models is that they can separate physiological system- from drug-
/formulation-specific properties, which carries several advantages including the 
possibility to explore how different drug- and formulation-specific properties, or 
combinations thereof, relate to important endpoints such as the lung-selectivity of a 
drug treatment. Such information could for instance be used to guide: 1) the design 
of chemical series in the early phases of drug discovery, and 2) the choice of drug 
formulations for clinical trials. 
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   This chapter will describe the development of a mechanistic rat PBPK model 
including lung disposition, in which knowledge of the system (physiology) is 
integrated with drug- and formulation-specific properties. The developed model is 
subsequently used to theoretically explore different aspects of pulmonary drug 
disposition after single as well as repeated inhaled dosing. 
 
5.2 Development of a PBPK model including lung disposition 
5.2.1 Model structure 
5.2.1.1 Structural model  
A mechanistic PBPK model including lung disposition was developed and 
implemented in MATLAB R2013a (Mathworks Inc., Natick, MA, USA). Within 
PBPK modelling, tissues with similar properties are commonly lumped together to 
reduce the complexity of the model [109]. Focus is instead put on organs that are 
judged as important for the processes which are being studied in the particular 
model. Thus, for inhalation purposes the lung, the nose and the gut were included. 
The first two organs were included as inhaled drug particles will deposit both in the 
lung and the nose after nose-only exposure [65,66]. The gut was included to account 
for oral absorption of drug that has been transported to the pharynx by the 
mucociliary clearance and subsequently swallowed to reach the gut [8]. The rationale 
for including the spleen was to enable model validation with regard to both 
measurements of receptor occupancy and tissue concentrations. As perfusion rate is 
an important feature for drug distribution, the remaining tissues were lumped 
together into either richly or poorly perfused tissues. The adipose tissue was 
described separately from the other poorly perfused tissues since it may have a much 
higher partition coefficient for lipophilic compounds. Accordingly, the included 
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organs were as follows: nose, lung, gut, spleen, liver, richly perfused tissues, poorly 
perfused tissues and adipose tissue.  The structural model is illustrated in figure 5.1a. 
Blood flows and volumes of the included tissue compartments are presented in table 
5.5 in section 5.2.2.3.  
 
Figure 5.1 Schematic representation of the developed PBPK model. a) Structural model of the whole-
body PBPK model, and b) compartmental representation of the central lung, peripheral lung and the 
nose: solid drug (Asolid), dissolved drug in the epithelial- or nasal lining fluid (Cfluid), and drug in tissue 
(Ctissue). In the nose and the central lung, solid particles are transported away by mucociliary clearance 
(kmcc). Drug particles are dissolved in the lining fluid (1), once dissolved drug may permeate through 
the epithelial membrane to the tissue (2).  
 
   Due to anatomical and physiological differences the lung was divided into a 
tracheobronchial and alveolar region. One of the main differences between these two 
regions is the blood flow. The alveolar region, in which the gas-exchange takes 
place, is perfused by the entire cardiac output via the pulmonary circulation. The 
lung parenchyma, on the other hand, is perfused by arterial blood via the bronchial 
circulation which constitutes approximately 1-2% of the cardiac output [150]. The 
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thickness of the epithelial lining fluid (ELF) is also known to gradually decrease 
along the lung generations [151], as is the thickness of the epithelium [11]. The latter 
property is expected to give rise to permeability differences across the lung. 
Interestingly, studies by Gerde et al. showed that the highly lipophilic substance BaP 
was rapidly absorbed through the thin alveolar epithelium [152], whereas the 
absorption through the tracheobronchial epithelium was several-fold slower [153]. 
Hence, these studies point towards the importance of treating the lung as a 
heterogeneous organ.  
   Each of the two lung regions was in turn divided into three separate compartments 
(fig. 5.1b). The same compartmental representation was used for the nose: 1) 
undissolved drug (Asolid), 2) dissolved drug in the epithelial or nasal lining fluid 
(Cfluid), and 3) drug in tissue (Ctissue). The tracheobronchial region is perfused by the 
bronchial blood flow (Qbronch), the alveolar region by the entire cardiac output (QCO) 
and the nose by the nasal blood flow (Qnose). The compartmental representation of 
the nose and the two lung regions is shown in figure 5.1b. The system-specific input 
parameters for the nose and lung are summarised in table 5.6 in section 5.2.2.3. Once 
the drug has dissolved (see section 5.2.1.3) it may permeate through the epithelial 
membrane to the tissue according to:  
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where dQ/dt is the molar flow of drug (nmol/h), P is the permeability, Asurf is the 
surface area, fu,fluid is the unbound fraction in the lining fluid, Ci is the tissue 
concentration of drug and Kp,u,i is the tissue-to-unbound plasma partition coefficient. 
A detailed description of the prediction of Kp,u-values as well as the subsequent 
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calculations of Kp-values is provided in section 5.2.2.1. The in vitro apparent 
permeability across CaCo2-monolayers was measured and used as the parameter P 
(tables 5.3 and 5.4 in section 5.2.2.1).  
   Perfusion rate-limited distribution was assumed to apply for all tissues. For 
compartment i, the rate of change of quantity of drug within the organ was described 
as [103] 
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where Vi is the tissue volume, Ci is the drug tissue concentration, Qi is the blood flow 
to the tissue, CA is the arterial drug concentration, R is the blood/plasma ratio and Kp,i 
is the tissue-to-plasma partition coefficient.  
 
5.2.1.2 Particle size distribution, regional deposition and mucociliary clearance  
Inhaled drug particles can be deposited in the extrathoracic, tracheobronchial and 
alveolar region. This model neglects deposition in the pharynx and the larynx, hence 
only nasal deposition is considered in the extrathoracic region. Henceforth, the 
tracheobronchial and alveolar regions are referred to as the central and the peripheral 
lung, respectively. 
   Several models have been developed for prediction of regional particle deposition 
in rat lungs [65,66,69,154]. By extracting the regional deposition fraction for the 
relevant aerodynamic diameters from [65], the number of deposited particles can be 
calculated based on the deposition fraction and the mass fraction of the relevant 
particle size class via: 
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where Nj,i is the number of particles of size i in region j, fi is the mass fraction of 
particles of size i, fj,i is the deposition fraction of particle size i in region j, ID is the 
total inhaled dose and Aj,i(0) is the amount of drug in a particle of size i in region j at 
t = 0 (nmol/particle). The aerodynamic diameters are obtained from the impactor 
measurements. Assuming spherical particles, the geometric diameter (dg) can 
calculated from the aerodynamic diameter (da):  
 

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where ρ is the density of the particle and χ is the dynamic shape factor of the particle 
(χ = 1 for spheres). The initial geometric radii (r1, …, r8), i.e. prior to particle 
dissolution, are presented in tables 5.3 and 5.4 in section 5.2.2.1. Aj,i(t) can 
subsequently be obtained from the geometric radius of particle i in region j (rj,i) and ρ 
(nmol/dm3): 
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Given that the mass fractions of different aerodynamic diameters (f1, …, f8) had been 
measured using an impactor, the fraction of central (fc,1, …, fc,8) and peripheral 
deposition (fp,1, …, fp,8) had been extracted from [65] and the lung deposited dose 
146 
 
(LDD) was obtained from filter analysis (see section 4.5.1), it follows that ID can be 
calculated accordingly: 
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where DF is the total lung deposition fraction. 
   The nasal deposition fractions (fn,1, …, fn,8) had also been extracted from [65]. 
Nj,i(0) could thus be calculated for particle size i in each of the three considered 
regions (eq. 5.3). Due to MCC, Nj,i was described to decline exponentially: 
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 ,,, )0()( ,   (5.9) 
 
where Nj,i(0) is the number of particles of size i in region j at t = 0 (eq. 5.3) and kmcc,j 
is MCC in region j. MCC in the central lung (kmcc,lung) was estimated from [155] as 
described in section 5.2.2.3 and MCC in the nose (kmcc,nasal) was extracted from 
[156]. MCC in the peripheral lung was assumed to be negligible, since it has been 
primarily associated with the tracheobronchial region [74]. Clearance by macrophage 
uptake was not accounted for in this model since it has been reported to be a slow 
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process [41]. However, in case of repeated dosing of compounds with very slow 
dissolution rates, it might be worthwhile considering extending the model by also 
incorporating this process. Consequently, Nj,i in the peripheral region is constant. The 
total amount of solid drug in region j (Asolid,j) for all particle size classes (i ∈ {1, ..., 
8}) is thus as follows: 
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Aj,i(t) can be obtained from 
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Inserting eq. 5.12 in eq. 5.10 gives  
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Drug removed by MCC is transported to the gut, where the bioavailable fraction 
subsequently can be absorbed into the systemic circulation. The ODE governing the 
mass transport by MCC of solid drug particles from the nose and the central lung to 
the gut is given by 
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where the subscripts c and n assign central lung and nose, respectively. Since the oral 
bioavailability (F) determines the degree of absorption from the gastrointestinal (GI) 
tract, only the bioavailable fraction of solid drug particles will be transported to the 
gut absorption compartment (Agut). The ODE governing mass transfer of Agut is thus 
obtained by also accounting for F and the absorption to the systemic circulation. By 
inserting eqs. 5.9 and 5.13, it follows that  
 
 
 
   (5.15)  
       
 
where ka is the absorption rate constant and F is defined as 
 
habsgut fffF  .    (5.16)  
That is, F accounts for the fraction absorbed from the GI-tract (fabs), the fraction that 
escapes gut (fgut) and hepatic extraction (fh) [36]. For both investigated substances, 
fluticasone propionate (FP) and budesonide, fabs and fgut were set to be 1. For 
budesonide, fh was calculated as 
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where EH is the hepatic extraction ratio, CLB is the blood clearance and Qh,tot is the 
total hepatic blood flow, 
gsphtoth QQQQ ,  ,    (5.18) 
 
where Qh is the hepatic blood flow, Qsp is the spleen blood flow and Qg is the gut 
blood flow. Due to the high CLB of FP, fh for FP was set to 0. Clearly, since FP is a 
poorly soluble compound, it can be argued that its fabs most likely is less than 1. 
However, as the high CLB leads to a negligible F (caused by fh = 0), the value of fabs 
will not affect the outcome of the simulations and it was therefore arbitrarily set to 1. 
   Similarly, as F was set to 0 for FP, no absorption will take place from the GI-tract 
and the value of ka is thus irrelevant. Orally administered budesonide has been 
reported to be rapidly absorbed in rats [157], its ka was therefore set to be high (5 h
-1) 
to reflect the rapid absorption process. 
 
5.2.1.3 Dissolution of drug  
Drug particles are dissolved in the ELF or in the nasal lining fluid, which is modelled 
by the Nernst-Brunner equation [158,159]: 
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where h is the thickness of the boundary layer of solvent at the surface of the 
dissolving particle. Empirical evidence suggests that h is of the order of r for 
particles with r < 30 µm, h has therefore previously been set equal to r when r < 30 
µm [160]. Eq. 5.19 can thus be simplified as 
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where dQdiss/dt is the rate of dissolution (nmol/h), D is the diffusion coefficient, Cs is 
the solubility of the drug, Cfluid is the concentration of drug in the ELF or the nasal 
lining fluid and fu,fluid is the unbound fraction in the ELF or the nasal lining fluid.  
   According to [4], the ELF is slightly acidic (pH 6.6) and mainly consists of water 
(96%), salts, phospholipids, protein and mucins. Although there is a dispute about 
the presence of albumin in ELF, it cannot be excluded that the investigated 
compounds are bound to other proteins in the ELF. However, experimental 
methodologies need to be developed in order to experimentally determine fu,fluid. As it 
is currently not possible to do this, fu,fluid was assumed to be 1. The same assumption 
was made in a recently published paper by Gaohua et al. [161], which presented a 
model intended for simulating drug concentrations in the ELF following systemic 
administration of antituberculosis drugs.  
   There are eight different particle sizes in the model, hence the ODE describing the 
change of concentration in Cfluid in region j will be as follows: 
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where the latter term describes the flux of drug to/from the systemic circulation (eq. 
5.1). The function r(t) will change over time accordingly:  
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where ρ is the density of the particle. Calculation of D is described in section 5.2.2.1. 
The derivation of eq. 5.22 is included in the following section (5.2.1.4). 
   Note that the inverse radius term in eq. 5.22 will cause numerical problems for 
small r, as a sufficiently small step size cannot be achieved. To ensure numerical 
stability, the inverse radius is assumed to decay exponentially with regard to r for r ≤ 
ra, (ra = 0.075 µm). The rate of the exponential decay is chosen such that the function 
remains continuous at ra. 
   However, simply switching between these two functions at r = ra can lead to 
numerical instability, since the derivative of this new function is discontinuous at ra. 
This can be solved by adding yet another switching point rb, such that the new 
numerically stable version of the inverse radius switches between three functions: 
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where g(r) is a function which should ensure that f(r) and its first order derivative 
remains continuous. 
   In this thesis, a circular segment is used for g(r), in order to create a smooth 
transition. The radius and position of the circular segment are defined such that the 
continuity conditions just posed hold. In other words g(r) is defined as 
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where y0 and x0 define the centre co-ordinates and s0 the radius of the circle segment. 
Note that the exponential decay factor k0 is chosen together with these to ensure 
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continuity. Setting rb = 0.15 µm provided a sufficiently smooth transition. Therefore 
eq. 5.22 is replaced by the following equation, with f(r) defined by eq. 5.23 and g(r) 
by eq. 5.24: 
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5.2.1.4 Derivation of the change of radius equation  
The radius, r, changes over time as described in eq. 5.22. A step-wise description of 
the derivation of dr/dt is provided in this section. 
   The dissolution process can be described by the Nernst-Brunner equation [158,159] 
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where h is the thickness of the diffusion layer. Empirical evidence suggests that h is 
of the order of r for particles with r < 30 µm. Setting h = r, eq. 5.26 becomes 
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Since the radius r changes during dissolution, the mass balance expression for a 
dissolving particle can be written as follows [162]: 
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Eqs. 5.27 and 5.28 are independent of each other, thus equating eqs. 5.27 and 5.28 
gives 
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dr
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Solving for dr/dt yields 
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5.2.1.5 Receptor binding  
Receptor binding was included in all tissue compartments and was described as  
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where RDi is the concentration of the drug-receptor complex in compartment i, Kon is 
the association rate constant, Bmax,i is the receptor density in compartment i and Koff is 
the dissociation rate constant.  
   Receptor occupancy in compartment i (ROi) can be calculated via: 
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Bmax for the spleen was obtained from [138], Bmax for the lung from section 3.2.2.2 
and Bmax in the other tissue compartments was set to the mean value of Bmax in five 
brain regions [163]. 
   Since the lung has been divided into a central and a peripheral compartment, 
receptor occupancy is predicted for each region individually. The whole-lung can 
also be considered by using a weighted average based on the occupancy for the two 
regions (ROave). The volume fractions of a rat lung consisting of central (fv,c) and 
peripheral lung (fv,p) were estimated to be 0.81 and 0.19, respectively (see section 
5.2.2.3). ROave could therefore be calculated via: 
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Since the experimental methodology cannot discriminate between central and 
peripheral occupancy, ROave corresponds to the observations. 
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5.2.2 Parameterisation 
The input parameters are divided into three categories: 1) drug-specific, 2) 
formulation-specific, and 3) system-specific input parameters. In this section, the 
parameterisation of each of these categories will be described. 
 
5.2.2.1 Drug-specific input parameters 
All drug- and formulation-specific input parameters for budesonide and FP are 
summarised in tables 5.3 and 5.4, respectively. The following sections contain 
information on how the drug-specific input parameters were obtained.  
   Prediction and measurements of tissue-to-unbound plasma partition 
coefficients. Tissue-to-unbound plasma partition coefficients (Kp,u) were predicted 
using a method described in [105], which has been found to have good predictive 
capabilities [106]. Since both FP and budesonide are neutral compounds, logD7.4 is 
not expected to be different from logP. LogD7.4 was therefore used as input together 
with the unbound plasma fraction (fu) for prediction of Kp,u-values. LogD7.4 was 4.2 
and 2.9 for FP and budesonide, respectively [164]. fu was 0.016 and 0.09222 for FP 
and budesonide, respectively [164]. In order to simplify the model structure, richly 
and poorly perfused organs were lumped together to form one compartment each. 
The mean value of the predicted Kp,u-values of the heart and the kidney was used as 
Kp,u,richly, whereas Kp,u,poorly was defined as the mean value of the predicted Kp-values 
of the bones and the muscles. All predicted Kp,u-values are presented in table 5.1. 
   The unbound lung volume of distribution (Vu,lung), corresponding to Kp,u,lung, was 
measured for FP and budesonide by Dr. Erica Bäckström at AstraZeneca R&D 
according to the protocol described in [77]. Kp,i was subsequently obtained from: 
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iupuip KfK ,,,  .    (5.34) 
    
   Neither prediction methodologies nor measurements of Kp,u,nose were available, this 
was therefore set to Kp,u,lung.   
   The resulting steady-state volume of distribution (Vdss) was calculated from the 
predicted and measured Kp-values (eq. 5.35) and compared to the observed Vdss 
(Vdss,obs, eq. 5.36) obtained from modelling of PK-data from in vivo studies using:  
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where Vp is the volume of the plasma and Vt,i is the volume of tissue i. The calculated 
Vdss should equal Vdss,obs. Any discrepancy between the calculated Vdss and Vdss,obs can 
be corrected by introducing a Kp-factor (f) given by [99]: 
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   Since the Kp-value of the lung was known and the nose was assumed to have the 
same value, these two values were not corrected by f. The equation was thus written 
in the following form:    
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   All predicted Kp-values were multiplied by f in order to obtain Vdss,obs. The final 
Kp-values are presented in table 5.2. 
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Table 5.1 Tissue-to-unbound plasma partition coefficients 
 (Kp,u) for budesonide and fluticasone propionate 
Tissues Kp,u,Bude Kp,u,FP 
Adipose 206 4083 
Bone 15.0 285 
Brain 32.5 628 
Gut 34.6 657 
Heart 15.1 268 
Kidney 17.1 309 
Liver 18.3 331 
Lung 21.9 403 
Muscle 10.8 195 
Pancreas 35.3 683 
Skin 50.3 979 
Spleen 10.4 168 
Thymus 16.9 312 
Poorly1) 12.9 240 
Richly2) 16.1 289 
1)Kp,u,poorly is the mean value of the predicted Kp,u-values of bone and muscles.2)Kp,u,richly is the mean 
value of the predicted Kp,u-values of the heart and kidney. Abbreviations: Bude=budesonide; 
FP=fluticasone propionate 
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Table 5.2 Calculated tissue-to-plasma partition coefficients (Kp) for budesonide and fluticasone 
propionate (multiplied by the Kp-factor, f, calculated from eq. 5.38) 
Tissue 
Volume 
(L/kg) Kp,Bude Kp,FP Method 
Liver 0.04 1.95 10.4 Rodgers et al. 
Spleen 0.002 1.10 5.29 Rodgers et al. 
Poorly1) 0.789 1.37 7.86 Rodgers et al. 
Richly2) 0.0388 1.71 9.46 Rodgers et al. 
Gut 0.0259 3.68 20.7 Rodgers et al. 
Adipose 0.04 21.9 129 Rodgers et al. 
Lung 0.00413 2.13 3.41 Vu,lung 
Nose 0.000254 2.13 3.41 Vu,lung 
Venous blood 0.02 NA NA   
Arterial blood 0.04 NA NA   
f 
 
1.15 1.97   
Vdss,obs (L/kg) 2.27 12.5   
1)Kp,poorly is the mean value of the predicted Kp-values of bone and muscles.2)Kp,richly is the mean value 
of the predicted Kp-values of the heart and kidney. Abbreviations: Bude=budesonide; FP=fluticasone 
propionate; f=Kp-factor; Vdss,obs=observed steady-state volume of distribution; Vu,lung=unbound lung 
volume of distribution 
 
   Estimation of the diffusion coefficient. The diffusion coefficient (D) was 
estimated using the Hayduk-Laudie equation [36]:  
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where µ represents the viscosity of water (37°C), MW the molecular weight and ρ the 
density of the particle. The calculated D for budesonide and FP is presented in table 
5.3 and 5.4, respectively. 
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   Calculation of blood clearance. The blood/plasma drug concentration ratio (R) 
was determined to be 0.95 and 0.78 for FP and budesonide, respectively [164]. 
Experimental measurements of R were done by Pharmaron® (Pharmaron Beijing, 
Co. Ltd., Bejing, China). The blood clearance (CLB) was calculated from the plasma 
clearance (CLP) obtained from the PK study described in section 4.3 according to: 
 
R
CL
CL PB   .    (5.40) 
 
As CLP was estimated from venous drug concentrations, elimination was set to occur 
from the venous compartment. Accordingly, CLB acts on absorbed drug prior to 
entering the other organs.   
   Parameter estimation of the solubility. FP is a poorly soluble drug with a 
measured water solubility of <779.1 nM and a fasted-state small intestinal fluid 
(FaSSIF) solubility of 3120 nM [164]. FaSSIF is defined as a biorelevant medium. 
As opposed to buffer, these media better reflect the composition of physiological 
fluids by, for instance, containing lipids, surfactants and buffers, where the purpose 
of the latter is to maintain physiological pH [165]. In contrast, budesonide has a 
higher solubility with an aqueous solubility of 38.56 µM and a FaSSIF solubility of 
103.6 µM [164]. Whilst the composition of the FaSSIF (pH 6.5, osmolality 270 ± 10 
mOsmol/kg, 3 mM sodium taurochlorate, 0.75 mM lecithin, 28.7 mM KH2PO4 and 
103.3 mM KCl [166]) is not expected to precisely reflect the composition of the 
ELF, it clearly serves to illustrate how a biologically relevant medium significantly 
can change the solubility of a compound. 
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   Since the aqueous solubility of a poorly soluble compound tends to under-predict 
the in vivo dissolution rate [55], the solubility (Cs) of FP, but not budesonide, was 
estimated. 
   Cs was estimated as 4530 nM (95% CI [3845-5215] nM) using nonlinear least 
squares in the MATLAB Curve-Fitting Toolbox, which minimised the sum of 
squared deviations between observed and predicted total lung concentrations (11.3 
nmol/kg, LDD). The Levenberg-Marquardt algorithm was used to find the minimum 
of the cost function. The root mean squared error (RMSE) of the fit was 272 nM. The 
estimated Cs was thus of the same magnitude as the measured FaSSIF solubility of 
FP. 
   The initial estimate was selected from an exhaustive search, in which the sum of 
squares was initially evaluated for 1000 candidates over a broad search space where 
Cs ranged from 10
2 to 105 nM (fig. 5.2a). The cost function turned out to be locally 
convex in the explored interval and a minimum was found at 4529.7 nM. The search 
space was then confined to the proximity of the best solution Cs,0 (Cs,0-200 ≤ Cs ≤ 
Cs,0+200 nM), in which 300 candidates were evaluated (fig. 5.2b). The best solution 
of the confined search was 4530 nM, which was close to the measured FaSSIF Cs 
(3120 nM). Fig. 5.2c shows simulations of total lung concentrations using the 
optimised Cs (blue line) and the FaSSIF Cs (dashed line).  
   Sensitivity analysis of Clung with respect to D and Cs indicated that these two 
parameters might be indistinguishable (fig. 5.2d), in which case only the product can 
be estimated. However, calculation of D (eq. 5.39) enables unique determination of 
Cs. A detailed description of the sensitivity analysis is provided in section 5.3.1.3. 
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Figure 5.2 Parameter estimation of the solubility (Cs). An exhaustive search was performed to find an 
initial estimate of Cs. The cost function (sum of squares) was evaluated firstly using a) a broad search 
space (102 ≤ Cs ≤ 105 nM), which was followed by b) a confined search space in the proximity to the 
best solution, obtained from the first exhaustive search. c) Simulations of the total lung concentration 
of drug (Clung) using the optimised Cs (blue line) and the measured FaSSIF Cs (dashed line). d) 
Sensitivity analysis: influence of a 0.1% increase in Cs (black line) and the diffusion coefficient (D, 
blue line) on the dynamic behaviour of Clung. 
 
5.2.2.2 Formulation-specific input parameters 
Two different formulation-specific input parameters are used in the model: 1) 
particle density, and 2) particle size distribution. 
   Calculation of particle density. The particle density (ρ) was assumed to be the 
same as the bulk density of the densely compressed pellet used in the inhalation 
study, which was calculated via: 
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V
m
 ,     (5.41) 
where m is the mass of substance and V is the volume of the pellet. 
   Characterisation of particle size distribution. Prior to preclinical inhalation 
studies, the aerodynamic particle size distribution is typically characterised using a 7-
stage Mercer cascade impactor (model 02 110, In-tox Products, USA), providing a 
discrete particle size distribution with eight different size classes. The analytical 
procedures applied for the characterisation are described in section 4.5.2. 
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Table 5.3 Drug- and formulation-specific input parameters for budesonide 
Parameter Value 
Blood/plasma ratio 0.78 
CLB (L/h/kg) 3.80 
CLP (L/h/kg) 2.96 
Cs (nM)
* 103.6 
D (m2/s) 2.28×10-11 
f1,...,f8
** 0.047, 0.017, 0.060,  0.19, 0.31, 0.074, 0.15, 0.16 
F*** 0.22  
fu  0.0922 
fu,fluid 1 
ka (h
-1) 5 
Kd (nM) 1.16 ± 0.343  
Koff (h
-1) 1.30 ± 0.351 
Kon (L/nmol/h) 1.12 ± 0.621 
logD7.4 2.9 
Molecular weight (g/mol) 430.54 
Papp (cm/s) 65.9×10
-6   
ρ (nmol/dm3) 1.428×109 
Vdss (L/kg) 2.27 
Vu,lung (mL/g lung tissue) 23.1 
 
*FaSSIF solubility. ** 1
8
1

i
if when all decimal places are used. 
***F=fabs×fgut×fh. Abbreviations: 
CLB=blood clearance; CLP=plasma clearance; Cs=solubility; D=diffusion coefficient; f1,...,f8=mass 
fractions for particle sizes 1,...,8, respectively; F=oral bioavailability; fabs=fraction absorbed; 
fgut=fraction escaping gut metabolism; fh=fraction escaping hepatic metabolism;  fu=fraction unbound 
in plasma; fu,fluid=fraction unbound in epithelial or nasal lining fluid; Kd=dissociation constant; 
Koff=dissociation rate constant; Kon=association rate constant; Papp=apparent permeability; ρ=particle 
density; Vdss=steady-state volume of distribution; Vu,lung=unbound lung volume of distribution 
 
165 
 
 
Table 5.4 Drug- and formulation-specific input parameters for fluticasone propionate 
Parameter Value 
Blood/plasma ratio 0.95 
CLB (L/h/kg) 11.53 
CLP (L/h/kg) 10.95 
Cs (nM) 4530 
D (m2/s) 2.27×10-11 
f1,...,f8
* 0.17, 0.30, 0.26, 0.18, 0.073, 0.0091, 0.0032, 
0.0035* 
F** 0 
fu  0.016 
fu,fluid 1 
Kd (nM) 0.015 ± 0.0045 
Koff (h
-1) 0.51 ± 0.17 
Kon (L/nmol/h) 34 ± 20 
logD7.4 4.2 
Molecular weight (g/mol) 500.6 
Papp (cm/s) 46.9×10
-6   
ρ (nmol/dm3) 1.430×109 
Vdss (L/kg) 12.5 
Vu,lung (mL/g lung tissue) 213.4 
 
* 1
8
1

i
if when all decimal places are used.
 **F=fabs×fgut×fh. Abbreviations: CLB=blood clearance; 
CLP=plasma clearance; Cs=solubility; D=diffusion coefficient; f1,...,f8=mass fractions for particle sizes 
1,...,8, respectively; F=oral bioavailability; fabs=fraction absorbed; fgut=fraction escaping gut 
metabolism; fh=fraction escaping hepatic metabolism;  fu=fraction unbound in plasma; fu,fluid=fraction 
unbound in epithelial or nasal lining fluid; Kd=dissociation constant; Koff=dissociation rate constant; 
Kon=association rate constant; Papp=apparent permeability; ρ=particle density; Vdss=steady-state 
volume of distribution; Vu,lung=unbound lung volume of distribution 
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5.2.2.3 System-specific input parameters 
The model includes several system-specific input parameters describing the anatomy 
and physiological processes for the rat. Where possible, anatomical values were 
obtained from the literature. In the absence of literature values, calculations of 
parameter missing values were made based on available anatomical data. All system-
specific input parameters are summarised in tables 5.5 and 5.6, where the latter 
specifies parameters for the central lung, peripheral lung and the nose. 
   Calculation of VELF and Vnasal. The volume of the epithelial lining fluid in the 
central (VELF,C) and the peripheral lung (VELF,P) as well as the corresponding volume 
in the nose (Vnasal) was calculated accordingly: 
 
iisurfifluid dAV  ,, ,    (5.42) 
 
where Asurf,i is the surface area in compartment i and di is the thickness of the lining 
fluid in compartment i. d in the central lung was set to be 5 µm [56], as was d in the 
nose [167]. Since d is known to gradually decrease along the lung generations [151], 
a smaller d was used peripherally (0.07 µm, [11]). 
   Calculation of central and peripheral lung tissue fractions. The volume of 
region j was calculated from:  
 
jjsurfj hAV , ,    (5.43) 
 
where Asurf,j is the surface area and hj is the lung wall thickness of region j. Since 
limited information on surface areas and lung wall thickness in the different 
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subregions of the central lung was available, the bronchial wall thickness was 
assumed to be representative of the entire region. The rationale for choosing the 
bronchial wall as a representative was that it is thinner than the tracheal- but thicker 
than the bronchiolar wall. The bronchial (hc = 29 µm) and alveolar wall thickness (hp 
= 1.42 µm) were obtained from [168] and [30], respectively. The central (fv,c) and 
peripheral (fv,p) tissue fractions were subsequently calculated using eqs. 5.44 and 
5.45, respectively, as follows: 
 
pc
c
cv
VV
V
f

, ,    (5.44) 
cvpv ff ,, 1 .    (5.45) 
 
   Calculation of nasal mucosa volume. The volume of the nasal mucosa (Vn) was 
calculated using:  
 
nnsurfn hAV , ,    (5.46) 
 
where Asurf,n is the surface area of the nose and hn is the average thickness of the 
nasal epithelium. The average thickness (hn = 61 µm) was obtained from [169]. 
Measurements from 60 day-old Sprague Dawley rats were chosen as this was in the 
proximity of the age range used in the studies (9-11 weeks). 
   Estimation of mucociliary rate constant. The mucociliary rate constant (kmcc) 
was estimated using data from [155], where clearance of a tracer from the airway by 
mucociliary transport was studied in rats after inhalation (0 ≤ t ≤ 6 h, median spray 
droplet size 4-6 µm) using a single-photon emission computed tomography 
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(SPECT)-based method. The fraction retained (fret) was assumed to decline 
exponentially and MCC was assumed to be negligible in the peripheral region. 
Hence, a baseline corresponding to the fraction of the total lung dose deposited in the 
peripheral region (f0) was introduced as this fraction should not be affected by MCC. 
There were no data available on the droplet size distribution, the mean value (5 µm) 
was therefore used for calculation of regional deposition. The peripheral (fp,mcc) and 
central deposition fractions (fc,mcc) for particles with an aerodynamic diameter of 5 
µm were extracted from [65] and f0 was calculated accordingly: 
 
2.0
,,
,
0 


mcccmccp
mccp
ff
f
f .    (5.47) 
 
The resulting equation for fret was as follows: 
 
tktk
ret
mccmcc eefff
  8.02.0)1( 00   (5.48) 
 
kmcc was estimated as 0.0472 ± 0.0011 h
-1 using the MATLAB Curve Fitting Toolbox 
(Mathworks Inc., Natick, MA, USA), corresponding to a half-life of 14.7 h. The 
observations and model fit are shown in figure 5.3. 
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Figure 5.3 Characterisation of mucociliary clearance (MCC): a tracer was administered via inhalation 
in order to characterise MCC in rats. The retention of the tracer was governed by SPECT-imaging and 
data are presented as the fraction of tracer retained in the lung (fret). Observations from [155] are 
indicated by circles and the model fit by a solid line.  
 
Table 5.5 System-specific input parameters for the rat. 
Tissue 
 
Volume 
(fraction of BW) 
Blood flow  
(fraction of QCO)  
Adipose 0.040b) 0.009217b) 
Gut 0.0259c) 0.14c) 
Liver 0.04a) 0.024c) 
Lung 0.004127d) 0.021c)/1 
Nose 0.000254e) 0.0015f) 
Poorly perfused* 1-(the rest) 1-(the rest) 
Richly perfused** 0.039a) 0.5096 a) 
Spleen 0.002c) 0.0715g) 
Arterial blood 0.02 a) NA  
Venous blood 0.04 a) NA  
*Poorly perfused = 1 – other organs; **Richly perfused = richly perfused + brain + kidney from a); QCO 
= cardiac output, 20.77 L/h/kga); a) [140]; b) [170]; c) [142]; d) Internal AstraZeneca data, han Wistar 
(n = 100); e) eq. 5.46, section 5.2.2.3; f) [171]; g) [141] 
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Table 5.6 System-specific input parameters for the central lung, the peripheral lung and the nose. 
Parameter Central lung Peripheral lung Nose 
Blood flow  
(fraction of QCO) 0.021
a) 1 0.0015b) 
Surface area  
(dm2/kg) 3.27c) 276.4d) 0.416e) 
Lining fluid volume 
(µL/kg) 163.6* 193.5* 20.8* 
Fraction of tissue volume 0.19* 0.81*  NA  
kmcc (h
-1) 0.0472 NA 0.2079 
*Calculations of the lining fluid volume and tissue fractions are provided in section 5.2.2.3; 
References: a) [142] b) [171] c) [172] (normalised per kg, 330 g rat, 108 cm2) d) [173] (normalised 
per kg, 140 g rat, 3870 cm2 e) [174] (normalised per kg, 10.4 cm2, 250 g rat). Abbreviations: 
QCO=Cardiac output; kmcc=rate constant for mucociliary clearance 
 
5.3 Application of the developed model 
This section focuses on application of the model, firstly in terms of model validation 
and verification. Administrations via the IV-route and via nose-only inhalation were 
simulated using drug- and formulation-specific input parameters for FP or 
budesonide (tables 5.4 and 5.3, respectively). The simulations were subsequently 
compared with experimental data obtained from work contained in this thesis or from 
AstraZeneca’s internal data base. The source of the data is clearly stated in the text. 
As FP was used as a model substance in the development of the experimental in vivo 
receptor occupancy methodology, more data were available for that substance. 
Secondly, emphasis was put on exploring which properties are beneficial for inhaled 
drugs to advance the understanding of inhalation PK. 
   The MATLAB built-in solver ode15s was used throughout the thesis to 
numerically solve the system of coupled ODEs in the PBPK model. This solver was 
chosen since it is suitable for treating stiff problems.  
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5.3.1 Fluticasone propionate (model validation and verification) 
5.3.1.1 Intravenous administration  
Administrations via the IV-route (20, 90, 150, 750 and 1000 nmol/kg) were 
simulated using drug-specific input parameters for FP (table 5.4). The simulations 
were subsequently compared with experimental data on drug concentrations (plasma, 
spleen and lung) and receptor occupancy obtained from work contained in this thesis 
(sections 3.3.2.1, 3.3.2.2 and 4.3).  
   Model predictions of the plasma profiles as well as the time course of occupancy 
(figs. 5.4a-b) were consistent with experimental IV-data (90 and 1000 nmol/kg), 
supporting a perfusion rate-limited distribution of FP and validating the capability to 
predict plasma PK. As expected from IV-dosing, the predicted occupancy profiles in 
the two lung regions and the spleen were identical. No occupancy measurements 
were available for the higher dose. Of note is that the binding kinetics parameters 
(Kon and Koff) were obtained from modelling of IV-data (90 nmol/kg). As the model 
was predictive of the plasma PK for this particular dose, it follows that it should also 
be predictive of the corresponding receptor occupancy profile. This consistency can 
thus be regarded as a verification step of the model. A test set independent of the 
training data set was also available to validate model predictions of occupancy after 
IV-administration. The model proved to be predictive of the test set, which 
comprised of receptor occupancy measurements made 1.5 h after three IV-doses of 
FP (section 3.3.2.1). Simulated occupancies were 27, 64 and 86% for 20, 150 and 
750 nmol/kg, respectively. Simulations agreed well with observed data: 27 ± 9.7, 74 
± 5.0 and 100 ± 3.5% for 20, 150 and 750 nmol/kg, respectively. 
   It was shown that inclusion of the receptor-bound concentration was essential for 
the predictive capability of both the lung- and the spleen concentrations. This is 
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illustrated by figure 5.4c-d, showing predictions of tissue concentrations inclusive 
(solid red line) and exclusive (dashed black line) of receptor binding.  
   In conjunction with the IV-simulations, it was also verified that mass balance was 
preserved in the PBPK model. This was done by simulating the cumulative amount 
of drug cleared from the system (Acum) and subsequently comparing Acum at t = 72 h 
to the input (90 nmol/kg, IV, fig. 5.4e).  
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Figure 5.4 Model predictions and observations of fluticasone propionate administered as an IV-bolus 
to rats. The figures show: a) plasma concentrations (Cp) after IV-administration of 90 (blue line) and 
1000 nmol/kg (red line), b) receptor occupancy after IV-administration of 90 nmol/kg (blue line), c) 
lung concentration (Clung) after IV-administration of 90 nmol/kg (red line) the dashed line shows Clung 
excluding the receptor-bound concentration, d) spleen concentrations (Cspleen) after IV-administration 
of 90 nmol/kg (red line), the dashed line shows Cspleen excluding the receptor-bound concentration, e) 
verification of preserved mass balance by comparing the cumulative amount cleared (Acul, red line) to 
the IV-dose (blue line). For the receptor occupancy simulation, a 90% CI was created by a Monte 
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Carlo simulation which repeatedly sampled random values from a lognormal distribution of the 
binding kinetics parameters (n = 1000, dashed lines). 
 
5.3.1.2 Nose-only exposure  
Nose-only exposures with two different LDD (11.3 and 100 nmol/kg) were simulated 
using drug- and formulation-specific input parameters for FP (table 5.4). Neither 
particle size distribution nor density was available for the higher LDD, it was 
therefore assumed to have the same formulation-specific properties as the lower 
dose. Model predictions were subsequently compared with experimental data on drug 
concentrations (plasma, spleen and lung) and receptor occupancy. Observations from 
the lower dose (11.3 nmol/kg, LDD) were generated as part of this thesis (section 
4.5), whereas observations corresponding to the higher dose (100 nmol/kg, LDD) 
were obtained from AstraZeneca’s internal data base [164]. The latter data set only 
contained measurements of total lung concentrations.  
   Total lung-, plasma- and spleen concentrations were well-predicted by the model 
after nose-only inhalation (fig. 5.5a-c). In line with the IV-predictions, inclusion of 
the receptor-bound concentration was necessary for the model’s predictive capability 
of total spleen concentrations (fig. 5.5c). In contrast to the spleen, the relative 
contribution of the receptor-bound concentration to the total lung concentration was 
small after inhalation (fig. 5.5d). This difference can be attributed to the large 
amount of FP retained in a solid state in the lung after inhalation.    
   The single parameter Cs was estimated from observations made in one inhalation 
study (11.3 nmol/kg, LDD). When the model was tested on another data set (100 
nmol/kg, LDD), it was shown to be predictive of the total lung concentrations with 
the exception of the last time point (fig. 5.5a). As the particle size distribution was 
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not available for the latter study, larger particles could be a possible explanation for 
the under-prediction seen at 24 h. 
   Model predictions of the systemic occupancy were consistent with the observations 
(fig. 5.5e). Comparison of observations and model predictions of pulmonary 
occupancy was slightly more complex as the experimental methodology cannot 
distinguish between occupancy in the central and the peripheral lung. ROave (eq. 
5.33), a weighted average of the occupancy accounting for the relative contribution 
of each region, was found to capture key trends in the data, although a tendency 
towards under-prediction was noted (fig. 5.5f). Given the uncertainty in fv,c and the 
slightly lower accuracy of lung occupancy measurements, a whole-lung occupancy 
prediction that qualitatively captures key features including lung-selectivity and late 
occupancy peak can be regarded as a good description of the data. 
   Neither plasma concentrations nor receptor occupancy had been measured 
following inhalation of the higher dose. 
   It was noted that, given the particle size distribution of the batch used, the nasally 
deposited dose was predicted to be approximately six times higher than LDD (fig. 
5.5g). 
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Figure 5.5 Model predictions and observations after nose-only exposure of fluticasone propionate, the 
figures show: a) total lung concentrations (Clung) after a lung deposited dose (LDD) of 11.3 nmol/kg 
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(blue line) and 100 nmol/kg (red line), b) Cp after a LDD of 11.3 nmol/kg (blue line), c) spleen 
concentration (Cspleen) after a LDD of 11.3 nmol/kg (blue line), the dashed line shows Cspleen excluding 
the receptor-bound concentration, d) Clung after a LDD of 11.3 nmol/kg (blue line), the dashed line 
shows Clung excluding the receptor-bound concentration, e) receptor occupancy in the spleen after a 
LDD of 11.3 nmol/kg (red line), and f) whole-lung receptor occupancy after a LDD of 11.3 nmol/kg 
(blue line). For each receptor occupancy simulation, a 90% CI was created by a Monte Carlo 
simulation which repeatedly sampled random values from a lognormal distribution of the binding 
kinetics parameters (n = 1000, dashed lines). g) Distribution of the deposited dose between the central 
lung region (black), the peripheral lung region (grey) and the nasal region (white). 
 
5.3.1.3 Sensitivity analysis for fluticasone propionate  
A sensitivity analysis was performed to investigate how the dynamic behaviour of 
the system responds to changes in selected input parameters. The sensitivities were 
generated by considering the partial derivatives of the output Y with respect to each 
parameter pi and these were calculated keeping all other parameters fixed at their 
nominal values (p0), i.e. 
 
0p
ip
Y

      (5.49) 
 
Two outputs were investigated: receptor occupancy in the central lung (ROc) and 
receptor occupancy in the spleen (ROsp). This was done by firstly simulating the 
system with all parameters at their nominal values [f(t,p0)]. Subsequently, a 
simulation was performed after considering a 0.1% increment in the parameter of 
interest, pi, [f(t,p)] while all other parameters were kept at their nominal values. As 
mentioned in section 5.3, the MATLAB built-in solver ode15s was used to solve the 
system of coupled ODEs. The choice of integrator accuracy was important to enable 
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the use of a low perturbation fraction (0.001). An accuracy of 10-12 was therefore 
chosen (i.e. ‘RelTol’ in MATLAB was set to 10-12). The sensitivities here were 
calculated according to the same principle as that is used in, for example, Berkeley 
Madonna™ and carried out follows: 
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As expected, the sensitivity analysis (fig. 5.6a-b) showed that the parameters D and 
Cs, both essential for the dissolution process, have a big impact on the dynamic 
response of ROc and ROsp. The sensitivity curves with regard to D and Cs have 
several peaks as a result of the dissolution of eight different particle sizes. The 
change in sign of the derivative of the sensitivity function coincides with the time 
points when the radius r approaches 0. Increasing the bronchial blood flow (Qbronch) 
had a negative impact on ROc, whereas ROsp was principally unaffected. ROsp was 
largely affected by CL, whereas this parameter only had a small impact on ROc. As 
the extent of nasal absorption is in part determined by kmcc,nasal, it follows that ROsp 
should be sensitive to perturbations in this parameter. This hypothesis was confirmed 
by the sensitivity analysis, which also verified that kmcc,nasal does not have a big effect 
on ROc. The analysis showed that Papp had a bigger impact on ROsp than ROc during 
the dissolution process. This reflects the effect of Papp on the absorption of drug to 
the systemic circulation as well as the fast equilibration between unbound 
concentrations in the systemic circulation and the spleen.    
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Figure 5.6 Sensitivity analysis. Influence of a 0.1% increase in the values of six different parameters 
on the dynamic behaviour of a) receptor occupancy in the spleen (ROsp), and b) receptor occupancy in 
the central lung (ROc) was investigated. The following parameters were included in the analysis: the 
mucociliary clearance rate in the nose (kmcc,n), the diffusion coefficient (D), the apparent permeability 
(Papp), the clearance (CL), the bronchial blood flow (Qbronch) and the solubility (Cs). 
 
5.3.2 Budesonide 
5.3.2.1 Intravenous administration  
IV-administration (167 nmol/kg) was simulated using drug-specific input parameters 
for budesonide (table 5.3). The simulations were subsequently compared with 
experimental data on drug concentrations (plasma, spleen and lung) and receptor 
occupancy, i.e. data obtained from work contained in this thesis (section 4.2 and 4.3, 
respectively).  
   The initial distribution phase in the plasma profile (t < 1.1 h) was well-captured by 
the model predictions, whereas a consistent deviation between experimental and 
predicted Cp was observed at later time points (fig. 5.7a). This discrepancy suggests 
the presence of a mechanism that is unaccounted for by the model. In fact, reversible 
fatty acid esterification of budesonide has been demonstrated to take place both in 
vitro [175] and in vivo [79]. Earlier research aiming at characterising the PK of 
budesonide and its ester, budesonide-oleate, showed that budesonide-oleate was 
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rapidly formed both after IV-administration and inhalation of budesonide in rats [79]. 
As the resulting budesonide-oleate concentrations were in the proximity of the 
budesonide concentrations, the formation and subsequent hydrolysis of the ester is 
likely to have a pronounced effect on the PK of budesonide. The latter hypothesis has 
also been confirmed via semi-empirical modelling approaches [79,176]. Hence, the 
current PBPK model structure is not expected to be able to accurately describe the 
PK of budesonide neither in plasma (fig. 5.7a) nor in tissues (5.7b and 5.7c for the 
lung and the spleen, respectively).  
   Further research would have been required to adequately describe the esterification 
of budesonide in a quantitative manner, which was not considered to fall within the 
scope of this thesis. However, since budesonide-oleate is rapidly formed in tissues 
[79], this process may well be reflected in the plasma profile by a rapid initial decline 
followed relatively flat second phase caused by the ester accumulated in tissues 
slowly being hydrolysed back to budesonide. This phenomenon is seen in the 
experimental data (fig. 5.7a), but cannot be captured by the current model structure 
as it does not account for this process. 
 
  
181 
 
 
Figure 5.7 Model predictions and observations of budesonide administered as an IV-bolus (167 
nmol/kg) to rats. The figures show: a) plasma concentrations (Cp, blue line), b) lung concentrations 
(Clung, red line), the dashed line shows Clung excluding the receptor-bound concentration, c) spleen 
concentrations (Cspleen, red line), the dashed line shows Cspleen excluding the receptor-bound 
concentration, and d) receptor occupancy (blue line). For the receptor occupancy simulation, a 90% CI 
was created by a Monte Carlo simulation which repeatedly sampled random values from a lognormal 
distribution of the binding kinetics parameters (n = 1000, dashed lines)  
 
5.3.2.2 Nose-only exposure  
AstraZeneca’s internal data base was searched for inhalation PK-studies with 
budesonide. Three studies were found in which budesonide had been administered as 
a dry powder [164]. The time profile of Clung had been characterised in all three 
studies and two studies also comprised measurements of Cp. In two studies, the LDD 
had been determined to be 100 and 127 nmol/kg, respectively by filter analysis (the 
principles are described in section 2.2.6.2). The LDD had not been determined in the 
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third study. However, since the measured lung concentrations were approximately 
equal in the aforementioned study and the study with an LDD of 100 nmol/kg, the 
LDD of the third study was also assumed to be 100 nmol/kg. For simplicity, the 
details for each study have been summarised in table 5.7. The formulation-specific 
parameters (particle size distribution and density) were only available for study 3 and 
were assumed to be identical across the three studies (table 5.3).  
   Nose-only exposures with two different LDD (100 and 127 nmol/kg) were 
simulated using drug- and formulation-specific input parameters for budesonide 
(table 5.3). Model predictions were subsequently compared with experimental data 
on lung- and plasma concentrations. There was only a small difference between the 
concentration profiles generated from simulations of the two different LDD. The 
initial drop in Clung was well captured by the model predictions, suggesting that 
budesonide is rapidly dissolved. However, there was a consistent under-prediction of 
Clung from approximately 5 h after dosing and onwards (fig. 5.8a). As expected from 
the deviations between model predictions and observations of Cp after IV-
administration, the model could not describe the plasma profile after inhalation (fig. 
5.8b). The discrepancy patterns between model predictions and observations were 
similar for both routes of administration (IV and inhalation), again suggesting the 
presence of a mechanism that is unaccounted for by the model. 
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Table 5.7 Details for the inhalation studies with budesonide 
Study 
 
Observations 
 
LDD 
(nmol/kg) 
1 Clung 100 
2 Clung, Cp 127 
3 Clung, Cp 100
1) 
Abbreviations: LDD=lung deposited dose; Clung=total lung concentrations; Cp=plasma concentrations. 
1) The LDD in study 3 was assumed to be identical to the LDD in study 1. 
 
 
Figure 5.8 Observations and model predictions after nose-only exposure of budesonide. The figures 
show: a) total lung concentrations (Clung), and b) plasma concentrations (Cp) after a lung deposited 
dose (LDD) of 100 and 127 nmol/kg.  Data were taken from three studies with the following colour 
codes and LDD: study 1 (black, LDD = 100 nmol/kg), study 2 (red, LDD = 127 nmol/kg) and study 3 
(blue, LDD = 100 nmol/kg). Lines represent model predictions and circles represent observations. Cp 
was not measured in study 1. The dotted line in a) represents Clung exclusive of the receptor-bound 
concentration.  
 
5.3.3 Evaluation of concepts for lung-selectivity 
This model can distinguish between drug-, formulation- and system-specific 
properties. As such, it enables assessment of important factors determining lung-
selectivity including properties of the molecule, formulation as well as the 
physiology of the animal species. Hence, this section will focus on exploring what 
properties are beneficial for inhaled drugs. In addition, it will also address possible 
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limitations of the animal models currently used for characterisation of inhalation 
drugs. 
 
5.3.3.1 Definition of lung-selectivity  
Lung-selectivity can be defined as the ratio between pulmonary and systemic 
receptor occupancy, where a ratio of unity implies absence of lung-selectivity. In 
accordance with the previous line of reasoning, the spleen is used as a reference 
organ for the systemic exposure. Since the lung is divided into a central and a 
peripheral region, lung-selectivity can be evaluated for each region individually. 
Regardless of the scenario simulated, it was noted that lung-selectivity could not be 
achieved if the peripheral lung was considered as the pulmonary region. A ratio of 
unity was thus obtained between the occupancy in the peripheral lung (ROp) and the 
spleen (ROsp) in this model. This is attributed to the high perfusion rate of this region 
(entire cardiac output, QCO), which thus rapidly equilibrates with the systemic 
circulation. However, under certain circumstances lung-selectivity could be obtained 
in the central lung after inhalation. Henceforth, the occupancy in the central lung 
(ROc) is therefore used as the pulmonary region for evaluation of lung-selectivity. In 
other words, the criterion for lung-selectivity is fulfilled when  
 
1
sp
c
RO
RO
.     (5.51) 
 
5.3.3.2 Evaluation of drug-, formulation- and system-specific input parameters  
In the following simulations, the impact of an individual parameter pi on the degree 
of lung-selectivity obtained by inhalation will be evaluated by simulating the system 
using varying values of pi while all other parameters (p) are fixed at their assigned 
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values. Unless otherwise specified, drug- and formulation-specific input parameters 
for FP (table 5.4) are used for the parameter vector p. For consistency, an LDD of 
11.3 nmol/kg will be used unless stated otherwise. 
   The impact of the following drug-specific input parameters on lung-selectivity was 
evaluated: CL, F, Cs, Papp and Koff. Furthermore, one formulation- and one system-
specific input parameter were investigated: particle size and nasal blood flow (Qn), 
respectively. The latter parameter was included to evaluate the contribution of nasal 
drug absorption following nose-only exposure, which was done by simulating and 
comparing the plasma PK profile from a base-case scenario (input parameters from 
tables 5.4-6) to a scenario where Qn was set to 0. The particle size distribution was 
investigated by comparing the base-case scenario to one where the particles were 
evenly distributed between the four smallest size classes, that is fi = 0.25 for 
i ∈ {5, …, 8} and fi  = 0 otherwise.  
   As can be seen in figure 5.9a, a longer period of lung-selectivity was obtained for a 
poorly soluble drug (Cs = 2.5 µM) than for a highly soluble drug (Cs = 50 µM). Since 
the dissolution phase can be prolonged by decreasing Cs (eq. 5.20), a lower Cs 
resulted in an extended period of lung-selectivity. Nevertheless, a transient 
concentration gradient created during dissolution of a highly soluble compound (Cs = 
50 µM) could also give rise to a prolonged lung-selectivity given a slow Koff (fig. 
5.9b).  
   The dissolution rate is not only dependent on Cs. From eq. 5.20 and 5.22 it is 
evident that the particle size is also important. Moreover, the regional deposition 
depends on the particle size. Accordingly, given a certain LDD, simulations showed 
that the particle size distribution had an impact on the occupancy profile as well as 
on the degree of lung-selectivity (fig. 5.9c).   
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   According to the simulations, nasal absorption significantly contributed to the 
systemic exposure (fig. 5.9d) and decreased the degree of lung-selectivity following 
nose-only inhalation of FP (fig. 5.9e). Noteworthy is that the nasally deposited dose 
was predicted to be several-fold higher than LDD (fig. 5.5e, section 5.3.1.2). 
   Papp-values are known to differ across laboratories, thus there are no strict cut-off 
values for Papp assigning low, moderate and high permeability, respectively. 
However, as a benchmark the following permeability ranges are used for CaCo-2 
[177]:  
 
 2×10-6 cm/s > Papp (low permeability) 
 2×10-6 cm/s ≤ Papp ≤ 20×10-6 cm/s (moderate permeability) 
 20×10-6 cm/s < Papp (high permeability) 
 
In the simulations Papp = 0.2×10
-6 cm/s and Papp = 100×10
-6 cm/s assigned low and 
high permeability, respectively. In order to distinguish permeability from other 
mechanisms of lung retention, the following changes were made in the simulations: 
1) drug was administered as a solution directly in the central ELF, and 2) the Koff was 
set to be 10-fold higher than the corresponding value for FP; i.e. Koff = 5.1 h
-1. 
Administration of a solution was done by setting the initial central ELF concentration 
(CELF,C) to 
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where VELF,C is the volume of ELF in the central lung. As can be seen in figure 5.9f, 
simulations suggest that a low permeability alone can give rise to a prolonged period 
of lung-selectivity despite the drug already being dissolved and having a fast Koff. 
However, administration of a dissolved, highly permeable compound with the same 
properties did not produce any lung-selectivity.      
   Simulations also showed that F was negatively correlated with lung-selectivity, 
whereas a positive correlation was found for CL (simulations not shown). 
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Figure 5.9 The impact of different drug-, formulation- and system-specific properties on lung-
selectivity was evaluated by varying the following parameters: a) solubility; Cs = 2.5 µM (blue line) 
and Cs = 50 µM (black line), b) dissociation rate; t½,Koff = 7.5 h (black line) and t½,Koff = 0.3 h (blue 
line), c) particle size distribution; f1, ..., f8 from table 5.4 (black line) and fi  = 0.25 for i = 5, …, 8 and 
fi = 0 otherwise (blue line), d) nasal absorption; nose included (blue line) and nose excluded (red line), 
e) nasal absorption; nose included (blue line) and nose excluded (black line) and f) permeability; Papp 
= 0.2×10-6 cm/s (blue line) and Papp = 100×10-6 cm/s (black line). Except for subfigure d), which 
shows predictions (lines) and observations (open circles) of plasma concentrations of fluticasone 
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propionate (Cp), dashed lines represent receptor occupancy in the central lung and solid lines represent 
occupancy in a systemic reference organ.  
 
5.3.4 Evaluation of different concepts 
5.3.4.1 Intravenous administration versus instillation of dissolved drugs without 
any pulmonary retention mechanism 
With exception of the intravenous route, inhalation is the fastest route of systemic 
delivery of small molecules. This is particularly prominent for small lipophilic 
molecules, where the absorption half-life is approximately 1-2 minutes [21]. The 
model was used to confirm this feature by firstly simulating the plasma profile 
following instillation of a compound in solution (LDD, 20 nmol/kg). This was done 
by setting the initial concentration in the ELF in the central lung to 
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where CELF,C is the drug concentration in the ELF in the central lung and VELF,C is the 
volume of the ELF in ditto. An IV-dose matching the instilled dose (20 nmol/kg) was 
subsequently simulated in order to compare the resulting plasma profile to the 
corresponding profile obtained after inhalation. As can be seen in fig. 5.10, the 
resulting arterial concentration profiles from the two administration routes were 
similar for a drug without any specified pulmonary retention mechanism. 
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Figure 5.10 Plasma concentration (Cp) profiles were simulated after intratracheal instillation of 
dissolved drug (20 nmol/kg, blue line) and intravenous (IV) administration (20 nmol/kg, red line). 
 
 
   Despite the similar blood exposure, the inhaled route gave rise to a transient period 
of lung-selectivity whereas a ratio of unity was obtained after IV-administration. The 
duration of lung-selectivity is dependent on the binding kinetics of the drug, which 
was illustrated by simulating ROsp and ROc for varying values of Kd and Koff 
accordingly: 1) Kd = 15 pM and Koff = 0.51 h
-1, 2) Kd = 150 pM and Koff = 5.1 h
-1, and 
3) Kd = 1.5 pM and Koff = 0.051 h
-1. 
   In the first simulation, the binding kinetics parameters of FP were used (fig. 
5.11a-b). Increasing Kd and Koff by a factor of 10 led to a significantly shorter period 
of lung-selectivity (fig. 5.11c-d).  In the third simulation, when Kd and Koff were 
decreased by a factor of 10, a prolonged period of lung-selectivity was obtained (fig. 
5.11e-f). Needless to say, this method for prolonging the duration of lung-selectivity 
will be accompanied by a prolonged systemic occupancy profile. 
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Figure 5.11 Receptor occupancy profiles were simulated after intratracheal instillation of dissolved 
drug (20 nmol/kg) and intravenous (IV) administration (20 nmol/kg). Receptor occupancy profiles 
were simulated in the spleen (red line) and the central lung (dashed blue line) using varying values of 
binding kinetic parameters and different routes of administration accordingly: a) Kd = 15 pM and Koff = 
0.51 h-1, inhalation, b) Kd = 15 pM and Koff = 0.51 h-1, IV, c) Kd = 150 pM and Koff = 5.1 h-1, inhalation, 
d) Kd =150 pM and Koff = 5.1 h-1, IV, e) Kd = 1.5 pM and Koff = 0.051 h-1, inhalation, and f) Kd = 1.5 
pM and Koff = 0.051 h-1, IV.  
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5.3.4.2 Impact of mucociliary clearance on the pharmacokinetics 
The impact of MCC on the PK will be dependent on the residence time of the drug in 
the lung and the nose. As poorly soluble compounds are anticipated to be retained in 
a solid state for a longer time period than drugs with a high Cs, MCC is expected to 
have a bigger effect on that compound class. Indeed, the effect of MCC was shown 
to be more pronounced for poorly soluble drugs. The amount of drug transported by 
MCC from the nose and the central lung to the gut (Amcc) was simulated for a broad 
range of Cs (0.01-10
5 nM, 300 steps) after an LDD of 10 nmol/kg (ID, 97.0 nmol/kg) 
using drug- and formulation-specific input parameters for FP. Amcc decreased with 
higher Cs, which can be attributed to the higher dissolution rate as described in eq. 
5.20. Accordingly, the percentage of drug removed by MCC tends towards 100% as 
Cs approaches 0 (fig. 5.12). The model thus suggests that the impact of MCC on the 
PK is high for compounds with a low Cs and negligible for compounds with a high 
Cs. This is in line with previous research, which suggests that MCC has a larger 
impact on slowly dissolving compounds [8].  
   Expressed differently, these simulations suggest that MCC will act by decreasing 
the pulmonary bioavailability for poorly soluble drugs. Interestingly, a clinical study 
showed less systemic side-effects of inhaled FP (poorly soluble compound) in 
patients with moderately severe asthma as compared to healthy volunteers. However, 
there was no statistically significant difference between the two groups for the highly 
soluble compound budesonide [178]. Another clinical study showed a significantly 
lower bioavailability of inhaled FP in asthmatic patients as compared to healthy 
volunteers [179]. Since FP has a very low oral bioavailability it is reasonable to 
assume that this difference is primarily caused by pulmonary absorption. The lower 
pulmonary bioavailability of inhaled FP in asthmatic patients was suggested to be 
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caused by a higher central lung deposition of drug in the asthmatic group, which 
makes the drug particles more prone to clearance by MCC [179]. Indeed, asthmatic 
patients have been shown to have a higher central deposition of drug [180], which 
has been suggested to be caused by the airway narrowing in this patient population 
[179]. To summarise, clinical data also suggest that slowly dissolving drugs are more 
prone to be cleared by MCC. Since MCC primarily is associated with the 
tracheobronchial region [74], this effect is expected to be more pronounced after 
central drug deposition.  
 
 
Figure 5.12 Percent of drug particles deposited in the nose and central lung that are removed by the 
mucociliary clearance (MCC) as a function of solubility (Cs).  
 
5.3.4.3 Evaluation of the impact of permeability on pulmonary absorption 
As mentioned in section 2.2.4, inhaled drugs may be rapidly absorbed to the systemic 
circulation. The pulmonary absorption rate of a dissolved drug is for instance 
expected to be dependent on the permeability of the compound. In fact, a weak 
relationship (r2 = 0.45) between the lung absorption half-life in rats and the measured 
CaCo-2 permeability has been shown in . It is worth mentioning that only limited 
information on the experiments is available in the cited publication. Nevertheless, the 
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authors investigated the correlation between the CaCo-2 permeability and pulmonary 
absorption half-life (t½,lung) after IT-instillation of solutions to rats. Since several of 
the 19 included compounds were bases, the t½,lung cannot be expected to be explained 
by permeability alone. Both protonation of the compound in the slightly acidic ELF 
(pH 6.6 [4]) as well as intracellular lysosomal trapping might be possible 
mechanisms for prolongation of t½,lung. One could argue that the slowness of the 
lysosome might already be described by the Papp obtained from CaCo-2 experiments. 
However, the cell model’s feasibility to capture this mechanism as well as the 
relative abundance of lysosomes in CaCo-2 and lung epithelial cells remain to be 
experimentally evaluated prior to confirming or rejecting that hypothesis.  
   Since only neutral compounds have been explored in this thesis, the current model 
structure does not account for lung retention caused by basicity and the aim of this 
thesis is not to theoretically/experimentally explore the mechanisms thereof. 
Nevertheless, the impact of permeability on pulmonary absorption was theoretically 
explored to investigate whether the model predictions are in line with the 
observations made in . In that study, t½,lung was calculated based on measurements of 
Clung. That approach was subsequently mimicked in this simulation study. 
   Administration by IT-instillation means that the drug is directly dosed into the 
lung, i.e. nasal drug deposition is avoided. It has been shown that the pulmonary 
deposition pattern of drug after IT-instillation is highly dependent upon the technique 
of the experimentalist [164]. However, IT-instillation tends to result in a higher 
deposition centrally in the lung . Hence, to mimic this dosing method drug was 
administered as a solution directly in the central ELF. That is, the initial condition in 
this compartment was set to 
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where VELF,C is the volume of the central ELF. LDD was set to 10 nmol/kg and P 
varied between 0.1×10-6 and 100×10-6 cm/s, where 40 values were selected from a 
logarithmic scale. The system was simulated iteratively for 0 ≤ t ≤ 25 h for each 
value of P. For each simulation, the time point at which Clung had decreased to 50% 
of its value at t = 0 was extracted and used as the model prediction of t½,lung. Clearly, 
this value will also be dependent on the systemic PK both in the simulations as well 
as in the experimental data. This simulation exercise was subsequently repeated with 
the aim of mimicking a more homogenous distribution of drug after IT-instillation, 
i.e. the initial condition in each of the two ELF compartments was set to 
0.5LDD/VELF. 
   It follows that two important assumptions are made in these simulations: 1) the 
permeability is identical throughout the entire lung (i.e. the measured Papp applies for 
all lung regions, which probably is not true for the alveolar region where a higher 
permeability is expected), and 2) the CaCo-2 Papp equals the effective permeability. 
Thus, two assumptions were made in areas which still remain to be investigated by 
future research. Nevertheless, in a theoretical situation where only P differs, the 
model-derived values of t½,lung can be used to evaluate the impact of P on pulmonary 
absorption on a qualitative level. 
   Starting by evaluating the simulations resulting from a central deposition of drug, 
figure 5.13a shows that t½,lung decreased with a higher permeability. The model 
predictions thus agreed with the observations made by Cooper et al. [7] on a 
qualitative level. As can be seen in figure 5.13b, model simulations indicate that the 
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initial profile of the lung PK-profile, which often is referred to as the ‘alpha phase’, 
would be less steep for poorly permeable compounds. 
   As expected, lower values of P resulted in higher drug concentrations in the ELF 
(CELF, fig. 5.13c), which can have interesting implications for drugs with targets 
localised in the airway lumen. The same pattern, although not as pronounced, was 
seen for Clung (fig. 5.13b). 
   Interestingly, despite the assumption of P being identical throughout the entire 
lung, the simulations suggested that the pulmonary PK is largely influenced by the 
initial deposition pattern. This was particularly prominent when comparing the lung 
PK-profiles over the first few minutes. After IT-administration of an evenly 
distributed dose, the model predictions indicated that a particularly rapid pulmonary 
absorption phase took place during the first few minutes after dosing (fig. 5.13d). 
However, this pattern was not present when drug administration was restricted to the 
central lung (fig. 5.13e). The simulations thus suggest that pulmonary absorption is 
more rapid in the rapidly perfused peripheral lung region. In contrast, a poor P 
appears to be an effective mechanism for lung-retention in the central lung region. 
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Figure 5.13 The impact of permeability (P) on pulmonary absorption was theoretically explored by 
simulating pulmonary drug administration of a solution (10 nmol/kg). The dose was either only 
administered in the central lung region (subfigure a-c and e) or evenly distributed between the central 
and the peripheral lung (subfigure d). The subfigures show: a) pulmonary absorption half-life (t½,lung) 
for different values of P (blue line), the measurements of t½,lung were obtained from  (black triangles), 
b) total lung concentrations of drug (Clung, blue lines) over 25 h, c) concentration of drug in the 
epithelial lining fluid (CELF, red lines), and d-e) Clung (blue lines) focused on the first 15 minutes. The 
system was simulated iteratively for 40 different values of P, where P varied between 0.1×10-6 and 
100×10-6 cm/s. In subfigures b-e each line corresponds to a simulation using one value of P. The 
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different lines can be identified by the observation that a lower P consistently made the curves less 
steep. 
 
5.3.4.4 Evaluation of the extent of nasal drug absorption 
Under certain conditions, model simulations indicated that extensive nasal drug 
absorption might be present after nose-only exposure. This is perhaps not surprising 
as intranasal drug delivery is a common route of drug administration, both for local- 
and systemic drug delivery. Clearly a high degree of nasal absorption is desired when 
the aim is to induce systemic effects. Hence, numerous research groups have 
investigated what factors influence nasal drug absorption. For simplicity, these 
factors are often divided into three different categories: 1) nasal physiological factors 
(system-specific parameters), 2) characteristics of the drug (drug-specific 
parameters), and 3) properties of the formulation (formulation-specific parameters) 
[181].  
   System-specific parameters for instance include blood-flow, nasal MCC, enzymatic 
degradation and transporters [181]. Neither enzymatic degradation nor transporters 
are included in this model structure. Model simulations showed that a higher nasal 
MCC and a lower blood-flow decreased the extent of nasal drug absorption 
(simulations not shown). Noteworthy is that some drugs might cause 
vasoconstriction and hence decrease the blood-flow. It has been shown that such 
drugs can inhibit the nasal absorption [182], which thus is in line with the model 
predictions. If the drug of interest is expected to induce vasodilatation or 
vasoconstriction, the nasal blood flow can thus be changed in the model to 
investigate the effect on nasal drug absorption.  
   Drug-specific parameters include, for instance, solubility and permeability. As the 
nasal membrane primarily has a lipophilic character, a lower permeability can be 
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expected from hydrophilic drugs [183]. Conversely, a highly lipophilic drug may 
have a low water solubility, which would slow down the dissolution rate of drug 
particles in the aqueous environment in the nose [181]. As such compounds remain 
in a solid state for a longer time period they are more prone to be removed by the 
nasal MCC. The extent of nasal drug absorption is thus determined by complex 
interactions between several different parameters. In order to investigate how 
changes in the solubility (Cs) and the permeability (P) affect the extent of nasal 
absorption following nose-only exposure, the system was simulated 625 times using 
different combinations of these two parameters. More specifically, the cumulative 
amount of drug absorbed from the nose (Anose) after 24 h was simulated for a broad 
range of Cs and P after an LDD of 11.3 nmol/kg. Cs varied between 0.1 and 50 µM 
and P varied between 0.1×10
-6 and 50×10-6 cm/s. The parameter values were 
subsequently selected from a logarithmic scale. Figure 5.14 shows the interplay 
between Cs and P.  
   The same exercise was carried out for the lung. As can be seen in figure 5.15, the 
impact of Cs and P was less pronounced in the lung. This can primarily be attributed 
to: 1) kmcc = 0 in the peripheral lung region, i.e. all drug deposited in this region will 
be absorbed as t → ∞ provided Cs ≠ 0 and P ≠ 0, and 2) kmcc is several-fold slower in 
the central lung as compared to the nose. The second model feature translates to a 
longer pulmonary- than nasal residence time, i.e. the time during which drug can 
absorbed will be longer in the lung. 
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Figure 5.14 The amount of drug absorbed from the nose (Anose) after nose-only exposure was 
simulated for different combinations of two parameters: permeability (P) and solubility (Cs). 
 
Figure 5.15 The amount of drug absorbed from the lung (Alung) after nose-only exposure was 
simulated for different combinations of two parameters: permeability (P) and solubility (Cs). 
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5.3.4.5 Impact of permeability in the central lung  
Absorption of dissolved drug from the lung to the systemic circulation is generally 
assumed to be slower from the tracheobronchial region as compared to the alveolar 
region. This has been attributed both to the lower blood perfusion and to the thicker 
airway walls in this region [15]. The proposed differences in regional absorption 
rates have also been demonstrated experimentally after regional administration of 
solutions [184,185]. Furthermore, the differences in regional perfusion rates and 
surface area alone were shown to have a pronounced impact on the pulmonary 
absorption by a simulation study described in section 5.3.4.3. 
   In [186], the drug permeability (P) is described as a constant that depends on the 
diffusion coefficient (D) of the drug in the barrier, the thickness of the barrier (h) and 
the partition coefficient into the barrier (γ): 
 
h
D
P

 .     (5.55) 
 
Moving from the trachea to the alveolar region, both the type of epithelium and its 
thickness will change. In humans, the thickness of the epithelium decreases from 58 
µm in the bronchi to 0.1-0.2 µm, in the alveoli [11]. In rats, the bronchi epithelium 
thickness is 13 µm [29].  From eq. 5.55 it thus seems plausible that P will not be 
constant throughout the lung. Furthermore, it specifies that region-specific 
knowledge about both γ and h is needed for proper scaling of P in different lung 
regions. To the best of my knowledge, such data is currently not available. New 
experimental methodologies would be desired to further investigate this issue. 
Nevertheless, as the thickness of the epithelium gradually decreases when moving 
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distally throughout the lung, it is plausible that this gradual decrease in epithelium 
thickness is also applicable for P.  
   Three different scenarios were simulated in order to investigate what impact a 
lower P in the central lung region would have on the pulmonary drug disposition if 
the peripheral P was kept high. The LDD was set to be 100 nmol/kg and the drug- 
and formulation-specific parameters of FP specified in table 5.4 were used in all 
three scenarios, whereas Papp in the central lung region varied accordingly: 1) Papp, 2) 
Papp/10, and 3) Papp/100. That is, the resulting central Papp in each of the three 
simulations was 46.9×10-6 cm/s (high P), 4.69×10-6 cm/s (moderate P) and 
0.469×10-6 cm/s (low P), respectively. 
   As can be understood from eq. 5.1 (the ODE describing the flux to/from the 
systemic circulation), a lower P would result in a slower permeation into the lung 
tissue. The result of the slower permeation is an increased drug concentration in the 
ELF (CELF, fig. 5.16a). As a higher CELF would slow down the dissolution rate (eq. 
5.20) this would in turn lead to an increased retention time of drug in the lung (fig. 
5.16b). The latter example thus also serves to demonstrate that P is an important 
parameter for accurately predicting the lung retention of slowly dissolving drugs. 
The profile of ROc would also change (fig. 5.16c), whereas the impact on ROsp would 
be less pronounced (fig. 5.16d). Briefly, according to model simulations a lower P in 
the central lung region might lead to a prolonged lung-retention. A lower P would 
also have an effect on the Cp-profile (fig. 5.16e), where simulations show that P is an 
important parameter for determining both the amplitude of the maximum Cp (Cmax) 
and the time point when it occurs (tmax). 
   Considering the regional differences with respect to both the type of epithelium as 
well as its thickness, differences in P are highly likely. As previously mentioned in 
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section 5.3.4.3, further research is required in this area to increase the understanding 
of regional pulmonary permeability as well as the feasibility to use different in vitro 
models for the description thereof. The Papp obtained from CaCo-2 experiments is 
more likely to reflect the P in the central lung than the peripheral lung owing to the 
characteristics of the cells. Simulations using the drug- and formulation-specific 
input parameters for FP (table 5.4) showed that a 100-fold higher P in the peripheral 
region were indistinguishable from the earlier simulations (simulations not shown 
since they were indistinguishable from fig. 5.5). Hence, the model validation step has 
not been biased by using the same P throughout the lung. Nevertheless, the final 
model structure presented in this thesis, which also allows for repeated dosing, will 
have a 100-fold higher permeability in the peripheral lung. The primary rationale for 
scaling by a factor of 100 is based on the differences in epithelium thickness. 
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Figure 5.16 Three different scenarios were simulated to investigate what impact a lower permeability 
in the central lung would have on the pharmacokinetics. The lung deposited dose was set to 100 
nmol/kg and the drug- and formulation-specific parameters of FP specified in table 5.4 were used in 
all three scenario, whereas the apparent permeability (Papp) in the central lung varied accordingly: 1) 
Papp (solid line), 2) Papp/10 (dashed line), and 3) Papp/100 (dotted line). The following model outputs 
were simulated: a) drug concentration in the epithelial lining fluid (CELF), b) total lung concentration 
of drug (Clung), c) receptor occupancy in the central lung (ROc), d) receptor occupancy in the spleen 
(ROsp), and e) plasma concentration of drug (Cp). 
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5.3.5 Repeated dosing 
Up until now, the simulations have aimed to explore the fundamental principles for 
systemic and local pharmacokinetics after inhaled drug delivery. Single dosing has 
thus been sufficient to address these questions. Nevertheless, in the clinical situation, 
inhalation is often used to treat chronic diseases such as chronic obstructive 
pulmonary disease (COPD) and asthma. It is therefore essential to understand the 
effects of long-term use of inhaled drug therapy. Repeated dosing was thus 
implemented to enable theoretical investigations of how chronic dosing affects the 
PK and PK/PD of inhaled drugs. Previously, the regional deposition fractions for the 
different regions (nose, central lung and peripheral lung) and the relevant 
aerodynamic diameters have been extracted from Lee et al. [65]. To enable 
simulations of repeated dosing of any particle size classes, the model by Lee et al. 
[65] was implemented in MATLAB and integrated with the lung simulation model. 
The technical implementation of this deposition model is described in the section 
5.3.5.2 below. 
 
5.3.5.1 Technical implementation of repeated dosing 
Repeated dosing was implemented in MATLAB by adding a new set of 24 ODEs 
describing the change of the radius rij (where i ∈ {1, …, 8} and j ∈ {1, 2, 3}) (eq. 
5.25) for each dosing occasion k, where k ∈ {1, …, n}. That is, k = 1 assigns the first 
dose, k = 2 assigns the second dose and so on. The number of states in the PBPK 
model was updated automatically by having k as an input to the function defining the 
coupled ODEs. 
   Except for k = 1, the initial conditions for the set of ODEs describing the change of 
rij for each dosing occasion k were initially set to 0. The parameter τ was used to 
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define time span between dosing, which is often referred to as the dosing interval. A 
for-loop was used to enable simulations of repeated dosing by iteratively solving the 
coupled ODE-system. The interval of integration for the ODE-solver was set to [(k-
1)×τ, k×τ]. At each iteration k, the initial condition for each state y was updated to the 
solution of y at t = k×τ. The initial conditions for the set of ODEs describing the 
change of rij for the following dosing occasion (k+1) was changed from 0 to the 
geometric radius corresponding to each particle size class i. The entire code is 
attached as Appendix A. For clarity, all PBPK model ODEs are summarised in 
Appendix C. 
 
5.3.5.2 Technical implementation of a deposition model 
The deposition model by Lee et al. was implemented in MATLAB and the entire 
code is attached as Appendix B. Details of the model are provided by the authors in 
the original paper [65] whereas this subsection aims to define the most important 
equations as well as to specify the breathing conditions and the anatomical model 
used in the simulations.  
   The anatomical model structure is presented in table 5.8. To summarise, each lung 
generation i is described to consist of a number of cylindrical tubes (Ni), which are 
characterised by a length (Li), a diameter (Di), an average angle with gravity (φi) and 
a branching angle (θi). In this model, the lung is divided into three regions: 1) the 
extrathoracic region (i = 1, 2), 2) the tracheobronchial region (i = 3, …, 18), and 3) 
the alveolar region (i = 19, …, 26). The alveolar region is also characterised by a so-
called “effective airway diameter” (Deff), which is added to account for the alveoli 
volume. In contrast to the airways, the nose is described as an artificial rectangular 
channel as suggested by Schmid et al. [66]. Unless stated differently, the normal 
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breathing conditions specified by Lee et al. were used with a tidal volume (VT) of 2.6 
cm3 and breathing frequency (fbr) of 97.4 min
-1. As the anatomical data in table 5.6 
refers to a lung at nearly full inflation, the dimensions were scaled to conform to a 
more realistic average respiration lung volume (ARLV). This was done by 
multiplying Li and Di with a factor fscale [65], which was defined as 
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where TLC is the total lung capacity, FRC is the functional residual capacity and VT 
is the tidal volume. As can be understood from eq. 5.56, it is assumed that  
 
TLCFRC 4.0     (5.57) 
and 
TT VTLCVFRCARLV 5.04.05.0  ,  (5.58) 
where TLC is calculated as suggested by Yeh et al. 1979 [172]: 
05.1032.0 BWTLC  ,    (5.59) 
 
where BW is the body weight in gram. In line with Lee et al., the BW was set to be 
381 g. Thus, given VT = 2.6 cm
3 and BW = 381 g, fscale was calculated to be 0.7825. 
The length of the last ventilated generation is subsequently adapted such that VT 
matches the total volume of the anatomical model [66]. 
   The average inspiratory flow rate (Qin) was calculated as described by Schmid et 
al. [66] 
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brTin fVQ 2  .    (5.60) 
 
The flow pattern was assumed to be constant (i.e. a square wave flow pattern), the 
flow rate (Qi) and the average velocity in each generation i (ui) were subsequently 
calculated as [187]  
 
i
in
i
N
Q
Q  ,     (5.61) 
and 
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respectively. In eq. 5.62 Ai denotes the cross-sectional area of generation i, i.e. 
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This model accounts for deposition by three different mechanisms: 1) inertial 
impaction, 2) gravitational sedimentation, and 3) Brownian diffusion. The deposition 
probability by inertial impaction (DEim) was calculated according to Zhang et al. 
1997 [188]: 
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with 
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where Stki is Stokes number in generation i, Rei is Reynold number of the airflow in 
generation i, ρ0 is the unit particle density (1 g/cm3), da is the aerodynamic diameter, 
ui is the mean air flow velocity in generation i, η is the viscosity of air and ρa is the 
air density. The deposition probability by gravitational sedimentation (DEs) was 
calculated according to Thomas 1958 [67]: 
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where vg is the gravitational settling velocity, ti is the mean residence time in 
generation i, g is the gravitational acceleration, Cd is the Cunningham slip correction 
factor and λ is the mean free path of air molecules. In the alveolar region, Deff,i was 
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used as the airway diameter in eq. 5.68. The deposition probability by Brownian 
diffusion (DEd) was calculated according to Ingham 1975 [189]: 
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where Dmol is the Brownian diffusion coefficient, kB is the Boltzmann constant and T 
is the absolute temperature. In the alveolar region, (Di+Deff,i)/2 was used as airway 
diameter in eq. 5.72 [65]. The authors’ rationale behind this choice was that while the 
alveoli increases the surface area for deposition, the larger effective diameter of the 
airway will also lead to a decreased deposition by diffusion. 
   The deposition equations above are applicable for all generations where i ≥ 2, i.e. 
the nasal deposition probabilities are calculated by other equations. The nasal 
deposition probability by inertial impaction was approximated according to an 
empirical equation by Zhang and Yu 1993 [190]: 
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where da is the aerodynamic diameter in µm, Q is the flow rate in cm
3/s and α, β and 
C are constants estimated by Zhang and Yu [190]. For the rat, these constant values 
are 2.553, 0.627 and 105, respectively. Except for eq. 5.74, MKS-units are used for 
all equations. The nasal deposition probability by diffusion was calculated as 
suggested by Cheng 1993 [191]: 
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where L, W and H are the length, width and height of the nasal passage, respectively. 
The nasal deposition by gravitational sedimentation was assumed to be negligible 
compared to the other two deposition mechanisms (eqs. 5.74-5.75). 
   The resulting deposition probability in generation i (Pi) was subsequently given by 
[68] 
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Deposition in generation i during inhalation (DEi
in) was calculated by 
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where Vj is the volume of generation j and imax is the last ventilated generation. 
Deposition in generation i during exhalation (DEi
ex) was calculated by 
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The aforementioned equation can be divided into two parts: 1) the first term in eq. 
5.80 indicates the deposition (during exhalation in generation i) of particles that were 
in generation i + 1 at the end of inhalation, 2) the second term specifies the 
deposition of particles that were between generations i + 2 to imax at the end of 
inhalation. Since the breath hold time between inhalation and exhalation is short 
compared to the breathing cycle, Lee et al. chose to assume that there was no 
deposition during breath holding. The resulting total deposition during a breath 
(DEi
tot) is thus given by 
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and the deposition in a lung region (DEregion) between region j and k is then defined 
as 
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Studies relying on computational simulations have suggested that penetration of 
particles into the alveoli not only rely on diffusion and sedimentation but there is an 
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additional mechanism: convective transport. In the absence of realistic models for 
describing this phenomenon Lee et al. assumed that deposition enhancement by this 
mechanism occurs for particles with da in the range 0.02 ≤ da ≤ 2.0 µm. This was 
mathematically described as 
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The resulting deposition fraction (df) was subsequently obtained by dividing the 
amount deposited (eq. 5.83) by the amount inhaled. The resulting df for the 
extrathoracic region (dfET), tracheobronchial region (dfTB), alveolar region (dfAL) and 
all regions (dftot) are shown in figure 5.17. The result of varying VT (2.6, 3.9 and 5.2 
cm3) was investigated by calculating df for the three regions mentioned above while 
keeping fbr constant (97.4 min
-1). As can be seen in figure 5.18, the effect of 
changing VT was most pronounced in the alveolar region. Increasing VT has an effect 
both on the flow rate (eqs. 5.60 and 5.61) and the ventilation depth. In contrast, the 
fbr only affects the flow rate (eqs. 5.60 and 5.61). Hence, changing fbr (97.4, 195 and 
390 min-1) while keeping VT constant (2.6 cm
3) should have a slightly different effect 
on df, which is shown in figure 5.19. 
   As can be understood from the equations governing the deposition by the three 
included deposition mechanisms, different mechanisms will be dominant in different 
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regions of the lung depending on e.g. the lung anatomy (Di, Li, φi and θi), regional 
flow velocity (ui) and residence time (ti). To investigate the importance of different 
mechanisms across the lung, the deposition probability by each mechanism was 
calculated for da in the range 0.001 ≤ da ≤ 10 µm. Fig. 5.20a-c shows how DEIM, DEs 
and DED for each particle size changes with the lung generations. Similarly, figure 
5.21a-c shows how DEIM, DEs and DED for each generation changes with da. Inertial 
impaction is particularly important in the tracheobronchial region (fig. 5.20a) with 
the exception of generation 2-3 where the branching angle θ = 0◦, which precludes 
deposition by this mechanism. Fig. 5.21a highlights that larger particles are likely to 
deposit by inertial impaction, whereas small particles are unaffected. The latter is 
caused by small particles having low Stokes number (eq. 5.65), which implies 
smaller inertial effects and the particles thus tend to follow the streamlines. 
Gravitational sedimentation is an important mechanism for larger particles in the 
alveolar region (fig. 5.20b and fig 5.21b). This is an effect of the probability of this 
mechanism increasing with ti, which is longer in the distal lung regions, and vg, 
which increases with da (eq. 5.69). Brownian diffusion on the other hand is the 
dominant deposition mechanism for smaller particles (fig. 5.21c), especially in the 
alveolar region where ui is lower (fig. 5.20c). 
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Figure 5.17 The deposition fractions (df) in a) the extrathoracic region, b) the alveolar region, c) the 
tracheobronchial region, and d) all three regions, i.e. total df, for normal breathing conditions (VT = 2.6 
cm3 and fbr = 97.4 min-1). The predictions were made after implementing the deposition model by Lee 
et al. [65] 
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Figure 5.18 The effect of the tidal volume (VT) on the deposition fraction (df) was investigated by 
simulating df for different VT: 2.6 (solid line), 3.9 (dashed line) and 5.2 cm3 (dotted line). The df was 
simulated in different regions: the extrathoracic- (upper panel), tracheobronchial- (middle panel) and 
alveolar region (lower panel). 
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Figure 5.19 The effect of the breathing frequency (fbr) on the deposition fraction (df) was investigated 
by simulating df for different fbr: 97.4 (solid line), 195 (dashed line) and 390 min-1 (dotted line). The df 
was simulated in different regions: the extrathoracic- (upper panel), tracheobronchial- (middle panel) 
and alveolar region (lower panel). 
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Figure 5.20 The probability of deposition by three deposition mechanisms: inertial impaction (DEIM, 
upper panel), gravitational sedimentation (DES, middle panel) and Brownian diffusion (DED, lower 
panel) was investigated for each airway generation i where i ∈ {1, …, 26}. Each line represents the 
deposition probability for a particle with a certain aerodynamic diameter (da), where da is in the range 
0.001 ≤ da ≤ 10 µm. 
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Figure 5.21 The probability of deposition by different deposition mechanisms: inertial impaction 
(DEIM, upper panel), gravitational sedimentation (DES, middle panel) and Brownian diffusion (DED, 
lower panel) was investigated for a range of aerodynamic diameters (da) in the range 0.001 ≤ da ≤ 10 
µm. Each line represents the deposition probability in an airway generation i where i ∈ {1, …, 26}. 
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Table 5.8 Lung structure of a rat lung at 81 postnatal days [65].
i 
 
Ni 
 
Li  
(cm) 
Di 
 (cm) 
Deff,i 
(cm) 
φi 
 (◦) 
θi  
(◦) 
1 1 1.95 0.016a, 5.7b 90 0 
2 1 3 0.2700 0.2700 90 0 
3 1 2.68 0.3153 0.3153 86 0 
4 2 0.8079 0.2651 0.2651 90 15 
5 3 0.3781 0.2343 0.2343 86 43 
6 5 0.176 0.2030 0.2030 71 36 
7 8 0.208 0.1630 0.1630 59 32 
8 14 0.117 0.1340 0.1340 58 22 
9 23 0.114 0.1230 0.1230 61 16 
10 38 0.13 0.1120 0.1120 58 17 
11 65 0.099 0.0950 0.0950 55 20 
12 109 0.091 0.0870 0.0870 58 15 
13 184 0.096 0.0780 0.0780 61 16 
14 309 0.073 0.0700 0.0700 56 17 
15 521 0.075 0.0580 0.0580 56 17 
16 877 0.06 0.0490 0.0490 58 22 
17 1477 0.055 0.0360 0.0360 57 24 
18 2487 0.035 0.0200 0.0200 58 44 
19 4974 0.0288 0.0189 0.0879 60 45 
20 9948 0.0263 0.0179 0.0857 60 45 
21 19896 0.0263 0.0170 0.0838 60 45 
22 39792 0.024 0.0162 0.0820 60 45 
23 79584 0.0219 0.0155 0.0804 60 45 
24 159168 0.0201 0.0149 0.0789 60 45 
25 318336 0.0184 0.0143 0.0776 60 45 
26 636672 0.0168 0.0138 0.0764 60 45 
Abbreviations: i is the lung generation number; Ni is the number of airways in generation i; Li and Di 
are the airway length and diameter, respectively; Deff,i is the effective diameter also considering the 
alveolar volume; φi and θi are the gravity and the branching angles, respectively. Generations 1, 2 and 
3 represent the nose, the pharynx and the trachea, respectively. The nasal passage is described as a 
rectangular channel where the height and width are indicated by the superscripts a and b, respectively.  
The tracheobronchial and the alveolar region are defined as i = 3, …, 18 and i = 19, …, 26, 
respectively. 
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5.3.5.3 Repeated dosing of poorly and highly soluble compounds 
As many inhaled drugs have a poor solubility and only a small volume of ELF is 
available for dissolution, an accumulation of drug might be expected after repeated 
dosing of this compound class. To theoretically explore this, repeated nose-only 
exposure (LDDk = 100 nmol/kg, where k ∈ {1, …, 5} and τ = 24 h) was simulated for 
a poorly (Cs = 0.5 µM) and a highly soluble compound (Cs = 50 µM), respectively, 
using a moderate permeability (Papp = 5×10
-6 cm/s). Otherwise, the drug- and 
formulation-specific properties for FP (table 5.4) were used. As mentioned in section 
5.3.4.5, the permeability is expected to be lower centrally. The P was therefore set be 
a hundredfold higher in the peripheral lung as compared to the central lung (i.e. the 
peripheral P was set to 100×Papp). Since nasal absorption is absent for orally inhaled 
compounds in the clinic, the nasal blood flow was set to 0 to decouple the nose from 
the system and thereby mimic the clinical situation. 
   As can be seen in figure 5.22a, all solid drug particles of the poorly soluble drug 
will not be dissolved nor be removed by MCC during one dosing interval. Hence, an 
accumulation of solid drug particles will take place. Noteworthy is that the system 
appears to be close to steady-state conditions after five dosing intervals. In contrast, 
no solid drug remains at the end of one dosing interval for the highly soluble 
compound (fig. 5.22b). Obviously, the same patterns are seen in the simulations of 
the total lung concentrations (fig. 5.22c-d). For the poorly soluble compound, CELF in 
the central lung will be fairly high during the entire dosing interval (fig. 5.22e). A 
small accumulation is also present in the ELF, potentially leading to a slightly slower 
dissolution rate for repeated as compared to single dosing (eq. 5.20). For highly 
soluble compounds, the corresponding concentrations in the central ELF will initially 
be close to Cs and then rapidly decline (fig. 5.22f). As an accumulation does not take 
222 
 
place in the ELF, the dissolution rate will not be different for repeated and single 
dosing. Obviously, the same patterns are found in the plasma profiles. That is, a 
small accumulation is seen for the poorly soluble drug (fig. 5.22g), but not for the 
highly soluble drug (fig. 5.22h). Clearly, the different dissolution profiles are 
reflected in the plasma PK, where the poorly soluble compound has a flat PK-profile 
with small fluctuations. In contrast, the highly soluble compound has a relatively 
high peak concentration, which then rapidly declines leading to large fluctuations in 
the plasma profile. The different solubilities also lead to diverse receptor occupancy 
profiles. The poorly soluble drug only has small fluctuations in the receptor 
occupancy profile. Moreover, lung-selectivity is obtained over the entire dosing 
interval (fig. 5.22i). In contrast, the highly soluble compound has large fluctuations 
in receptor occupancy and lung-selectivity is only transiently obtained directly after 
dosing (fig. 5.22j). 
   There are few data available for validating predictions of PK after repeated 
nose-only exposure. Nevertheless, unpublished AstraZeneca data of one poorly 
soluble compound confirm that the systemic exposure, in terms of the maximum 
plasma concentration (Cmax) and AUC0-24h, was higher after repeated dosing 
compared to after a single dose. In line with the predictions, no difference in 
systemic exposure was found after single and repeated dosing of a highly soluble 
compound [164].  
223 
 
 
224 
 
Figure 5.22 Simulations of repeated nose-only exposure. A lung deposited dose of 100 nmol/kg was 
administered every 24 hours. The left panel shows simulations of a poorly soluble drug (solubility, Cs 
= 0.5 µM), whereas the right panel shows the corresponding simulations of a highly soluble 
compound (Cs = 50 µM). The following variables are simulated: 1) solid amount of drug in the lung 
(Asolid), 2) total lung concentration (Clung), 3) concentration in epithelial lining fluid in the central lung 
(CELF), 4) plasma concentrations (Cp), and 5) receptor occupancy in the central lung (ROC, dashed blue 
line) and the spleen (ROsp, red line). 
 
5.3.5.4 Effect of increasing inhaled doses 
As mentioned in section 2.2.4, meta-analyses have shown a relatively flat dose-
response curve for efficacy measurements of inhaled corticosteroids. In contrast, a 
steeper dose-response curve has been noted for the side-effects. Taken together, these 
two relationships imply that although only a small clinical benefit is expected from 
increasing the inhaled dose, the risks of side-effects is considerably increased [47].  
   Simulations were used to investigate the dose-response relationship of inhaled 
corticosteroids with respect to both the local beneficial effects and the systemic side-
effects. Firstly, a poorly soluble compound (Cs = 0.5 µM) with a moderate 
permeability (Papp = 5×10
-6 cm/s) was administered repeatedly (k = 5, τ = 24 h) using 
a broad range of doses (LDD = 10, 50, 250, 750 and 1250 nmol/kg). ROc and ROsp 
was assumed to reflect the beneficial local effects and the systemic side-effects, 
respectively. Since nasal absorption is absent for orally inhaled compounds in the 
clinic, the nasal blood flow was set to 0 to decouple the nose from the system and 
thereby mimic the clinical situation. In line with the reasoning in section 5.3.5.3, P 
was set to be a hundredfold higher in the peripheral lung as compared to the central 
lung (i.e. the peripheral P was set to 100×Papp). Otherwise, the drug- and 
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formulation-specific parameters defined in table 5.4 were used. Noteworthy is that 
F = 0.  
   Secondly, a highly soluble compound with a moderate permeability (Papp = 5×10
-6 
cm/s) was used in the simulations (Cs = 50 µM). A broad range of LDD was used 
(LDD = 1, 5, 25, 125 and 250 nmol/kg). Except from Cs and LDD, all parameters and 
settings were identical in the two different simulation sets.   
   The simulations of a poorly soluble drug showed that the degree of lung-selectivity 
decreased at higher LDD (fig. 5.23a-e). Expressed differently, ROsp was more 
sensitive to changes in LDD at higher doses since ROc was already in the proximity 
of its maximum value. Increasing LDD at that stage should thus not be expected to 
provide a significantly better local effect but rather act by increasing the risk of side-
effects. Furthermore, the model elucidated an interesting phenomenon: the ELF in 
the central region will be in the proximity of Cs throughout the entire dosing interval 
after repeated dosing of a high LDD. For poorly permeable compounds, this 
phenomenon will occur at lower LDD (simulations not shown). It thus follows that 
the maximum central lung tissue concentration (and thus ROc) that can be obtained 
via flux from the ELF will be limited by the interplay between e.g. P, Cs, the particle 
size and the regional blood flow (i.e. Qbronch). Under such circumstances, the small 
rise in ROc that results from increasing the LDD will primarily be systemically 
driven as the input from the central ELF is close to its maximum.   
   As can be seen in figure 5.24a-e, the maximum ROc was reached already at a low 
LDD for the highly soluble compound. The same pattern was subsequently noted; the 
degree of lung-selectivity decreased with increasing LDD. Thus, regardless of the 
solubility characteristics, the simulations at the higher end of the dose-spectrum were 
consistent with the dose-response relationships found in clinical studies.   
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   It is worth noting that the lung-selectivity obtained for the highly soluble 
compound is the result of the dissolution process, the slow Koff (Koff = 0.51 h
-1) as 
well as the P. In order to investigate how the last two properties can affect the dose-
response after repeated inhaled dosing of a highly soluble compound, two additional 
scenarios were explored. Firstly, Koff was set to be 10-fold lower (i.e. Koff = 0.051 h
-
 1). Secondly, the P was set to be 10-fold lower (i.e. Papp = 0.5×10
-6 cm/s). Except 
from these changes, all drug- and formulation-specific input parameters as well as 
the choice of LDD remained unchanged.  
   As can be seen in figure 5.25a-e, a slow Koff acted by increasing the degree of lung-
selectivity. Importantly, it prolonged the period during which lung-selectivity was 
obtained. In fact, for the three lower doses (LDD = 1, 5 and 25 nmol/kg) lung-
selectivity was obtained throughout the entire dosing-interval. As in the previous 
simulations, the degree of lung-selectivity subsequently decreased with higher LDD. 
In this simulation set, Koff was lowered by a factor of 10 whereas Kd remained 
unchanged. Since Kd is defined as the ratio between Koff and Kon (eq. 4.8), it follows 
that Kon was 10-fold lower. The lower receptor occupancy levels seen in figure 
5.25a-c as compared with figure 5.24a-c are thus the result of the lower Kon (the 
drug-receptor association is driven by Cu(t)KonR(t) as described in eq. 5.31). 
   Figure 5.26a-e presents the simulations in which a highly soluble compound with a 
10-fold lower P was used. When comparing these simulations to the base-case 
(fig. 5.24a-e), it was found that the receptor occupancy profiles were similar at the 
three lowest doses used in this simulation study (LDD = 1, 5 and 25 nmol/kg). In 
contrast, at the two highest doses the effect of lowering P was more pronounced (fig. 
5.24d-e and 5.26d-e for the base-case and the 10-fold lower P, respectively). As a 
result of the lower P and thus slower absorption from the airway lumen, high drug 
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concentrations will be maintained in the ELF over a prolonged time period. This 
effect will be particularly pronounced after a high LDD since the CELF will be in 
close proximity to Cs (i.e. it will be saturated with respect to drug) and thus 
significantly slow down the normally rapid dissolution process. Hence, the net effect 
of increasing LDD in combination with lowering P was a more sustained receptor 
occupancy profile with a prolonged period of lung-selectivity. 
   To summarise, in all simulations described in this subsection (figs. 5.23-5.26) the 
lung-selectivity decreases at high LDD. Expressed differently, 
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LDD RO
RO
.    (5.85) 
 
It is also clear that the ratio between ROc and ROsp will tend to infinity as LDD 
approaches 0, i.e. 
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Expressed differently, as LDD approaches 0 it follows that both ROc and ROsp tend to 
0; i.e. an undesired situation where no pharmacological effect is exerted. This clearly 
emphasises the need to have a PK/PD model in place prior to making a dose 
optimisation in order to establish approximately what level of receptor occupancy is 
needed to exert the desired effect. Once this information is in place, it would be 
possible to apply constrained optimisation for dose optimisation purposes. 
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Figure 5.23 Simulations of receptor occupancy in the central lung (ROc, dashed lines) and in the 
spleen (ROsp, solid lines) after increasing lung deposited doses (LDD): a) 10 nmol/kg, b) 50 nmol/kg, 
c) 250 nmol/kg, d) 750 nmol/kg, and e) 1250 nmol/kg. A poorly soluble compound with moderate 
permeability was used in the simulations (solubility = 0.5 µM, permeability = 5×10-6 cm/s). 
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Figure 5.24 Simulations of receptor occupancy in the central lung (ROc, dashed lines) and in the 
spleen (ROsp, solid lines) after increasing lung deposited doses (LDD): a) 1 nmol/kg, b) 5 nmol/kg, c) 
25 nmol/kg, d) 125 nmol/kg, and e) 250 nmol/kg. A highly soluble compound with moderate 
permeability was used in the simulations (solubility = 50 µM, permeability = 5×10-6 cm/s). 
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Figure 5.25 Simulations of receptor occupancy in the central lung (ROc, dashed lines) and in the 
spleen (ROsp, solid lines) after increasing lung deposited doses (LDD): a) 1 nmol/kg, b) 5 nmol/kg, c) 
25 nmol/kg, d) 125 nmol/kg, and e) 250 nmol/kg. A highly soluble compound with moderate 
permeability and a slow dissociation rate constant (Koff) was used in the simulations (solubility = 50 
µM, permeability = 5×10-6 cm/s, Koff = 0.051 h-1). 
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Figure 5.26 Simulations of receptor occupancy in the central lung (ROc, dashed lines) and in the 
spleen (ROsp, solid lines) after increasing lung deposited doses (LDD): a) 1 nmol/kg, b) 5 nmol/kg, c) 
25 nmol/kg, d) 125 nmol/kg, and e) 250 nmol/kg. A highly soluble compound with a poor 
permeability was used in the simulations (solubility = 50 µM, permeability = 0.5×10-6 cm). 
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5.4 Discussion 
This chapter presents the development of a mechanistic PBPK model including lung 
disposition for prediction of systemic and pulmonary PK for inhaled drugs, which 
was validated by experimental measurements of drug concentrations and receptor 
occupancy obtained from studies where FP was used as test compound. By virtue of 
being mechanistic, this model provides a tool to theoretically explore pulmonary 
drug disposition and how key processes in a physiological context produce lung-
selectivity. 
   Two different compounds were used for evaluating the model: FP and budesonide. 
The model predictions for FP were consistent with experimental data collected from 
studies utilising the IV- as well as the inhaled route, which will be described in detail 
the subsequent paragraph. In contrast, regardless of the route of administration, there 
were discrepancies between model predictions and observations for budesonide. 
Since the model was predictive of FP, this systematic discrepancy for budesonide 
might suggest the presence of a drug-specific mechanism that is unaccounted for by 
the model. Indeed, as mentioned in section 5.3.2.1, a reversible fatty acid 
esterification of budesonide has been shown to take place both in vitro [175] and in 
vivo [79]. Upon characterisation of the PK of budesonide and its ester, budesonide-
oleate, it was demonstrated that budesonide-oleate was rapidly formed both after IV-
dosing and inhalation of budesonide in rats [79]. Since the resulting budesonide-
oleate concentrations were in the proximity of the budesonide concentrations [79], 
the process of esterification and the subsequent hydrolysis is likely to have a 
pronounced effect on the PK of budesonide. This hypothesis has also been confirmed 
via semi-empirical modelling approaches [79,176]. Hence, the current model 
structure should not be expected to accurately describe the PK of budesonide. Further 
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research would thus be required to adequately describe this mechanism in a 
quantitative manner, which was not considered to fall within the scope of this thesis. 
   Data generated from IV-dosing as well as inhalation of FP were used for model 
validation, which thus allows the model to be used to compare the two administration 
routes. Model predictions of IV-administrations were consistent with experimental 
data (figs. 5.4a-d), supporting a perfusion rate-limited distribution. Notably, input 
parameters (CL, Vd,ss, Kon and Koff) obtained from the modelling of one data set (90 
nmol/kg, IV) proved predictive of data from four other IV-dose levels (20, 150, 750 
and 1000 nmol/kg), thus offering strong support and confidence in its predictive 
capability to determine systemic PK and receptor occupancy. Interestingly, inclusion 
of receptor binding was necessary for accurate predictions of spleen concentrations 
after IV-administration as well as nose-only exposure (fig. 5.4d and 5.5c, 
respectively), which verifies that FP has a high receptor-bound fraction as suggested 
from the results presented in section 3.3.2.3. Similarly, inclusion of the receptor-
bound concentration was necessary for accurate predictions of Clung after IV-
administration of FP (fig. 5.4c). Taken together, this elucidates the potential pitfall of 
only relying on Kp-values when predicting tissue concentrations after low doses of 
highly potent compounds. Under such circumstances, under-predictions are 
inevitable as Kp-values do not account for receptor binding. In contrast, since Clung 
after nose-only exposure was substantially higher than the receptor density (i.e. Clung 
>> Bmax, where Bmax = 21 nM), the contribution of receptor binding to Clung was 
negligible after inhaled drug delivery. 
   As the aqueous solubility of poorly soluble compounds, such as FP, tends to under-
predict the in vivo dissolution rate [55], the single parameter Cs was estimated from 
observations of total drug concentrations in the lung made in one inhalation study 
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(11.3 nmol/kg, LDD). It is worth noting that the estimate of Cs (4530 [3845-5215] 
nM) was close to the measured FaSSIF-solubility (3120 nM) [164]. When the 
optimised model was tested on another data set (100 nmol/kg, LDD), it was shown to 
be predictive of the total lung concentrations with the exception of the last time point 
(fig. 5.5a). It should be noted that neither the particle size distribution nor the density 
was available for the study comprising of the higher LDD, which therefore was 
assumed to have the same formulation-specific properties as the low-dose study. The 
discrepancy between the predicted and observed Clung at t = 24 h could thus possibly 
be explained by an inaccurately described particle size distribution. Nevertheless, it 
might also reflect limitations of the Nernst-Brunner equation for the alveolar region 
where the ELF layer might be smaller than the particle diameter. 
   Model predictions of plasma concentrations and systemic occupancy after nose-
only inhalation agreed well with experimental data (figs. 5.5e-f). This consistency 
confirms that FP has a dissolution rate-limited absorption and underscores the 
importance of mechanistically describing the dissolution process for such 
compounds. 
   Validation of lung occupancy predictions was slightly more complex as these 
measurements reflect whole-lung occupancy. For comparison of observations and 
predictions, a weighted average accounting for the relative contribution of each 
pulmonary region was thus needed. Although exact determination of the tissue 
fractions cannot be made, the volume fraction of central lung (fv,c) was approximated 
to be 0.19 (section 5.2.2.3). Given the uncertainty in fv,c and the slightly lower 
accuracy of lung occupancy measurements (section 3.4), a whole-lung occupancy 
prediction that qualitatively captures key features including lung-selectivity and late 
occupancy peak (fig. 5.5d) can be regarded as a good description of the data. 
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   For validation purposes, emphasis was not placed on explaining the variability in 
the data, which is partly caused by the use of destructive sampling (one animal/time 
point). Apart from interindividual differences in model input parameters, a high 
variation in LDD is expected from preclinical studies utilising nose-only exposure 
systems. The latter can partly be explained by the individual animals having slightly 
different breathing patterns, the effect thereof on the deposition was illustrated by 
figs. 5.18 and 5.19. Since this is not monitored in preclinical studies, the validation 
instead focused on how well the model captured key features in the observations, 
both at a quantitative and a qualitative level. 
   Since the model proved to be predictive of FP, i.e. a neutral compound with a 
dissolution rate-limited absorption, it was used to theoretically explore various 
aspects of pulmonary drug disposition. As expected, simulations showed that lung-
selectivity could not be obtained if the drug was administered via the IV-route. More 
interestingly, a previously unforeseen finding resulting from the simulation studies 
was that lung-selectivity is possibly unattainable in the well-perfused parts of the 
lung after inhaled drug delivery. This can be attributed to the high perfusion rate of 
the alveoli region (entire cardiac output, QCO), which thus rapidly equilibrates with 
the systemic circulation. In fact, the model predicted the tissue distribution half-life 
of FP in the peripheral lung to be below 2 s. However, lung-selectivity could be 
obtained in the central region after inhalation as its lower perfusion rate allows for a 
longer equilibration time. The receptor occupancy in the central lung (ROc) was thus 
used as the pulmonary region for evaluation of lung-selectivity. 
   It was shown that a concentration-gradient, and thus lung-selectivity, was obtained 
during the dissolution phase (fig. 5.9a). It was also demonstrated that a low oral 
bioavailability and a high clearance were both important for obtaining a high degree 
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of lung-selectivity (simulations not shown). These three concepts have been 
demonstrated in an earlier simulation study by Hochhaus et al. [14]. Those 
simulations relied on a very simple model structure, in which the lung was described 
by a single compartment, the dissolution process by a rate constant, kdiss, and the 
receptor binding by a static Emax-model. The model presented in this thesis can thus 
explore further aspects of pulmonary drug disposition since it has: 1) a physiological 
parameterisation, 2) more sophisticated and mechanistic mathematical descriptions 
of drug disposition processes, and 3) a dynamic description of receptor binding, i.e. it 
is parameterised by the association rate constant (Kon) and the dissociation rate 
constant (Koff).  
   In line with results from previous research [14], this model also described the risk 
of only obtaining transient lung-selectivity after IT-administration of a dissolved 
drug without any additional mechanisms enhancing its lung-retention, i.e. a scenario 
resembling IV-administration where no lung-selectivity is obtained. Nevertheless, it 
was unravelled that a transient concentration-gradient can give rise to an extended 
period of lung-selectivity provided that the drug-receptor dissociation-rate is 
relatively slow (figs. 5.11a and 5.11e). The latter feature was unforeseen by earlier 
models since the receptor binding was described by a static Emax-model [14]. 
Interestingly, the lung-selectivity obtained via this mechanism could not be detected 
from the plasma profile after inhalation, which was close to identical to the 
corresponding profile obtained after administering the same dose as an IV-bolus (fig. 
5.10). This example thus also serves to demonstrate that it might be inappropriate to 
interpret inhalation studies solely on the basis of plasma concentrations. Simulations 
in section 5.3.3.2 demonstrated how yet another drug-specific property, namely a 
poor permeability, can lead to a prolonged period of lung-selectivity after IT-
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administration of a solution (fig. 5.9f). Besides, since a poor permeability results in a 
slower permeation into lung tissue and thus an increased drug concentration in the 
ELF (CELF, fig. 5.13c), this property might be even more interesting if the drug target 
resides in the airway lumen. According to model predictions, drug discovery projects 
with targets localised in the airway lumen would benefit from chemically design 
compounds that exhibit a poor permeability. 
   Moving back to lung-selectivity obtained by designing poorly soluble compounds 
and thereby creating a slow dissolution process. As mentioned in section 4.1, a more 
in-depth knowledge is needed to better understand the potential benefits and 
limitations of this strategy. Clearly, simulations indicate that this strategy is 
beneficial for highly potent compounds (figs. 5.9a, 5.22i, and 5.23a-e). Notably, at 
the other end of the spectrum are low-affinity compounds for which a low Cs might 
disrupt the opportunity of obtaining sufficiently high target site concentrations to 
elicit a pharmacological response. Simulations of repeated dosing of poorly soluble 
compounds elucidated this interesting phenomenon (fig. 5.23): the ELF in the central 
lung region will be in the proximity of Cs throughout the entire dosing interval after 
repeated doses of high LDD. The saturation of the ELF with respect to drug creates 
an interesting situation where the maximum central tissue concentration, and thus 
ROC, that can be obtained via flux from the airway lumen is limited by an interplay 
between e.g. P, Cs, Kd and the regional blood flow (i.e. Qbronch). Thus, after having 
saturated the ELF, ROC can only increase via flux from the systemic circulation. That 
is, an undesirable situation has come to exist where the increase in the local effect is 
driven from the systemic side and a higher LDD will thus act by decreasing the 
degree of lung-selectivity. Again, this illustrates the importance of having an 
integrated understanding. Nevertheless, the strategy of designing compounds with a 
238 
 
poor solubility should primarily be considered if the chemical design also allows for 
a high affinity.   
   Simulations also demonstrated that particle size is an important determinant of the 
dissolution rate, which thus can be used to partly control the dissolution process (fig. 
5.9c). Due to the enlarged surface area, smaller particles will dissolve more rapidly 
(eq. 5.19). Indeed, reducing the particle size has been documented to increase the in 
vitro dissolution rate as well as the oral bioavailability for poorly soluble compounds 
[192,193]. Nevertheless, the impact of changing the particle size is more complex for 
the inhaled route as compared with the oral route. This is attributed to the particle 
size also being an important determinant of the regional drug deposition. Thus, the 
dissolution process should not be considered in isolation when evaluating the 
consequences of changing the particle size. If a reduction of the particle size leads to 
a greater drug deposition in the more rapidly perfused distal airways, one could also 
expect e.g. less drug removal by MCC and a more rapid absorption from the lung to 
the systemic circulation. The latter was highlighted by simulations and discussions 
contained in section 5.3.4.3, which showed a more rapid pulmonary absorption of 
drug deposited in the distal airways. Accordingly, for several reasons, this is 
expected to be reflected in the plasma profile by a higher and earlier peak plasma 
concentration (Cmax) as well as by a higher systemic bioavailability. However, when 
interpreting such data, it is thus difficult to separate the effect of a higher dissolution 
rate from the effects that are indirectly caused by a greater distal airway deposition. 
The presented mechanistic PBPK model, which describes the interplay between these 
different processes, could thus be a useful tool to understand the implications of 
changing a parameter, such as the particle size, that is expected to have a pronounced 
effect on several processes. This application can e.g. be useful for tailoring inhaled 
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drug formulations for clinical studies. It is worth mentioning that Usmani [194] has 
shown that inhalation of different sized particles of FP indeed produces different PK 
behavior. The smaller particles (1.5 µm MMAD) had a higher and earlier Cmax as 
compared to the larger particles (6 µm MMAD). Furthermore, the systemic 
bioavailability was higher for the smaller particles. Both simulations and 
experimental data thus emphasise the importance of also considering formulation-
specific parameters when designing preclinical- and clinical studies. By using a 
suboptimal particle size distribution, a compound might erroneously be considered to 
have PK-properties poorly suited for inhalation and/or to have a poor efficacy and 
safety profile. Clearly, the appropriate particle size distribution needs to be 
considered on a case-by-case basis depending on the compound as well as on the 
target. 
   Model predictions elucidated that a high nasal deposition, possibly accompanied by 
significant absorption, is expected following nose-only exposure studies (figs. 5.5g 
and 5.16a). While nasal absorption is absent for orally inhaled products in the clinic, 
simulations suggest that nasal uptake reduces the degree of lung-selectivity seen in 
preclinical models (figs. 5.9d-e). Accounting for this process might thus be important 
for interpretation and translation of preclinical data since drug candidates otherwise 
could be deselected based on false premises. Simulations indicated that the interplay 
between Cs and P will affect the degree of nasal absorption, where compounds with a 
high Cs and high P will be absorbed to a greater extent (fig. 5.14). A higher nasal 
MCC and a lower regional blood flow were also both shown to considerably 
decrease the extent of nasal absorption, suggesting that an even more careful 
characterisation of those two system-specific parameters would be informative for 
the model. It is worth noting that some drugs can cause vasoconstriction and thereby 
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reduce the nasal blood flow and thus the extent of nasal drug absorption, further 
emphasising the need for an integrated understanding of the entire system. If the 
technical challenges can be overcome, experiments addressing the extent of nasal 
absorption after nose-only exposure would indeed be useful.  
   As mentioned in section 2.2.4.1, meta-analyses of clinical studies have shown a 
relatively flat dose-response curve for inhaled corticosteroids [49,50]. In contrast, a 
steeper dose-response curve was found for the side-effects. This was theoretically 
investigated by model simulations, in which the nasal blood flow was set to zero to 
avoid nasal absorption and thereby mimic the clinical situation. Escalating LDD-
levels were used in the simulations and ROC and ROsp were used as readouts for the 
local beneficial effect and the systemic side-effect, respectively. Regardless of the 
solubility characteristics of the compound (i.e. highly or poorly soluble), the model 
predictions for the higher end of the dose-spectrum were consistent with the dose-
response relationships found in clinical studies (figs. 5.23-5.26). That is, at higher 
LDD ROC was close to its maximum value whereas ROsp still was increasing. Hence, 
these simulations combined with the results of the meta-analyses might imply a 
historical tendency to over-dose inhaled corticosteroids in clinical studies. 
   Furthermore, the two earlier examples illustrate how the model lends itself for 
translation. As it relies on a physiological parameterisation, translation from animal 
to human can be done by changing from nasal to oral inhalation and exchanging 
system- (rat vs. human physiology) and formulation-specific parameters (particle 
size etc.). Clearly, a deposition model specifically developed for humans should be 
used and the formulation-specific parameters should be adapted on a case-by-case 
basis for the compound of interest. This would thus be the next natural step for future 
research.  
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5.6 Summary 
This chapter presents the development of a PBPK model, which places emphasis on 
mechanistically describing pulmonary drug disposition after inhalation. The model 
was validated by comparing model predictions to experimental measurements of 
drug concentrations and receptor occupancy after administration of FP via the IV- 
and inhaled route (figs. 5.4 and 5.5, respectively). The developed model was 
subsequently used to theoretically explore different aspects of pulmonary drug 
disposition and to identify key-determinants for lung-selectivity. Specific findings 
from this work include: 1) lung-selectivity possibly being unattainable in well-
perfused parts of the lung, 2) preclinical inhalation studies might be contaminated by 
extensive nasal absorption (figs. 5.9d-e), and 3) identification of two more drug-
properties that can be used to provide lung-selectivity, namely a slow Koff and a poor 
permeability (figs. 5.9b and 5.9f, respectively). It was also shown that the former 
property might be even more interesting for drug targets residing in the airway lumen 
(fig. 5.13c), thus providing a rational strategy for drug design. Several examples 
demonstrated the value of understanding the interplay between different processes 
instead of focusing on one in isolation, e.g. changing the particle size distribution 
will not only affect the dissolution rate, but also the deposition pattern and thus the 
absorption rate to the systemic circulation as well as the extent of drug removal by 
MCC. Clearly, this can have a pronounced effect on the pharmacodynamics of the 
drug. 
   In summary, the work contained in this chapter demonstrates the value of 
mechanistically describing the underlying processes of drug disposition in the lung to 
understand how the delicate interactions between drug-, formulation- and system-
specific properties produce the final outcome of the system. The model can thereby 
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guide the design of compounds and inhaled drug formulations with optimal local 
pharmacology and provide a logic framework for translation of inhaled drug 
pharmacology. 
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Chapter 6 Conclusions 
This thesis set out to explore how the free target site exposure to inhaled drug relates 
to various drug- and formulation-specific properties. This aspect of inhalation 
pharmacokinetics has indeed been recognised as challenging for various reasons 
including: 1) the easily accessible unbound blood concentration cannot be assumed 
to reflect the free lung target site exposure after topical administration, 2) it is not 
possible to directly measure unbound drug concentrations locally in the lung tissue, 
and 3) pulmonary drug disposition is known to be a complex interplay between 
numerous processes, thus making the development and the subsequent validation of 
predictive models for inhaled drugs more demanding.  
   The difficulties associated with both measuring and predicting the unbound drug 
concentration(s) at the target site(s) after inhalation have had negative implications 
for drug discovery and drug development programmes, which have been struggling 
to identify rational strategies for chemical- and formulation design as well as for 
targeting appropriate dose ranges for clinical studies. The ultimate aim of this thesis 
has therefore been to increase the understanding of how different drug- and 
formulation-specific properties, or the combination thereof, relate to the level and 
time course of free lung target site exposure. As declared in the introduction chapter, 
several objectives were set in order to reach this aim: 
 
1. To continue and complete an ongoing development of an in vivo receptor 
occupancy methodology for an inhaled target, the glucocorticoid receptor 
(GR).  
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2. To apply the developed in vivo receptor occupancy methodology to 
characterise and compare the time course of receptor occupancy after 
intravenous- and inhaled drug delivery. 
3. To characterise the binding kinetics of a GR agonist using the intravenous 
route. 
4. To develop a mechanistic, mathematical framework to predict the time course 
of target site exposure to unbound drug and receptor occupancy after 
inhalation, taking into account the physiology of the species and processes 
judged to be important for pulmonary drug disposition.  
5. To apply the developed model to understand what drug- and formulation-
specific properties, or combinations thereof, that give rise to lung-selectivity 
in terms of local and systemic receptor occupancy.  
   
   The following paragraphs aim to briefly describe how each of these above-
mentioned objectives were fulfilled. 
   In chapter 3, the development of an in vivo receptor occupancy methodology for 
the GR was presented. This method is novel in terms of measuring GR occupancy 
strictly in vivo and by the analytical technique used for tracer quantification (LC-
MS/MS). An interesting feature is that it allows for simultaneous assessment of GR 
occupancy in the lung and in a reference organ for the systemic exposure (the 
spleen), which thus provides a quantitative readout of the degree of lung-selectivity 
that is achieved by inhaled drug delivery. After having established the experimental 
in vivo protocol, the method was evaluated by assessing its capability of establishing 
a dose-receptor occupancy relationship of intravenously administered fluticasone 
propionate (FP; 20, 150 and 750 nmol/kg). It proved capable of demonstrating such a 
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relationship (figs. 3.6a-b) and, as expected from IV-dosing, the receptor occupancies 
were of similar magnitude in the lung and the spleen (fig. 3.7). The method was also 
applied to study the time course of receptor occupancy after IV-administration of FP 
(90 nmol/kg, fig. 3.10). 
   In chapter 4, the developed methodology was used to characterise the time course 
of receptor occupancy after nose-only exposure of FP formulated as a dry powder 
(LDD, 11.3 nmol/kg, fig. 4.9). The receptor occupancy profiles that followed from 
drug delivery via the inhaled and intravenous route were shown to have distinct 
differences. Firstly, the observed receptor occupancy peak occurred at the first time 
point after IV-administration (t = 0.5 h), whereas the corresponding peak after nose-
only exposure was found at t = 4 h. Secondly, the receptor occupancy rapidly 
declined after IV-dosing and had returned to baseline within 7 hours after dosing. In 
contrast, the receptor occupancy profile was relatively flat after topical 
administration. Furthermore, the drug-concentration profiles (lung, plasma and 
spleen) were distinctly different after dosing via the inhaled and intravenous route. 
The PK-data from the nose-only exposure studies (fig. 4.10) followed a pattern 
expected from a poorly soluble inhaled drug: a large amount of unabsorbed drug in 
the lung over several hours after dosing accompanied by low drug levels in plasma. 
Furthermore, the plasma profile was flat as compared to the corresponding profile 
resulting from IV-dosing, which indicates a slow absorption of drug to the systemic 
circulation. 
   In chapter 4, the binding kinetics of two GR agonists (FP and budesonide) were 
characterised using the intravenous route. For the first time, the binding kinetics 
parameters, Kon and Koff, for these two substances were estimated based on in vivo 
data. The parameter estimation was performed in Phoenix™ and an exhaustive 
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search algorithm subsequently confirmed that the minimum objective function had 
been found by the optimisation algorithm (within the expected parameter space). 
Combined with the data on systemic and pulmonary receptor occupancy after nose-
only exposure of FP, the estimates of Kon and Koff provided an opportunity to, for the 
first time, validate model predictions of free lung target site exposure to inhaled drug. 
   Chapter 5 described the development of a whole-body rat physiologically based 
pharmacokinetic (PBPK) model, which placed emphasis on mechanistically 
describing important processes for pulmonary drug disposition after inhalation.  The 
following processes were included: regional drug deposition, mucociliary clearance 
(MCC), drug dissolution and flux to/from the systemic circulation. Furthermore, the 
model dynamically described receptor binding and thus allowed for the evaluation of 
lung-selectivity in terms of local versus systemic receptor occupancy. The model was 
subsequently evaluated without parameter re-estimation with FP using drug- and 
formulation-specific properties from experiments or literature sources as input 
parameters. Since, to the best of my knowledge, experimental methods currently do 
not allow for quantitative measurements of the solubility (Cs) in the ELF, Cs was the 
sole parameter to be estimated in the model. Data on drug concentrations in different 
biological matrices (lung, plasma and spleen) and receptor occupancy measurements 
were available for model validation with respect to both the intravenous and the 
inhaled route. Importantly, the validation data set comprised data generated across a 
broad dose-range in particular after intravenous- (20, 90, 150, 750 and 1000 
nmol/kg) but also after inhaled drug delivery (LDD, 11.3 and 100 nmol/kg). The 
model accurately described the PK and receptor binding of intravenously 
administered FP (fig. 5.4). Furthermore, the model predictions of the PK and 
receptor occupancy after nose-only exposure agreed well with experimental data (fig. 
247 
 
5.5). The model predictions could thereby confirm that FP has a dissolution rate-
limited drug absorption and highlight that drug in the solid state does not contribute 
to receptor occupancy. 
   In chapter 5, the developed PBPK model was subsequently applied to assess how 
different drug- and formulation-specific properties, or combinations thereof, could 
give rise to lung-selectivity in terms of receptor occupancy. Interestingly, model 
predictions suggested that lung-selectivity is possibly unattainable in the well-
perfused parts of the lung. This, previously unforeseen, finding can be attributed to 
the high perfusion rate of the alveolar region, which thus rapidly equilibrates with the 
systemic circulation.  
   This model thus elucidated the difficulties of obtaining lung-selectivity in the 
alveolar region. In retrospect, this is perhaps not surprising given the features of this 
region (large surface area, high vascularization). It is even less surprising when 
considering the properties of the investigated compounds (high permeability, 
neutral). Equally important, it cannot be excluded that other mechanisms 
unaccounted for by this model might offer the prospect of lung-selectivity in the 
alveolar region. Nevertheless, a general finding is that the anatomy of this region 
significantly impairs the prospect of obtaining lung-selectivity. 
   Lung-selectivity could be obtained in the less perfused central lung region, which 
was thus used as the pulmonary region for evaluation of lung-selectivity. Several 
strategies for obtaining lung-selectivity were identified: 1) slow drug dissolution, 2) 
slow drug-receptor dissociation as reflected by a slow Koff, and 3) poor permeability. 
Nevertheless, it cannot be emphasised enough that one property should not be 
considered in isolation, as the final outcome of the system will be the result of the 
interplay between different processes and properties. An illustrative example is that 
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lung retention by having a low Cs, and thus a slow dissolution rate, should only be 
considered for highly potent compounds to ensure that sufficiently high drug 
concentrations can be obtained at the target site. Poorly soluble compounds with low 
potency should thus not be progressed into extensive animal testing or clinical trials. 
The particle size distribution provides another manifestation of the interplay between 
different processes. If needed, decreasing/increasing the particle size might be used 
to change the dissolution rate. However, as outlined in the discussion in chapter 5, 
the particle size is expected to have a pronounced effect on several processes 
including the regional deposition pattern (fig. 5.17). Assume a situation where the 
pharmacological effect of a poorly soluble and highly potent inhaled drug candidate 
is planned to be evaluated using a nose-only exposure system. Results from earlier 
inhalation PK-studies, which used a particle size distribution with larger particles 
(aerodynamic diameter, da ~ N(5, 0.5) µm), indicated a very slow dissolution rate. 
Hence, the particle size needs to be reduced to obtain target site concentrations that 
are sufficiently high to exert a pharmacologically meaningful effect. Since the target 
of the drug is known to reside primarily in the central airways, the deposition pattern 
should also be taken into account when choosing an appropriate particle size 
distribution for the PD-study. Hence, the PBPK model presented in this thesis 
provides drug discovery with an important tool for identifying a particle size 
distribution, which satisfies these requirements. This example thus serves to illustrate 
how a mechanistic PBPK model can be used to theoretically explore the wider 
implications of changing a parameter such as the particle size and thereby e.g. aid the 
formulation design.   
   Earlier research has also evaluated lung-selectivity in terms of pulmonary and 
systemic receptor occupancy [14]. The simulation study conducted by Hochhaus et 
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al. [14] relied on a very simple model structure, in which the lung was described by a 
single compartment, the dissolution process by a rate constant, kdiss, and the receptor 
binding by a static Emax-model. Despite its simplicity, the previously published model 
could identify that lung-selectivity is attained during the dissolution phase. 
Furthermore, it demonstrated that low oral bioavailability and high clearance are 
both important for obtaining a high degree of lung-selectivity. The model presented 
in this thesis thus builds and expands on these concepts and differentiates from the 
earlier work through introduction of: 1) physiological parameterisation, 2) more 
sophisticated and mechanistic mathematical descriptions of pulmonary drug 
disposition processes, and 3) dynamic description of receptor binding. The added 
sophistication allows for the possibility to evaluate more aspects of pulmonary drug 
disposition, which thereby have led to previously unforeseen findings including lung-
selectivity possibly being unattainable in well-perfused lung regions and that slow 
drug-receptor dissociation can be a drug property yielding lung-selectivity. 
Furthermore, by virtue of being mechanistic and relying on a physiological 
parameterisation, model predictions were shown to agree with concepts of 
pulmonary drug disposition that earlier have been proposed and/or demonstrated in 
the literature such as: 1) MCC having a larger impact on slowly dissolving 
compounds, which has been suggested by e.g. Edsbäcker et al. [8] and shown by 
model predictions in fig. 5.12, 2) pulmonary absorption being more rapid in the 
alveolar region, which was demonstrated by Gerde et al. [152,153], suggested from 
results obtained from animal studies conducted by Schanker et al. [195,196] and 
shown by model predictions in fig. 5.13d, and 3) extensive nasal absorption taking 
place after nose-only exposure as shown in fig. 5.9d. Despite its important 
implications, the third concept has not received much attention in the literature. 
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However, this methodological insufficiency has been reported by Sakagami et al. 
[10]. Clearly, this issue would benefit from further experimental investigation to 
quantify how much nasal absorption contributes to the systemic exposure and 
thereby ‘contaminates’ the results obtained from nose-only exposure studies. If an 
extensive nasal absorption is confirmed to take place, it would have important 
implications for the interpretation of preclinical inhalation studies utilising nose-only 
exposure. In this context, it is important to underline that nasal absorption will not be 
an issue for orally inhaled products in the clinic and it is thus a finding that will not 
translate from animal to man. Clearly, not accounting for this process might lead to 
inappropriate ranking of compounds from PK- as well as PD-studies.  
   By having incorporated a mechanistic model that describes regional drug 
deposition, this work opens up interesting opportunities for: 1) targeting specific lung 
regions that are held to be particularly important for treating a given disease or 
condition, and/or 2) precluding deposition in lung regions devoid of drug target (e.g. 
if the target density is denser in the central lung such a strategy could minimise 
unnecessary systemic absorption). Clearly, a regionally targeted drug treatment 
requires in-depth knowledge about the drug target location and, in many instances, 
this is not known. This example thus serves to highlight the importance of 
understanding the target biology and its location. Furthermore, it also demonstrates 
how a modelling exercise can lead to further questions, opening for inter-disciplinary 
collaborations to break new ground.  
   To summarise, the PBPK model presented in this thesis provides a tool to 
theoretically explore various aspects of pulmonary drug disposition, including how 
the extent and time course of free target site exposure to inhaled drug relates to 
different drug- and formulation-specific properties; i.e. the aim of this thesis. The 
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model can thereby guide the chemical design of compounds and tailor inhaled drug 
formulations for clinical trials. Furthermore, it can provide a logical framework for 
translation of inhaled drug pharmacology. These application areas would be 
instrumental to any drug discovery or development programme targeting the lung via 
the inhaled route. 
 
6.1 Future research and limitations 
As discussed above, the PBPK model presented in this thesis represents an 
advancement of earlier simulation models and has thereby contributed to increasing 
the knowledge about pulmonary drug disposition. Nevertheless, several aspects of 
inhalation PK still remain to be explored, some of which may be relevant to 
incorporate in a PBPK model.  
   As mentioned in the previous section, the model lends itself to translation from 
animal to man since it is based on a physiological parameterisation. Translation to 
man can be done by changing the inhalation manoeuvre (from nasal to oral 
inhalation) and exchanging system-specific properties (from rat to human 
physiology). Clearly, a deposition model specifically developed for humans needs to 
be implemented prior to performing this research activity. Furthermore, the 
formulation-specific properties should be adapted on a case-by-case basis for the 
compound as well as the target of interest. The aforementioned steps would thus lead 
to a new mechanistic framework for translating inhaled drug pharmacology. A 
translation relying on mechanistic, instead of empirical, principles would provide a 
step-change for drug discovery and drug development programmes, which thus is 
expected to be a highly prioritised area for future research. 
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   Whilst the focus of this work has been on increasing the understanding of 
inhalation pharmacokinetics in healthy lungs, it opens up for interesting opportunities 
to advance the understanding of how inhaled drugs will behave in diseased lungs. By 
virtue of being mechanistic, the developed model has the potential to assess how the 
pathophysiology of a disease might affect processes of pulmonary drug disposition 
and thereby possibly alter the extent and/or time-course of the free drug 
concentration at the site of the disease. A recent review pointed out that the impact of 
pulmonary diseases on the fate of inhaled compounds is still a large underdeveloped 
area and such questions needs to be addressed to optimise inhaled therapies [16].  
   Clearly, a mechanistic model has the potential to provide an integrated 
understanding of how the pathophysiology of a given pulmonary disease affects the 
local pharmacokinetics of inhaled drugs. This can be exemplified by obstructive 
airway diseases such as asthma, where an enhanced deposition in the 
tracheobronchial region is expected due to airway narrowing [16]. An altered 
deposition pattern in asthmatic patients might not only lead to a higher drug 
concentration centrally, but it may well for instance: 1) reduce the systemic 
bioavailability following inhalation as a higher fraction of the dose can be cleared by 
the MCC, and 2) reduce the maximum plasma concentration following inhalation. 
The second feature would have been caused by a slower drug absorption in the 
tracheobronchial- as compared to the alveolar region. This is in line with model 
simulations in this thesis, which suggest that the pulmonary absorption is more rapid 
in the alveolar region (fig. 5.13). Both these features have been observed when 
comparing plasma profiles between healthy volunteers and asthmatic patients [197]. 
On the other hand, the rate of the MCC has been reported to be significantly slower 
in asthmatic patients as compared to healthy volunteers [198]. Incorporating the 
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pathophysiology of pulmonary diseases might thus aid the understanding of how 
lung diseases impact the fate of inhaled compounds and thereby e.g. tailor inhaled 
doses and formulation designs to fit the diseased population. Closely investigating 
the pathophysiology of pulmonary diseases and subsequently incorporating the 
information within a mechanistic modelling framework would thus be an interesting 
area for future research.   In the current model structure, the lung is divided into a 
tracheobronchial and an alveolar region. The anatomical model of the airway 
structure in [65] has 24 airway generations (excluding the nose and pharynx), thus 
making it possible to have up to 24 lung compartments. Increasing the number of 
pulmonary compartments would open up for incorporating more detailed information 
on regional physiological and anatomical differences as well as predicting drug 
concentrations in more defined regions. Clearly, a model with a higher regional 
resolution would be interesting, particularly if the drug target was known to be 
confined to a limited space in the lung. Nevertheless, the development of such a 
model would also require more detailed information on the regional differences and 
the modeller would need to make informed decisions on e.g. how to scale the 
permeability and blood perfusion across the lung. This leads the discussion to 
another interesting topic for future research: experimental characterisation of 
pulmonary permeability and, perhaps even more importantly, how it changes across 
the lung. Since both the type and the height of the epithelium changes across the lung 
[11], it is unlikely that one experimental assay, such as the Calu-3 cell line, would be 
representative of the permeability throughout the entire organ. 
   The model structure presented in this thesis was developed for predicting the PK of 
neutral compounds, such as FP, and does not therefore account for lung-retention 
caused by basicity. Even though basicity is a commonly used strategy for obtaining 
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lung-retention , the mechanism by which this occurs is still poorly understood. 
Recent research utilising empirical modelling demonstrated that a fraction of a 
dissolved, basic compound (olodaterol) was slowly absorbed from the lung [199]. 
The delayed absorption was proposed to be caused by lysosomal trapping. To the 
best of my knowledge, the temporal dynamics of this mechanism has not yet been 
investigated in the literature. Clearly, the field of inhalation PK would benefit from 
thoroughly investigating the mechanism(s) by which lung retention by basicity 
occurs at a quantitative level and subsequently develop a mechanistic model based 
on this information. This can be seen as a necessary step for progressing the 
understanding of the PK-behaviour of basic inhalation compounds and to thereby 
draw conclusions on how to optimise the chemical- and formulation-design of this 
compound class. 
   Another area, which would benefit from future research, is pulmonary drug 
dissolution. Firstly, measurement of compound solubility is an ongoing challenge 
and contemporary assays cannot provide quantitative measurements of the solubility 
in ELF, but should only be used to rank compounds with respect to solubility [200]. 
A quantitatively informative assay would require both a biorelevant dissolution 
medium as well as conditions similar to those seen in vivo (e.g. to mimic the thin 
fluid layer). Model predictions made in this thesis demonstrated that the solubility is 
an important parameter for predicting the pulmonary PK and the development of 
assays for measuring this property is thus an important avenue for future research. 
Secondly, the use of the Noyes-Brunner equation might be limited in the alveolar 
region where the particle diameter potentially exceeds the thickness of the ELF-
layer. Due to the surfactant content, there should not be a wetting problem in this 
region and smaller particles are expected to be surrounded by the ELF. However, 
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depending on the thickness of the layer and the particle size, it may still limit the 
legitimate use of the Noyes-Brunner equation. To assess these limitations, more 
complex dissolution models involving partial differential equations might be needed. 
To the best of my knowledge, such models have not yet been developed, but it is 
plausible that the development of more advanced models might improve the 
predictions of drug dissolution in the alveolar region.  
   In preclinical research, the effect of an anti-inflammatory inhaled drug is often 
investigated by firstly inducing inflammation, e.g. by instillation of Sephadex as 
described by Källström et al. [147]. An interesting area for future research would be 
to mechanistically describe these challenge models and subsequently combine PBPK 
model predictions of free target site concentrations in appropriate lung regions with a 
either a PK/PD- or a systems pharmacology model to describe the drug effect. 
Clearly, several obstacles need to be overcome before reaching this goal. Perhaps the 
biggest challenge would be to produce time-resolved data of relevant biomarkers and 
thereby enable a mechanistic description of the challenge model as well as the 
pharmacological effect of the treatment. However, overcoming these challenges 
would provide a step-change in the understanding of contemporary preclinical PD-
models and possibly also provide an opportunity for optimising the design of these 
studies. 
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6.2 Personal reflections  
This thesis not only concerns modelling of inhalation pharmacokinetics, but also 
touches upon a broader topic relevant to the entire field of pharmacokinetics: the 
distinct differences between descriptive, non-mechanistic modelling and predictive, 
mechanistic modelling.  
   Pharmacokinetics is a field where experimental assays are continuously developed 
with the purpose of carefully characterising drug candidates with respect to various 
drug- and formulation-specific properties. Yet, the field has been dominated by 
non-mechanistic modelling approaches, precluding any possibilities to incorporate 
these invaluable experimental results in the modelling. Clearly, descriptive models 
are indisputably useful for e.g. describing drug concentration profiles, quantifying 
interindividual variability and predicting plasma pharmacokinetic profiles of a 
particular compound. It should be noted that the latter application area requires 
identical formulation-specific properties and its predictive capability across a broad 
range of doses is highly dependent on the study design, such that nonlinearities are 
detected. In this context, it cannot be emphasised enough that the choice of 
modelling approach should be made based on the purpose of the modelling exercise. 
Nevertheless, putting informative experimental results aside and instead relying on 
non-mechanistic approaches is not likely to advance our mechanistic understanding 
of the underlying drug disposition processes. From my viewpoint, this implies that 
scientific progress can be made by moving towards predictive, mechanistic 
modelling. By using the proposed approach, the drug- and formulation-specific 
properties will not merely be characterised but also be incorporated into a 
mechanistic model to progress our understanding. This brings the discussion back to 
inhalation pharmacokinetics: the utility of using the inhaled route for local as well as 
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systemic drug delivery suggests that the proposed shift towards predictive, 
mechanistic modelling is even more important for this particular niche of 
pharmacokinetics. That is, a thorough mechanistic understanding is required to 
enable identification of appropriate strategies in terms of chemical- and formulation 
design to either: 1) efficiently deliver drug to the systemic circulation, or 2) create a 
lung-selective drug exposure. 
   During this proposed journey, we will inevitably experience that our mechanistic 
inhalation model occasionally fails to predict the fate of compounds. However, this 
should not be seen as a failure but as a result per se as it serves to identify yet another 
gap in our knowledge and thus points us towards mechanisms, which would benefit 
from further exploration. Modelling should thus be an iterative process, which, 
combined with cleverly designed experiments, can advance our understanding of 
drug disposition processes. Clearly, identification of knowledge gaps is crucial for 
any researcher. In my mind, an approach leading to the identification of knowledge 
gaps should doubtlessly be favoured over the previously used non-mechanistic 
modelling approaches, which cannot progress our understanding of the underlying 
processes.  
   Easy as it may sound, introducing a new way of approaching a problem and 
suggesting an approach, which might not necessarily provide the solution but point 
us towards our knowledge gaps will doubtlessly face resistance within the scientific 
community of pharmacokinetics. It thus needs to be communicated that this 
modelling approach serves a slightly different purpose than the one previously used: 
instead being a tool for describing observed data, it is a tool for increasing our 
understanding of how the dynamic behaviour of the system responds to changes in 
various properties. Once proven predictive, this new approach thus opens up for 
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opportunities to rationally guide the chemical- and formulation design. However, it 
takes courage to leave an established approach, which is not likely to be questioned 
by a project team within pharmaceutical industry. This paradigm shift would thus, 
except from an effective communication, also require a project team, which is open 
for approaching the problem from a different angle. If the team ends up in a situation 
where the model predictions do not agree with the observed data, they might need to 
challenge their current understanding of the processes involved in pulmonary drug 
disposition and/or the pharmacological response of the investigated compound class. 
This approach thus requires one of the toughest, yet one of the most important, 
requirements on successful researchers: a humble attitude towards our limitations 
and knowledge gaps. By honestly and accurately identifying these, we open up for 
progressing the science. 
   Up until now, the focus has been on identifying knowledge gaps in the mechanistic 
understanding of the underlying processes of drug disposition and/or the 
pharmacological response of an investigated compound class. However, another 
aspect, which is equally important for the progression of systems models in general 
and mechanistic inhalation models in particular, is the technical development. The 
shift from simple, empirical models to more sophisticated, mechanistic models not 
only requires in-depth knowledge about the underlying processes but also places 
higher demands on the technical implementation both in terms of mathematics and 
programming. In the ideal situation, the progression of the biological knowledge and 
the technical development will go hand in hand, enabling us to benefit the most from 
both activities. 
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   Personally, the shift from empirical to mechanistic models has changed my attitude 
towards modelling and how it can be used to rationally guide the chemical- and 
formulation design. 
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Appendix A 
Matlab code used for simulating repeated dosing 
 
Main script: 
 
% Main script used for simulating repeated dosing. 
% It uses; pbpk_repeated_ode.m (contains ODEs) 
% init_repeated.m (contains input parameters) 
% computeClung.m (calculates Asolid, Clung and RO) 
 
% Deposition model by Lee et al. is implemented 
 
% Define solubility (Cs) in nM 
Cs =5000;  
  
% Define aerodynamic diameters in um 
diameter=[6 3.9 2.4 1.5 0.92 0.59 0.39 0.2]; % Aerodynamic diameters 
 
% Define mass fraction (f_m) corresponding to each aerodynamic 
diameter 
f_m=[0.1736 0.3008 0.2605 0.1760 0.0733 0.0091 0.0032 0.0035]; % 
Mass fraction 
 
% Define tau and the lung deposited dose (LDD) 
tao=24; % tau in h 
ldd=100; LDD in nmol/kg 
 
% Gather all ldd in a vector to enable repeated dosing 
LDD=[ldd ldd] 
  
k=length(LDD) % Number of dosing occasions 
  
% Load input parameters from file 
% init_repeated automatically calculates deposition fractions for 
the 
% given aerodynamic diameters defined in 'diameter' 
[ data ] = init_repeated( Cs, LDD, diameter, f_m); 
  
% Assign how Papp relates to the permeability in the central and  
% peripheral lung using p_c and p_p, respectively 
% p_c=1 --> no difference; p_c=100 --> 100-fold lower 
% p_p=1 --> no difference; p_p=0.01 --> 100-fold higher 
p_c=1;  
p_p=0.01; 
  
% Error messages 
msg = 'You cannot use more than 8 different particle sizes'; 
if max(length(diameter),length(f_m))>8 
    error(msg) 
    break 
end 
  
msg2 = 'The code currently supports up to 11 dosing occasions'; 
if k > 11 
    error(msg2) 
    break 
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end 
  
x0 = data.x0; 
Y = []; 
T = []; 
  
% Information needed for calculating indices for updating initial 
% conditions (x0) in conjunction with repeated dosing 
  
n_eq=3*length(diameter); %nr of eq to be added at each dosing 
occasion 
step=n_eq-1; 
  
% Indices for updating x0 
index1=[49:n_eq:49+24*(k-2)] % Start values 
index2=[72:n_eq:72+24*(k-2)] % End values 
  
tic; 
for i = 1:k 
%i = 1 
    dt = [(i-1)*tao, i*tao]; 
    options=odeset('RelTol',1e-8);  
    [t,y] = ode15s(@(t,x) pbpk_repeated_ode( t, x, data, tao, p_c, 
p_p, k), dt, x0, options );  
    Y = [Y; y]; 
    T = [T; t]; 
    x0 = y(end,:); % Update x0 by extracting the value of each state 
y at  
% t_end, i.e. y(t_end),last sim time point 
     
    % Update initial values of radii from 0 to data.r_set prior to 
simulating % dosing occasion i+1 
    if i == 1 && k>=2 
        x0(index1(1):index2(1))=[data.r_set data.r_set data.r_set]; 
    elseif i == 2 && k>=3 
        x0(index1(2):index2(2))=[data.r_set data.r_set data.r_set]; 
         
    elseif i == 3 && k>=4 
        x0(index1(3):index2(3))=[data.r_set data.r_set data.r_set]; 
         
    elseif i == 4 && k>=5 
        x0(index1(4):index2(4))=[data.r_set data.r_set data.r_set]; 
         
    elseif i == 5 && k>=6 
        x0(index1(5):index2(5))=[data.r_set data.r_set data.r_set]; 
    
    elseif i == 6 && k>=7 
        x0(index1(6):index2(6))=[data.r_set data.r_set data.r_set]; 
         
    elseif i == 7 && k>=8 
        x0(index1(7):index2(7))=[data.r_set data.r_set data.r_set]; 
         
    elseif i == 8 && k>=9 
        x0(index1(8):index2(8))=[data.r_set data.r_set data.r_set]; 
         
    elseif i == 9 && k>=10 
        x0(index1(9):index2(9))=[data.r_set data.r_set data.r_set]; 
         
    elseif i == 10 && k>=11 
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        x0(index1(10):index2(10))=[data.r_set data.r_set 
data.r_set]; 
    end     
end 
  
% Simulate solid amount of drug (Asolid), receptor occupancy (RO) 
and total lung conc (Clung_tot) 
[Asolid_p, Asolid_c, Asolid_tot, RO_c, RO_sp, RO_ave, 
Clung_tot]=computeClung( T, Y, data, tao, k); 
toc 
  
  
%% Figures 
  
close all 
 
figure(1) 
semilogy(T,Y(:,7),'b-','LineWidth',1.5); hold on 
ylabel('\it{C_p}\rm (nM)','FontName','Times New 
Roman','FontSize',18); 
xlabel('Time (h)','FontName','Times New Roman','FontSize',18); 
title(['\it{C_p}\rm after inhalation, \it{C_{s}}\rm = ', num2str(Cs) 
' nM'],'FontName','Times New Roman','FontSize',18); % after 
inhalation 
set(gca,'fontsize',12,'LineWidth',1.4) 
axis([0 tao*k 0.0001 100]) % 
 
figure(2) 
plot(T,RO_c,'b--',T,RO_sp,'r-','LineWidth',1.5); hold on 
legend('\it{RO_c}\rm','\it{RO_{sp}}\rm','Location','SouthEast'); 
ylabel('\it{RO}\rm (%)','FontName','Times New Roman','FontSize',18); 
xlabel('Time (h)','FontName','Times New Roman','FontSize',18); 
title(['\it{RO}\rm  after inhalation, \it{C_{s}}\rm = ', num2str(Cs) 
' nM'],'FontName','Times New Roman','FontSize',18); 
set(gca,'fontsize',12,'LineWidth',1.4) 
axis([0 tao*k 0 100])  
  
figure(3) 
semilogy(T,Clung_tot,'b-','LineWidth',1.5); hold on 
ylabel('\it{C_{lung}}\rm (nM)','FontName','Times New 
Roman','FontSize',18); 
xlabel('Time (h)','FontName','Times New Roman','FontSize',18); 
title(['\it{C_{lung}}\rm after inhalation, \it{C_{s}}\rm = ', 
num2str(Cs) ' nM'],'FontName','Times New Roman','FontSize',18); % 
after inhalation 
set(gca,'fontsize',12,'LineWidth',1.4) 
xlim([0 k*tao]) 
ylim([1e-2 1e5]) 
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Function containing coupled ODEs 
 
% Coupled ODEs in the PBPK model 
% pbpk_repeated_ode( t, x, data, tao, p_c, k) 
% t=time; x=states; data=input parameters generated from 
init_repeated.m; 
% tao=tau; p_c=factor assigning how much lower the permeability is 
in the 
% central as compared to Papp; p_p=factor assigning how much  
% lower the permeability is in the peripheral as compared to 
Papp;k=number of dosing occasions 
  
function [ xDot ] = pbpk_repeated_ode( t, x, data, tao, p_c, p_p, k) 
Cs = data.Cs; % Solubility (nM) 
fu_f = data.fu_f; % Unbound fraction in the fluid 
factor_s = data.factor_s; % 
  
n_p=length(data.f_m); % number of particle sizes, double definition 
temp 
r_n=length(data.f_m); % number of particle sizes 
all_r=n_p*3; % number of particle sizes multiplied by number of 
regions 
  
% Initialise ODE vector xDot  
% 24 ODEs describing tissue conc, receptor binding etc. + k*all_r 
ODEs 
% describing change of radii 
xDot = zeros(24+(k*all_r),1);  
  
%% Based on number of dosing occasions (k), automatically generate 
index for the ODEs describing radii 
%  in the nose, central lung and peripheral lung 
  
% Step 1: Generate first index for each dosing occastion 
nose_r_index = [25, (25+n_p*3):all_r:((k-1)*n_p*3)+25]; 
cent_r_index = [25+n_p, ((25+n_p)+n_p*3):all_r:((k-
1)*n_p*3)+25+n_p]; 
peri_r_index = [25+(n_p*2), ((25+(n_p*2))+n_p*3):all_r:((k-
1)*n_p*3)+25+(n_p*2)]; 
  
% Step 2: Create full set for each dosing occasion based on n_p (nr 
of 
% particle size classes) 
nose_r_index = (nose_r_index')*ones(1,n_p) + ones(k,1)*(0:7); % Add 
0:7 to the first index of each dosing occasion 
cent_r_index = (cent_r_index')*ones(1,n_p) + ones(k,1)*(0:7); 
peri_r_index = (peri_r_index')*ones(1,n_p) + ones(k,1)*(0:7); 
  
% Step 3: Define the states describing the radius in the nose (r_n), 
% the central lung (r_c) and the peripheral lung (r_p) 
r_n = x(nose_r_index); 
r_c = x(cent_r_index); 
r_p = x(peri_r_index); 
  
% Define the states describing the fluid concentrations 
c_fluid = [x(22), x(23), x(24)]; % nose, central, peripheral 
  
xb = 1.5e-6; % Break-point for the radius in dm (150 nm) 
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s = xb/factor_s; 
  
% Create empty matrices for 
% 1) dissolution of drug 
diss_cent = zeros(k,n_p); %Central lung 
diss_nose = zeros(k,n_p); %Nose 
diss_peri = zeros(k,n_p); %Peripheral lung 
  
% 2) transport of drug to gut absorption compartment with drug 
% coming from either the nose (gut_n) or the central lung (gut_c) 
gut_n = zeros(k,n_p); 
gut_c = zeros(k,n_p); 
  
% 3) ODEs describing change of radius in  the nose (rnDot), 
% the central lung (rcDot) and the peripheral lung (rpDot) 
rnDot = zeros(k,n_p); 
rcDot = zeros(k,n_p); 
rpDot = zeros(k,n_p); 
  
% Create matrix of tau to use as input to equations 
% Rows for dosing occasion (k) and columns for particle sizes (n_p) 
Tau = (((1:k)-1)'*ones(1,n_p))*tao; 
  
% Simulations of: 
  
% 1) dissolution processes 
diss_nose = noseEquation(c_fluid(1), r_n, data.N_n, t, Tau, data); 
diss_cent = centEquation(c_fluid(2), r_c, data.N_c, t, Tau, data); 
diss_peri = periEquation(c_fluid(3), r_p, data.N_p, t, Tau, data); 
  
% 2) transport of drug to the gut absorption compartment 
gut_n = gutEquation(r_n, ones(k,1)*data.r_set, data.N_n, 
ones(k,1)*data.A_0_F, data.k_mcc_n, t, Tau, data); 
gut_c = gutEquation(r_c, ones(k,1)*data.r_set, data.N_c, 
ones(k,1)*data.A_0_F, data.k_mcc,   t, Tau, data); 
  
% 3) size of radius during dissolution  
rnDot = (Cs- (fu_f*c_fluid(1)) )*data.D/data.p  .*   
mRadiusTerm(r_n,xb,s); 
rcDot = (Cs- (fu_f*c_fluid(2)) )*data.D/data.p  .*   
mRadiusTerm(r_c,xb,s); 
rpDot = (Cs- (fu_f*c_fluid(3)) )*data.D/data.p  .*   
mRadiusTerm(r_p,xb,s); 
  
% Define ODEs describing change of radius wrt both index and 
equations 
xDot(nose_r_index) = rnDot; 
xDot(cent_r_index) = rcDot; 
xDot(peri_r_index) = rpDot; 
  
% ODEs for organs: x(1)=Cspleen; x(2)=Crichly; x(3)=Cpoorly; 
x(4)=Cadi; 
% x(5)=C_gut; x(6)=Chepatic; x(7)=Cartery; x(8)=Cvein 
xDot(1) = ( data.Q_s*(x(7) -(data.b_p*x(1)/data.Kp_s)) -
data.V_s*(data.Kon*(x(1)/data.Kp_s_u)*(data.Bmax_sp-x(11)) -
data.Koff*x(11)) )/data.V_s; 
xDot(2) = ( data.Q_richly*(x(7) -(data.b_p*x(2)/data.Kp_richly)) -
data.V_richly*(data.Kon*(x(2)/data.Kp_richly_u)*(data.Bmax_all-
x(12)) -data.Koff*x(12)) )/data.V_richly; 
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xDot(3) = ( data.Q_poorly*(x(7) -(data.b_p*x(3)/data.Kp_poorly)) -
data.V_poorly*(data.Kon*(x(3)/data.Kp_poorly_u)*(data.Bmax_all-
x(13)) -data.Koff*x(13)) )/data.V_poorly; 
xDot(4) = ( data.Q_adi*(x(7) -(data.b_p*x(4)/data.Kp_adi)) -
data.V_adi*(data.Kon*(x(4)/data.Kp_adi_u)*(data.Bmax_all-x(14)) -
data.Koff*x(14)) )/data.V_adi; 
xDot(5) = ( data.Q_g*(x(7) -(data.b_p*x(5)/data.Kp_g)) 
+data.ka*x(17)  -
data.V_g*(data.Kon*(x(5)/data.Kp_g_u)*(data.Bmax_all-x(15)) -
data.Koff*x(15)) )/data.V_g; 
xDot(6) = ( data.Q_g*(data.b_p*x(5)/data.Kp_g) + data.Q_h*x(7) 
+data.Q_s*(data.b_p*x(1)/data.Kp_s)-
(data.Q_h+data.Q_s+data.Q_g)*(data.b_p*x(6)/data.Kp_h) -
data.V_h*(data.Kon*(x(6)/data.Kp_h_u)*(data.Bmax_all-x(16)) -
data.Koff*x(16)) )/data.V_h; 
xDot(7) = (data.Q_CO*( (data.b_p*x(21)/data.Kp_l) -x(7)) ) 
/data.V_art ; %C_artery 
xDot(8) = (-data.CL_eh*x(8) -data.Q_richly*(x(8)-
(data.b_p*x(2)/data.Kp_richly)) -data.Q_poorly*(x(8)-
(data.b_p*x(3)/data.Kp_poorly)) - 
(data.Q_h+data.Q_g+data.Q_s)*(x(8)-(data.b_p*x(6)/data.Kp_h) )... 
- data.Q_bronch*(x(8)-(data.b_p*x(20)/data.Kp_l)) -data.Q_n*(x(8)-
(data.b_p*x(19)/data.Kp_n)) -data.Q_adi *(x(8) -
(data.b_p*x(4)/data.Kp_adi) ))/data.V_vein; %C_vein   
  
% ODEs for binding kinetics 
xDot(9) =data.Kon*(x(20)/data.Kp_l_u)*(data.Bmax-x(9)) -
data.Koff*x(9); % RD_C  
xDot(10) =data.Kon*(x(21)/data.Kp_l_u)*(data.Bmax-x(10)) -
data.Koff*x(10); % RD_P  
xDot(11) =data.Kon*(x(1)/data.Kp_s_u)*(data.Bmax_sp-x(11)) -
data.Koff*x(11); % RD_spleen  
xDot(12) =data.Kon*(x(2)/data.Kp_richly_u)*(data.Bmax_all-x(12)) -
data.Koff*x(12); % RD_richly  
xDot(13) =data.Kon*(x(3)/data.Kp_poorly_u)*(data.Bmax_all-x(13)) -
data.Koff*x(13); % RD_poorly  
xDot(14) =data.Kon*(x(4)/data.Kp_adi_u)*(data.Bmax_all-x(14)) -
data.Koff*x(14); % RD_adi  
xDot(15) =data.Kon*(x(5)/data.Kp_g_u)*(data.Bmax_all-x(15)) -
data.Koff*x(15); % RD_gut  
xDot(16) =data.Kon*(x(6)/data.Kp_h_u)*(data.Bmax_all-x(16)) -
data.Koff*x(16); % RD_hepatic 
  
% ODE describing change of drug amount in the gut absorption 
compartment 
xDot(17) = sum(sum(gut_c)) + sum(sum(gut_n)) -data.ka*x(17); 
  
% x(18) is not coupled to anyother ODE and xDot(18) can thus be used 
for looking at specific questions 
xDot(18) = sum(sum(diss_cent))+sum(sum(diss_peri)); %  
  
% ODEs for the nose, central lung tissue and peripheral lung tissue 
xDot(19) = ( data.A_nose*data.P*(fu_f*x(22)-x(19)/data.Kp_n_u) + 
data.Q_n* (x(7)-(data.b_p*x(19)/data.Kp_n)) )/data.V_n; %C_diss_nose 
xDot(20) = ( data.A_c*data.P/p_c*(fu_f*x(23)-x(20)/data.Kp_l_u) 
+data.Q_bronch *(x(7) -(data.b_p*x(20)/data.Kp_l)) -
data.V_lung_C*(data.Kon*(x(20)/data.Kp_l_u)*(data.Bmax-x(9)) -
data.Koff*x(9)) )/data.V_lung_C; 
xDot(21) = ( data.A_p*data.P/p_p*(fu_f*x(24)-x(21)/data.Kp_l_u) + 
data.Q_CO*(x(8)-(data.b_p*x(21)/data.Kp_l))-
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data.V_lung_P*(data.Kon*(x(21)/data.Kp_l_u)*(data.Bmax-x(10)) -
data.Koff*x(10)) )/data.V_lung_P; 
  
% ODEs for lining fluids 
% x(22)=C_fluid_nose 
xDot(22) =( (   sum(sum(diss_nose)) -data.A_nose*data.P*(fu_f*x(22)-
x(19)/data.Kp_n_u)) )/data.V_n_fluid;  
% x(23)=C_ELF_C        
xDot(23) =( sum(sum(diss_cent))... 
           -data.A_c*data.P/p_c*(fu_f*x(23)-
x(20)/data.Kp_l_u))/data.V_ELF_C; 
% x(24)=C_ELF_P        
xDot(24) =( sum(sum(diss_peri))-data.A_p*data.P/p_p*(fu_f*x(24)-
x(21)/data.Kp_l_u))/data.V_ELF_P;  
end 
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Functions called by pbpk_repeated_ode.m 
Function for simulating drug dissolution in the nose 
 
% Simulation of drug dissolution in the nose 
% noseEquation(con, rad, N_part,t, t0, data) 
% Input needed: con=Cfluid(t), rad=radius(t), N_part=number of 
particles 
% t=time, t0=tau, data=input parameters 
  
function [c] = noseEquation(con, rad, N_part,t, t0, data) 
  
c = (data.Cs- (data.fu_f*con) ).*(N_part.*exp(-data.k_mcc_n*(t-
t0))*data.D*4*pi.*rad); 
 
Function for simulating drug dissolution in the central lung 
 
% Simulation of drug dissolution in the central lung 
% centEquation(con, rad, Npart, t, t0, data) 
% Input needed: con=Cfluid(t), rad=radius(t), N_part=number of 
particles 
% t=time, t0=tau, data=input parameters 
  
function [c] = centEquation(con, rad, Npart, t, t0, data) 
  
c = (data.Cs-(data.fu_f*con) ).*(Npart.*exp(-data.k_mcc*(t-
t0))*data.D*4*pi.*rad); 
 
Function for simulating drug dissolution in the peripheral lung 
 
% Simulation of drug dissolution in the peripheral lung 
% periEquation(con, rad, Npart, t, t0, data) 
% Input needed: con=Cfluid(t), rad=radius(t), N_part=number of 
particles 
% t=time, t0=tau, data=input parameters 
  
function [c] = periEquation(con, rad, Npart, t, t0, data) 
c = (data.Cs- (data.fu_f*con) ).*(Npart.*data.D*4*pi.*rad);  
 
Function for dealing with the numerically instability caused by 1/r(t) in the ODE 
describing the change of the radius , dr/dt 
 
function [y] = mRadiusTerm(x,xb,s) 
 
% x=radius; xb=break point; s=radius in circle defined as 
xb/factor.s  
  
y = -(x > xb)./(max(x,xb)); 
 
x_l= xb-s*cos(pi/2-atan(1/(xb^2))); 
  
y_l = -1./xb+s*sin(pi/2-atan(1/(xb^2))); % 
  
u=x-x_l; 
  
% Compute angles 
l1 = sqrt(x_l.^2+y_l^2); % pythagoras theorem, using that [xb yb] is 
known 
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l2 = s; % radius in circle 
l3 = sqrt(l1.^2-l2^2); % pythagoras theorem 
gamma = atan(l2./l3); 
kappa = atan(y_l./x_l); 
beta = -gamma + kappa; %  
     
x_f = x_l+sin(beta)*s; %  
     
    
y = y + (x > x_f & (x <= xb)).*(y_l - sqrt(s^2-u.^2)); 
  
y = y + (x <= x_f & (x <= xb)).*(tan(beta)*x); 
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Function for calculating the total lung concentration (Clung), the solid amount of 
drug (Asolid) and receptor occupancy (RO)  
 
function [Asolid_p, Asolid_c, Asolid_tot, RO_c, RO_sp, RO_ave, 
Clung_tot] = computeClung( t, y, data, tao, k) 
  
% Calculation of total lung conc, receptor occupancy and solid 
amount of 
% drug 
  
Cs = data.Cs; 
fu_f = data.fu_f; 
factor_L = data.factor_L;% 
factor_s = data.factor_s;% 
  
% Calculate occupancy 
RO_c=100*y(:,9)./data.Bmax; %Receptor occupancy central lung 
RO_p=100*y(:,10)./data.Bmax; %Receptor occupancy peripheral lung 
RO_sp=100*y(:,11)./data.Bmax_sp; %Receptor occupancy spleen 
  
% Calc of weighted average lung occupancy 
f_cv=0.19; %Fraction calculated based on surface area and height of 
epithelium 
f_pv=1-f_cv; %fraction central lung volume 
RO_ave=100*(f_pv*y(:,10)+f_cv*y(:,9))./data.Bmax; 
  
% Initial amount in each particle at t=0 (nmol) 
A_0=data.A_c0; 
  
% Equations for A_solid in the central lung (A_solid_c), 
% peripheral lung (A_solid_p),nose (A_solid_n) 
  
n_p=length(data.f_m);  
all_r=n_p*3; 
  
nose_r_index = [25, (25+n_p*3):all_r:((k-1)*n_p*3)+25]; 
cent_r_index = [25+n_p, ((25+n_p)+n_p*3):all_r:((k-
1)*n_p*3)+25+n_p]; 
peri_r_index = [25+(n_p*2), ((25+(n_p*2))+n_p*3):all_r:((k-
1)*n_p*3)+25+(n_p*2)]; 
  
nose_r_index = (nose_r_index')*ones(1,n_p) + ones(k,1)*(0:7);  
cent_r_index = (cent_r_index')*ones(1,n_p) + ones(k,1)*(0:7); 
peri_r_index = (peri_r_index')*ones(1,n_p) + ones(k,1)*(0:7); 
  
r_n = y(nose_r_index); 
r_c = y(cent_r_index); 
r_p = y(peri_r_index); 
  
A_solid_c=[]; 
 
for j=1:k 
  
    for i=1:n_p 
    A_solid=data.N_c(j,i)*exp(-data.k_mcc*(t-tao*(j-
1)))*A_0(i).*((y(:,cent_r_index(j)+(i-
1))./data.x0(cent_r_index(1)+(i-1))).^3); 
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    A_solid_c(:,i,j)=A_solid; 
    end 
     
end     
  
A_solid_p=[]; 
for j=1:k 
  
    for i=1:n_p 
    A_solid=data.N_p(j,i)*A_0(i).*((y(:,peri_r_index(j)+(i-
1))./data.x0(peri_r_index(1)+(i-1))).^3); 
    A_solid_p(:,i,j)=A_solid; 
    end 
     
end   
  
A_solid_n=[]; 
for j=1:k 
  
    for i=1:n_p 
    A_solid=data.N_n(j,i)*exp(-data.k_mcc_n*(t-tao*(j-
1)))*A_0(i).*((y(:,nose_r_index(j)+(i-
1))./data.x0(nose_r_index(1)+(i-1))).^3); 
    A_solid_n(:,i,j)=A_solid; 
    end 
     
end    
  
% Summarize over particle sizes and dosing occasions 
per=sum(A_solid_p,2); % Sum the amount across all particle sizes for 
each t 
Asolid_p=sum(per,3); 
  
cen=sum(A_solid_c,2); % Sum the amount across all particle sizes for 
each t 
Asolid_c=sum(cen,3); 
  
% Summarize total solid amount of drug 
Asolid_tot=Asolid_p+Asolid_c; 
  
% Calculate total lung conc 
% y(23) = C_ELF_c; y(24) = C_ELF_p 
Alung_tot= (y(:,20).*data.V_lung_C) + (y(:,21).*data.V_lung_P) + 
(y(:,23).*data.V_ELF_C) + (y(:,24).*data.V_ELF_P) + Asolid_tot; 
%Total amount of drug in the lung 
Clung_tot = Alung_tot/(data.V_lung+data.V_ELF_C+data.V_ELF_P); 
%Total lung concentration, perhaps 
V_lung_tot=V_lung+v_fluid(1)+v_fluid(2) 
  
end 
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Function gathering all drug-, formulation- and system-specific parameters 
  
function [ data ] = init_repeated( Cs, LDD, diameter, f_m, 
parameters ) 
% Initial parameters are stored in data 
% [ data ] = init_repeated ( Cs, LDD, diameter, f_m, parameters ) 
% Input needed: solubility (Cs); LDD=lung deposited dose; 
% diameter=aerodynamic diameters; f_m=mass fractions of each 
particle size 
% class; parameters is not default input, only to be used in case of 
% MC-simulations wrt the binding kinetics parameters 
  
k=length(LDD); % Number of doses  
data.factor_s = 4;% 
  
data.Cs = Cs; % Solubility (nM) 
data.f_m=f_m; % Mass fractions of each particle size 
  
% Intravenous (iv) and intraarterial (ia) dosing 
data.dose_iv=0; % IV-bolus dose 
data.dose_ia=0; % ia dose 
  
% System-specific parameters 
data.k_mcc_n=0.2079; 
data.k_mcc=0.0472;  
  
% Input parameters 
data.my=13.82816; %mol/(dm*h)  
data.MW=500.6; % g/mol 
data.p_g=715; %Density (g/dm3) 
data.D=13.26*10^(-5)/(data.my^1.14*(data.MW/data.p_g)^0.589); 
%Diffussion coefficient 
data.p=1.430*10^9 ; %Density (nmol/dm3) 
  
data.fu_f=1; % fu_fluid 
data.Papp=46.9; %Papp (10^(-6) cm/s) 
data.P_app=data.Papp*10^(-6); 
data.P=3600/10*data.P_app; %Papp unit conversion 
data.fu=0.016; % Unbound fraction in plasma 
data.b_p=0.95; % Blood-plasma ratio 
data.ka=5; % Absorption rate constant 
data.F=0; % Oral bioavailability 
  
% Binding kinetics FP 
data.Kd_FP=0.0150934; %(nM) Value from modeling of FP-IV 
data.Koff=0.510892; %(h-1) Value from modeling of FP-IV 
data.Kon=data.Koff/data.Kd_FP; 
  
if nargin > 4 
    data.Koff = parameters(1); 
    data.Kd_FP = parameters(2); 
end 
  
% Receptor density 
data.Bmax=21; %Receptor density in the lung (nmol/L) 
data.Bmax_sp=31.5; %Receptor density in the spleen (nmol/L) 
data.Bmax_all=23; %Mean value brain Bmax 
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%Kp-values FP 
data.Vu_lung=213.4;  
data.kp_factor=1.93; 
data.Kp_h=data.kp_factor*5.293087;  
data.Kp_s=data.kp_factor*2.686034; 
data.Kp_richly=data.kp_factor*4.8; 
data.Kp_poorly=data.kp_factor*3.990; 
data.Kp_l=data.Vu_lung*data.fu; 
data.Kp_g=data.kp_factor*10.50719; 
data.Kp_adi=data.kp_factor*65.32998; 
data.Kp_n=data.Vu_lung*data.fu; 
  
%Kp,u-values 
data.Kp_h_u=data.Kp_h/data.fu;  
data.Kp_s_u=data.Kp_s/data.fu; 
data.Kp_richly_u=data.Kp_richly/data.fu; 
data.Kp_poorly_u=data.Kp_poorly/data.fu; 
data.Kp_l_u=data.Kp_l/data.fu; 
data.Kp_g_u=data.Kp_g/data.fu; 
data.Kp_adi_u=data.Kp_adi/data.fu; 
data.Kp_n_u=data.Kp_n/data.fu; 
  
% Blood flows 
% 1) Fraction of cardiac-output, fi. From Gearhart et al. 1990 
unless stated otherwise 
data.f_n=0.0015; % A hybrid CFD-PBPK model 
data.f_h=0.024;  % Brown et al. 
data.f_s=0.0715 ; % Kaufman et al 1996 
data.f_richly=0.5096; % Sum of Qrichly+Qkidney+Qbrain Gearthart et 
al. 
data.f_g=0.14; % Delp et al 
data.f_bronch=0.021; %Brown et al. 
data.f_adi=0.009302; %Arundel:0.4 mL/min of 43 mL/min as QCO. 
data.f_poorly=1-
(data.f_h+data.f_s+data.f_richly+data.f_bronch+data.f_g+data.f_adi+d
ata.f_n);  
data.f_tot=data.f_h+data.f_s+data.f_richly+data.f_poorly+data.f_bron
ch+data.f_g+data.f_adi+data.f_n; 
  
% 2) Blood-flows, Qi 
data.Q_CO=20.77; % Gearthart et al 1990 (4.57 L/h / 220 g rat) 
data.Q_n=data.Q_CO*data.f_n; 
data.Q_h=data.Q_CO*data.f_h; 
data.Q_s=data.Q_CO*data.f_s; 
data.Q_g=data.Q_CO*data.f_g;  
data.Q_richly=data.Q_CO*data.f_richly; 
data.Q_poorly=data.Q_CO*data.f_poorly; 
data.Q_bronch=data.Q_CO*data.f_bronch; 
data.Q_adi=data.Q_CO*data.f_adi; 
  
% Surface areas 
data.A_nose=4*10.4*10^(-2) ; %Surface area nasal cavity, 10.4 cm2, 
250 g rat. 
data.A_c=1.08/0.330 ; % dm2, 108 cm2, tracheobronchial airways, 330 
g rat 
data.A_p=38.70/0.14 ; % dm2, 3870 cm2, alveolar region, 140 g rat 
  
% Tissue volumes, Vi  
data.v_fluid=lining_fluid; %v_fluid(1)=V_ELF_C; 
v_fluid(2)=V_ELF_P;v_fluid(3)=V_lining_nose; 
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data.V_ELF_C=data.v_fluid(1);%A_c*5*10^(-5); %Assuming ELF thickness 
5 um and continuous distribution  
data.V_ELF_P=data.v_fluid(2);%A_p*d_peri*10^(-5); %Assuming ELF 
thickness 0.07 um and continuous distribution 
data.V_n_fluid=data.A_nose*5*10^(-5); 
  
data.V_h=0.04; %Gearthart et al 
data.V_s=0.002; %Brown et al. 
data.V_art=0.02; %Gearhart et al  
data.V_vein=0.04; %Gearhart et al  
data.V_richly=0.0388; %Vrichly=Vkidney+Vrichly+Vbrain, Gearhart et 
al 
data.V_g=0.0259 ; %From Delp et al 
data.V_adi=0.040; %Arundel 10 mL/250 g rat 
data.V_lung=0.004127-(data.V_ELF_C+data.V_ELF_P); %4.127 g/kg from 
100 animals, mean BW: 0.285 kg, removing VELF 
data.V_n=data.A_nose*61*10^(-5); % Volume nasal mucosa, 0.2538 mL, 
comparison ET-volume taken from GastroPlus 0.046 mL TEMP!  
data.V_poorly=1-
(data.V_h+data.V_s+data.V_art+data.V_vein+data.V_richly+data.V_lung+
data.V_g+data.V_adi+data.V_n+data.V_n_fluid+data.V_ELF_C+data.V_ELF_
P); 
  
% Calculation of central and peripheral lung tissue volumes 
data.lung_vol=lung_volume(data.V_lung); %lung_vol(1)=V_lung_C; 
lung_vol(2)=V_lung_P  
data.V_lung_C=data.lung_vol(1); %Volume of central lung tissue  
data.V_lung_P=data.lung_vol(2); %Volume of peripheral lung tissue  
  
% Calculation of CL_blood based on CL_plasma and B:P-ratio 
% Extrahepatic CL to add up to obs CL 
data.CL_pl=10.95; %Plasma CL 
data.CL_bl=data.CL_pl/data.b_p; %CL blood 
data.CL_eh=data.CL_bl; 
data.CL_h=0; 
  
%Initial geometric radius expressed in dm 
x=diameter; 
  
p_g=data.p_g/1000; % Normalise to g/cm3 
n=length(x); 
  
% Calculation of geometric radius (note: x is diameter) 
r=[]; 
for i=1:n 
    r(i)=x(i)/2*10^(-5)/sqrt(p_g); 
end 
  
% Define vector data.x0 of initial values  
  
% Step 1: Initiate vector of 24 zeros for the 24 first states 
(tissue conc, RD etc.) 
set_1=zeros(1,24); % 24 zeros 
set_initial=set_1; 
  
% Step 2: Extract states where x(0) can be different from 0 
set_initial(7)=data.dose_ia/data.V_art; % C_arterial(0) 
set_initial(8)=data.dose_iv/data.V_vein; % C_vein(0) 
set_initial(18)=0; % Agut(0) 
290 
 
  
% Step 3: Define initial values of geometric radii 
data.r_set=r; 
  
% Step 4: Define data.x0, length of data.x0 defined by number of 
dosing 
% occasions, k 
data.x0=zeros(1,(24+k*24)); 
data.x0(1,1:(24+n*3))=[set_initial data.r_set data.r_set 
data.r_set]; 
  
% Calculate number of particles initially deposited in the nose 
(data.N_n), 
% central (data.N_c) and peripheral lung (data.N_p) 
  
data.N_n=[]; 
data.N_c=[]; 
data.N_p=[]; 
 
for i=1:k 
data.N_n(i,:)=number_n_test(LDD(i), data.f_m, diameter, data.p_g, 
data.p); 
data.N_c(i,:)=number_c_test(LDD(i), data.f_m, diameter, data.p_g, 
data.p); 
data.N_p(i,:)=number_p_test(LDD(i), data.f_m, diameter, data.p_g, 
data.p); 
end 
  
% Possibility to check data.N_x 
data.N_n; 
data.N_c; 
data.N_p; 
  
[row col]=size(data.N_n); 
  
% Initial amount in each particle at t=0 (nmol) 
data.A_c0=amount_particle(diameter, data.p_g, data.p); 
  
% Include F here to account for bioavailability 
data.A_0_F=data.A_c0.*data.F; 
  
% k=number of dosing occasions;n=number of particle size classes 
  
data.m_cen=zeros(k,n); % Changed from 8 to n 
for j=1:k 
    for i=1:n 
        data.m_=data.A_c0(i)*data.N_n(j,i); 
        data.m_cen(j,i)=data.m_; 
    end 
    data.dep_n(j)=sum(data.m_cen(j,:)); 
end 
  
data.m_c_lung=zeros(k,n); 
  
for j=1:k 
    for i=1:n 
        data.m_=data.A_c0(i)*data.N_c(j,i); 
        data.m_c_lung(j,i)=data.m_; 
    end 
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    data.dose_c(j)=sum(data.m_c_lung(j,:)); 
end 
  
data.m_p_lung=zeros(k,n); 
  
for j=1:k 
    for i=1:n 
        data.m_=data.A_c0(i)*data.N_p(j,i); 
        data.m_p_lung(j,i)=data.m_; 
    end 
data.dose_p(j)=sum(data.m_p_lung(j,:)); 
end 
  
for j=1:k 
data.dd_region(j,:)=[data.dep_n(j) data.dose_c(j) data.dose_p(j)]; 
end% deposited dose in each region 
  
end 
  
  
function [lining_fluids]=lining_fluid() 
% Returns lining fluid volumes [V_ELF_C,V_ELF_P,V_n_fluid] 
format long 
% Surface areas 
A_nose=4*10.4*10^(-2) ; %Surface area nasal cavity, 10.4 cm2, 250 g 
rat. 
A_c=1.08/0.330 ; % dm2, 108 cm2, tracheobronchial airways, 330 g rat 
A_p=38.70/0.14 ; % dm2, 3870 cm2, alveolar region, 140 g rat 
  
% Tissue volumes, Vi  
d_peri=0.07; %Byron and Patton 
V_ELF_C=A_c*5*10^(-5); %Assuming ELF thickness 5 um and continuous 
distribution  
V_ELF_P=A_p*d_peri*10^(-5); %Assuming ELF thickness 0.07 um and 
continuous distribution 
V_n_fluid=A_nose*5*10^(-5); 
lining_fluids=[V_ELF_C,V_ELF_P,V_n_fluid]; 
end 
  
function [V_lung_k]=lung_volume(V_lung) 
% Returns regional tissues volumes based on total tissue volume 
% (V_lung), [V_lung_C V_lung_P]  
% V_lung=0.004127; %4.127 g/kg from 100 animals, mean BW: 0.285 kg 
format long 
f_cv=0.19; %Fraction calculated based on surface area and height of 
epithelium 
f_pv=1-f_cv; %fraction central lung volume 
  
% Calculation of central and peripheral lung tissue volumes 
V_lung_C=f_cv*V_lung; %Volume of central lung tissue  
V_lung_P=f_pv*V_lung; %Volume of peripheral lung tissue  
  
V_lung_k=[V_lung_C V_lung_P]; 
end 
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Functions called by init_repeated.m 
 
Function used for calculating the amount in each particle 
 
function [A_zero]=amount_particle(diameter, p_g, p_mol) 
% Calculation of amount in each particle at t=0 
% [A_zero]=amount_particle(diameter, p_g, p_mol) 
% diameter=aerodynamic diameter (um); p_g=density in g/dm3 
  
x=diameter; 
  
p_g=p_g/1000; % Normalise to g/cm3 
n=length(x); 
  
% Calculation of geometric radius (note: x is diameter) 
r=[]; 
for i=1:n 
    r(i)=x(i)/2*10^(-5)/sqrt(p_g); 
end 
  
% Calculate volumes 
V=zeros(1,8); 
for i=1:8 
V_=(4*pi*r(i)^3)/3; 
V(i)=V_; 
end 
  
A_zero=zeros(1,8); 
for i=1:8 
A_=V(i)*p_mol; 
A_zero(i)=A_; 
end 
  
Function used for calculating the number of particles in the central lung (same 
principle applied for both lung regions and the nose) 
 
function [N_zero_c]=number_c_test(LDD, f_m, x, p_g, p_mol) 
% Calculation of numbers of particles deposited centrally 
% [N_zero_c]=number_c_test(LDD, f_m, x, p_g, p_mol) 
% LDD = lung deposited dose; f_m = mass fraction; x = aerodynamic 
diameter 
% (um); p_g = density in g/dm3; p_mol = density in nmol/dm3 
  
p_g=p_g/1000; % Normalise to g/cm3 
n=length(x); 
  
% Calculation of geometric radius (note: x is diameter) 
r=[]; 
for i=1:n 
    r(i)=x(i)/2*10^(-5)/sqrt(p_g); 
end 
r; 
  
% Extract deposition fraction given aerodynamic diameter x 
% 1) Define breathing conditions for deposition model 
V_T=2.6; % Tidal volume (mL) Lee et al. 
f_br=97.4; % Breathing frequency (min-1) 
  
293 
 
% 2) Run deposition model (for simplicity, the model code for the 
deposition is attached as a separate appendix) 
[et tb a] = get_df_lee(x, V_T, f_br); 
  
% Probability of peripheral deposition 
f_dep=a; 
% Probability of central deposition 
f_dep_c=tb; 
% Probability of nasal deposition 
f_dep_n=et; 
  
% Calculate prob of lung deposition in both c and p lung 
lung_dep=zeros(1,n); 
for i=1:n 
    lung_dep_=f_m(i)*f_dep(i)+f_m(i)*f_dep_c(i); 
    lung_dep(i)=lung_dep_; 
end 
lung_dep_sum=sum(lung_dep); 
  
% Density 
p=p_g; % g/dm3 
p_mol=p_mol; % Density (nmol/dm3) 
  
% Calculate volumes 
V=zeros(1,n); 
for i=1:n 
V_=(4*pi*r(i)^3)/3; 
V(i)=V_; 
end 
  
dose_inh=LDD/lung_dep_sum; % Calc of inhaled dose 
  
% Calculate number of particles initially deposited centrally 
N_zero_c=zeros(1,n); 
for i=1:n 
N_=f_m(i)*f_dep_c(i)*dose_inh/(V(i)*p_mol); 
N_zero_c(i)=N_; 
end 
  
m_zero=zeros(1,n); 
for i=1:n 
    m_=N_zero_c(i)*V(i)*p_mol; 
    m_zero(i)=m_; 
end 
total_m_cen=sum(m_zero); 
end 
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Appendix B  
Matlab implementation of regional drug deposition (Lee et al) 
Main function for calculating drug deposition 
function [df_et df_tb df_al] = get_df_lee(da, V_T, f_br) 
% Input: areodynamic diameter, da, [um]; tidal volume, V_T [mL] 
% and breathing frequency, f_br [min-1]  
% default values V_T=2.6 mL; f_br=97.4 min-1 
  
% Function for calculating deposition in the lung after rodent 
inhalation 
% "Particle deposition in juvenile rat lungs: A model study" by Lee 
et al.  
% Anatomy values for 81-day old rats 
% To couple to repeated dosing 
  
load('anat_2.mat') % anatomy data from Lee et al. 
  
% The model automatically transforms the anatomy based on V_T and BW 
ANAT = anat_2; 
 
% Extract anatomical input from the data set 
i_gen=ANAT(:,1); 
N_i=ANAT(:,2); 
L_i=ANAT(:,3); 
D_i=ANAT(:,4); 
D_i_eff=ANAT(:,5); 
V_i=ANAT(:,6); 
cum_Vi=ANAT(:,7); 
phi=ANAT(:,8); % Angle 1 
theta=ANAT(:,9); % Angle 2 
  
% Conversion from degrees to radians 
phi=phi.*(pi/180); 
theta=theta.*(pi/180); 
  
%% Breathing conditions and anatomy 
  
%V_T=2.6; %Tidal volume [cm3] from Lee et al. 
%f_br=97.4; % Breathing frequency (1/min) from Lee et al. 
V_min=V_T*f_br; % Minute respiration [cm3/min] 
Q=V_min*2/60; % Inhalation flow rate according to Schmid et al; 
Q=2*Vmin [cm3/s] 
  
BW=381; %BW [g] 
  
% Function for transforming volumes, diameters and length 
% Possible to exclude transformation of i=1:2 (Schmid et al) 
[L_i_scaled, D_i_scaled, f_scale, D_i_eff_scaled, imax, cum_Vi_2, 
V_i_2]=calcV(D_i,L_i,N_i,V_T,BW,D_i_eff,cum_Vi,V_i); 
  
% Anatomy data for the nose; transformation based on f_scale 
L_n=1.95*f_scale; % Length, cm. Lee et al 
H_n=0.016*f_scale; % Height, cm. Lee et al. 
W_n=5.7*f_scale; % Width, cm. Lee et al. 
 
% Unscaled values 
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L_i_unscaled=L_i; 
D_i_unscaled=D_i; 
  
% Choose input values 
L_i=L_i_scaled; 
D_i=D_i_scaled; 
D_i_eff=D_i_eff_scaled; 
 
%% Particle input parameters 
  
% Unit particle density 
po=1000; % 1 g/cm3 = 1000 kg/m3 
  
%% Calculation of airflow (Q_i), velocity (v_i) and mean residence 
time (t_i) 
  
[v_i,t_i,Q_i]=airflow(L_i,D_i,N_i,Q); 
  
% Transformation of v_i and Q_i to SI-units 
v_i=v_i./100; % from cm/s to m/s 
Q_i=Q_i./1e6; % from cm3/s to m3/s. Note, to nasal impaction, cm3/s 
should be used, otherwise m3/s.  
  
% Get deposition parameters  
[Cd,vg,Dp,ne,pa,Dmol]= get_parameters(da,po); % Dmol = Dp 
  
% Row 2 and 3 in IMP_i equals zero due to theta=0, sin(theta)=0 
[stk,mu,re,eps]=Deposition_equation_parameters_lee(da,po,ne,v_i,D_i,
Dp,t_i,pa,vg,phi,D_i_eff,Cd); 
  
% Deposition according to Lee et al. 
[IMP_i, SED_i,DIF_i]=deposition_probability2(stk,re,theta,eps,D_i, 
D_i_eff,L_i,v_i,Dmol);  
  
% Calculate nasal deposition; (IMP_n remains to be implemented 
properly) 
[DIF_n IMP_n SED_n mu_n]=nose(L_n,W_n,H_n,Q_i(1),Dmol, da); 
  
DEP_n=DIF_n + IMP_n + SED_n; 
  
% Add nasal deposition to the pulmonary deposition fractions 
IMP_i(1,:)=IMP_n; 
SED_i(1,:)=SED_n; 
DIF_i(1,:)=DIF_n; 
  
%% Change size of V_i and cum_Vi if imax<26 (maximum nr of 
generations) 
  
V_i_2=V_i_2(1:imax); 
cum_Vi_2=cum_Vi_2(1:imax); 
IMP_i=IMP_i(1:imax,:); 
SED_i=SED_i(1:imax,:); 
DIF_i=DIF_i(1:imax,:); 
 
%% Calculate resulting deposition fractions 
  
 [ df, DEP_in, DEP_ex, f_conv ] = dfCalc2( IMP_i, SED_i, DIF_i, 
V_i_2, da, imax ); 
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size(df); 
  
df_et=sum(df(1:2,:)); 
df_tb=sum(df(3:18,:)); 
df_al=sum(df(19:26,:)); 
  
end 
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Functions called by get_df_lee.m 
Function for scaling the anatomy 
function [L_i_scaled, D_i_scaled, f_scale, D_i_eff_scaled, imax, 
cum_Vi_2, V_i_2]=calcV(D_i,L_i,N_i,V_T,BW,D_i_eff,cum_Vi,V_i) 
% Calculation of scaled lengths (L_i_scaled), diameters (D_i_scaled) 
% and volumes (V_i_scaled) based on the scale factor f_scale, which 
is 
% calculated based on BW and tidal volume (V_T) 
% Note that V_i_scaled(1) needs to be calc separately since it is 
not a cylinder 
% Schmid et al only scales i=3:26 whereas Lee scales i=1:26 
  
% Calculation of scale factor (f_scale) 
TLC=0.032*BW^1.05; % Total lung capacity [cm3] 
f_scale=((0.4*TLC+0.5*V_T)/TLC)^(1/3); %Scale factor 
 
% Calculation of scaled volumes, i=1:2 not scaled by Schmid et al 
% Lee appears to have scaled the nose and the pharynx as well 
  
L_i_scaled=L_i.*f_scale; 
%L_i_scaled(1:2)=L_i(1:2); % Schmid et al 
D_i_scaled=D_i.*f_scale; 
%D_i_scaled(1:2)=D_i(1:2); % Schmid et al 
D_i_eff_scaled=D_i_eff.*f_scale; 
  
r_i=D_i_scaled./2; 
A=pi.*(r_i).^2; 
  
V_i_scaled=N_i.*A.*L_i_scaled;  
  
%V_i_scaled(1:2)=V_i(1:2); % Schmid et al 
  
% Scaled nose and pharynx volumes 
V_i_scaled(1)=0.1770*(f_scale^3); 
V_i_scaled(2)=0.17180*(f_scale^3); 
  
% Calculation of last ventilated generation, imax 
  
% 1) Calculate cumulative lung volume, sum_Vi 
sum_Vi=[]; 
for i=1:length(V_i) 
    sum_Vi(i)=sum(V_i_scaled(1:i)); 
end 
  
% 2) Test logical conidition: V_T > sum_Vi 
true=V_T>sum_Vi; 
[min_value index]=min(true); %index gives generation when V_cum > 
V_T 
  
if index==1 % If V_T never exceeds sum_Vi all generations are 
ventilated 
    imax=26;  
else 
    imax=index; 
end 
  
% 3) Adapt volume of imax such that sum_Vi=V_T by changing L_imax  
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% as done by Schmid et al 
V_i_scaled(imax)=V_T-sum_Vi(imax-1); 
L_i_imax=V_i_scaled(imax)/(N_i(imax)*A(imax)); 
L_i_scaled(imax)=L_i_imax; 
  
% Update cumulative V, i.e. sum_V_i 
for i=1:length(V_i) 
    sum_Vi(i)=sum(V_i_scaled(1:i)); 
end 
sum_Vi=sum_Vi; 
  
% Change name of variables 
cum_Vi_2=sum_Vi; 
V_i_2=V_i_scaled; 
  
% If imax < 26, set arbitrarily V to i > imax (will not be used) 
  
for i = 1:26 
    if i<=imax 
        cum_Vi_2(i)=cum_Vi_2(i); 
    elseif i>imax 
        cum_Vi_2(i)=cum_Vi_2(imax); 
    end 
end 
 
Function for calculating air velocity, mean residence time and flow 
 
function [v_i,t_i,Q_i]=airflow(L_i_scaled,D_i_scaled,N_i,Q) 
% Calcultion of air velocity (v) and residence time (t_i) in each 
tube 
% Prior to this, calculate the flow Qi for each generation i 
% Use L_i_scaled and D_i_scaled as input 
  
Q_i=Q./N_i; % Unit Q [cm3/s] 
A_i=pi.*(D_i_scaled./2).^2; % [cm2] A=r^2*pi 
v_i=Q_i./A_i; % [cm/s] 
t_i=L_i_scaled./v_i; % Mathematically the same as below [s] 
  
end 
   
%V_scaled=N_i*A_i.*L_i_scaled; 
%t_i=V_scaled./Q_i; 
 
Function for getting parameters 
 
function [Cd,vg,Dp,ne,pa,Dmol]= get_parameters(da,po) 
% po=unit density; da=aerodynamic diameter 
% cd=cummingham slip correction factor; vg=gravitational settling 
velocity 
% of a particle [m/s]; Dp=Dmol=particle diffusion constant [m2/s];  
% ne=viscosity of air [kg/m/s]; pa=density of air (kg/m3) 
% Use SI-units consistently 
  
da=da.*10^-6; % Transformation from um to m 
  
k = 1.38064852*10^-23 ; % boltzmann constant [m^2·kg/(s^2·K)]  
T = 273.15+37.5; %311.05; % absolute temp, 37.5 degree Celcius 
(range 37-37 degree C) 
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ne = 1.9224364E-5;% viscosity of air at 37.5 dgr C [kg/m/s] 
(1.846*10^-5 kg/m/s at 300K)  
g = 9.81;% gravitational acceleration [m/s^2] 
pa = 1.1372; % density of air 37.5 degr C [kg/m3]; 
http://www.gribble.org/cycling/air_density.html 
lamda=0.066*10^-6; % 0.066 um, 
http://myweb.uiowa.edu/tpeters/IH1/Aerosols/AerosolFormulae.pdf 
  
% Calculations 
Cd= 1 + (lamda./da).*(2.514+0.8*exp(-0.55*(da./lamda))); % from Lee 
et al. 
Dp =(k*T.*Cd)./(3*pi*ne.*da); % particle diffusion constant [m2/s] 
vg = (po.*((da.^2).*g.*Cd)./(18*ne)); % gravitational settling 
velocity of a particle 
Dmol=(k*T.*Cd)./(3*pi*ne.*da); %Brownian diffusion coefficient  
[m2/s] 
 
end 
  
Function for calculating parameters necessary for the deposition equations 
 
function 
[stk,mu,re,eps]=Deposition_equation_parameters_lee(da,po,ne,v_i,D_i,
Dp,t_i,pa,vg,phi,D_i_eff,Cd) 
% calculation of deposition parameters: eps, mu reynolds number and 
stokes 
% number 
 
% D_i_eff to be used for calc of eps if i>18 
 
% Unit transformations 
% v_i already written in the correct units 
da=da.*10^-6; % Transformation from um to m 
D_i=D_i.*10^-2; % Transformation from cm to m 
D_i_eff=D_i_eff.*10^-2; % Transformation from cm to m 
  
stk=[];  
mu=[];   
re=[];   
eps=[]; 
  
for j=1:length(da) 
    for i=1:length(v_i) 
         
            stk(i,j)=po*(da(j)^2)*v_i(i)/(9*ne*D_i(i)); 
            re(i,j)=pa*D_i(i)*v_i(i)/ne; 
 mu(i,j)=Dp(j)*t_i(i)/(D_i(i)^2);  
        if i <= 18 
            eps(i,j)=3*vg(j)*t_i(i)*sin(phi(i))/(4*D_i(i)); 
        else 
            eps(i,j)=3*vg(j)*t_i(i)*sin(phi(i))/(4*D_i_eff(i)); 
        end 
    end 
end 
  
end 
  
% eps = par in sedimentation equation 
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% mu = par in diffusion equation (not used by Lee et al but by 
Schmid) 
% re = Reynolds number 
% stk= stokes number 
 
Function used for calculating the deposition probability for the three included 
deposition mechanisms: inertial impaction, gravitational sedimentation and brownian 
diffusion 
 
function [DEP_i, SED_i, 
DIF_i]=deposition_probability2(stk,re,theta,eps, D_i, 
D_i_eff,L_i,v_i,Dmol) 
 
% Unit transformations 
D_i=D_i.*10^-2; % Transformation from cm to m 
D_i_eff=D_i_eff.*10^-2; % Transformation from cm to m 
L_i=L_i*10^-2; % Transformation from cm to m 
  
DEP_i=[]; 
SED_i=[]; 
DIF_i=[]; 
test=[]; 
[n m]=size(stk); % n=number of gen; m=number of particle sizes 
 
for j=1:m 
    for i=1:n 
        if stk(i,j)<0.04 
            
DEP_i(i,j)=0.000654*exp(55.7*stk(i,j)^0.954)*re(i,j)^(1/3)*sin(theta
(i)); 
        else 
DEP_i(i,j)=(0.19... 
-0.193*exp(9.5*stk(i,j)^1.565))*re(i,j)^(1/3)*sin(theta(i));  
        end 
    end 
end 
  
for j=1:m 
    for i=1:n 
        if i==1 
            SED_i(i,j)=0; 
        else 
        SED_i(i,j)=2/pi*(2*eps(i,j)*(1-eps(i,j)^(2/3))^(1/2)... 
        -(eps(i,j)^(1/3))*(1-eps(i,j)^(2/3))^(1/2)... 
            +asin(eps(i,j)^(1/3))); 
        test(i,j)=asin(eps(i,j)^(1/3)); 
        end 
    end 
end 
  
% In the alveoli region (i>=19) D=(D_i+D_i_eff)/2 
D_i_d=D_i; 
D_ex=(D_i+D_i_eff)/2; 
D_i_d(19:26)=D_ex(19:26); 
  
for j=1:m 
    for i=1:n 
    delta(i,j)=Dmol(j)*L_i(i)/(v_i(i)*(D_i_d(i)^2)); 
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    DIF_i(i,j)=1-0.819*exp(-14.63*delta(i,j))-0.0976*exp(-
89.22*delta(i,j))-0.0325*exp(-228*delta(i,j))... 
        -0.0509*exp(-125.9*delta(i,j)^(2/3)); 
    end 
end 
 
Function for calculating drug deposition in the nose 
function [DIF_n IMP_n SED_n mu_n]=nose(L,W,H,Q1,Dmol,da) 
  
% Unit transformation from cm to m (L,W and H are given in cm) 
L=L*0.01;  
W=W*0.01;  
H=H*0.01;  
  
mu_n=8*Dmol.*L*W./(3*Q1*H); 
  
[xx n_da]=size(da); 
  
DIF_n=zeros(1,n_da); 
for i=1:n_da 
    if mu_n(i) < 0.05 
        DIF_n(i)=1.526*mu_n(i)^(2/3)-0.15.*mu_n(i)-
0.0342.*mu_n(i)^(4/3); 
    else 
        DIF_n(i)=1-( 0.9104*exp(-2.8278.*mu_n(i)) + 0.0531*exp(-
32.147.*mu_n(i))... 
        +0.01528*exp(-93.475.*mu_n(i)) + 0.00681*exp(-
186.805.*mu_n(i))); 
    end 
end 
  
% Impaction, simplified formula 
  
al=2.553; 
beta=0.627; 
C=10^5; 
  
Q1_im=Q1*1e6; % m3/s to cm3/s 
  
da2Q=(da.^2).*Q1_im;  
% units da [um], Q [cm3/s]; Hence, da does not need unit 
transformation  
  
IMP_n=(da2Q.^al./(C+(da2Q.^al))).^beta; 
  
% Nasal deposition by sedimentation negligible 
[n,m]=size(IMP_n); 
SED_n=zeros(n,m); 
  
Function used for calculating the resulting deposition fraction 
 
function [ df, DEP_in, DEP_ex, f_conv ] = dfCalc2( IMP, SED, DIF, V, 
da, imax ) 
% Calculation of resulting deposition fractions 
  
% Calculation of resulting probability P 
P = 1-(1-IMP).*(1-SED).*(1-DIF); 
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% Convection factor for the alveolar region (i=19:26) Lee et al. 
f_conv = 1+0.5*(log10(da)-log10(2)).*(log10(da)-
log10(0.02))./((log10(0.1)-log10(2))*(log10(0.1)-log10(0.02))); 
f_conv(da < 0.02) = 1; 
f_conv(da > 2) = 1; 
  
N_g = imax; % Nr of generations 
N_p = size(P,2); % Nr of particle sizes 
  
% Augment P to compute fi, set the first row to 0 
% --> first row in fi should equal 1 (nothing has deposited when 
entering the nose) 
P_hat = [zeros(1,N_p); P]; 
  
% fi should consist of 27 rows (N_g+1) 
f = zeros(N_g+1,N_p); 
  
% prod returns the product of each column 
for i = 1:(N_g+1) 
    f(i,:) = prod([ones(1,N_p);1-P_hat(1:i,:)]);  
end 
  
% Clone V into a matrix 
V = V(:)*ones(1,N_p); 
  
% Create alpha, see definition below  
% fi(1)=1; fi(2)=(1-P1); fi(3)=(1-P1)(1-P2) etc. 
% term 2 exhalation starts with: f(i+3)*V(i+2)  
% term 1 exhalation starts with: f(i+2)*V(i+1)  
alpha = [f(3:end,:).*V(2:end,:)]; 
  
% Exhalation, no deposition in gen 26 
x = zeros(N_g, N_p); 
  
% x defines all that flows, the probability for deposition is taken 
into account afterwards in DEP_ex: DEP_ex(i)=P(i)*x(i) 
  
% At i = 25 alpha(25) = fi(27)*Vi(26), i.e. (1-P1)...(1-P26)*Vi(26) 
% --> x(26,:) = 0 
% --> x(25,:) = (1-P26)*0        + (1-P1)...(1-P26)*Vi(26) 
% --> x(24,:) = (1-P25)*x(25,:)  + fi(26)*Vi(25) 
% --> x(23,:) = (1-P24)*x(24,:) + fi(25)*Vi(24) 
  
for i = N_g-1:-1:1 % 25 to 1 
     
    x(i,:) = (1-P(i+1,:)).*x(i+1,:) + alpha(i,:); 
  
end 
  
DEP_ex = x.*P; 
  
% Inhalation 
% Create vector of cumulative volumes (take away V that stays in 
each generation) 
sum_V=zeros(length(N_g),1); 
for i = 1:N_g 
    V2=flipud(V(:,1)); 
    sum_V(i)=sum(V2(1:(N_g+1-i))); 
end 
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DEP_in = zeros(N_g, N_p); 
for j = 1:N_p 
    DEP_in(:,j) = f(1:end-1,j).*P(:,j).*sum_V'; 
end 
  
% Result: 
df = (DEP_in + DEP_ex)/sum(V(1:imax,1)); 
df(19:imax,:) = df(19:imax,:).*(ones((imax-18),1)*f_conv); 
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Appendix C 
Summary of PBPK model ODEs 
This appendix summarises the ODEs used in the PBPK model. Please note that all 
abbreviations are provided at the end of this appendix. 
 
ODEs describing the change of drug concentrations in the systemic tissues and 
the blood:  
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where i assigns the following five tissue compartments: nose, central lung, richly 
perfused tissue, poorly perfused tissues and adipose tissue. 
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ODEs describing pulmonary and nasal drug disposition 
a) ODEs describing the change of drug concentrations in the lining fluids 
There are eight different particle size classes in the model, hence the ODEs 
describing the change of concentration in the nasal lining fluid (Cfluid,n), the central 
epithelial lining fluid (Cfluid,c) and the peripheral epithelial lining fluid (Cfluid,p) will be 
as follows: 
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b) ODEs describing the change of drug concentrations in the nose and lung 
The ODEs describing the concentration in the central lung tissue (Clung,c), the 
peripheral lung tissue (Clung,p) and the nose (Cn). 
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c) ODE describing the change of the radius: 
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where j assigns the region (i.e. nose, central lung or peripheral lung) and i assigns the 
particle size class. A detailed description of f(rj,i) is provided in section ‘5.2.1.3 
Dissolution of drug’, particularly by eq. 5.23.  
 
ODE describing the change of drug amount in the gut absorption compartment 
Agut: 
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ODE describing receptor binding in tissue compartment i: 
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where i assigns the following tissues: central lung, peripheral lung, liver, spleen, gut, 
richly perfused tissues, poorly perfused tissues and adipose tissue. 
 
Abbreviations:  
Cx=concentration of drug in tissue compartment x; Vx=tissue volume of x; Qx=blood 
flow to x; R=blood/plasma ratio; Kp,x= tissue-plasma partition coefficient; 
Kon=association rate constant; Koff=dissociation rate constant; Bmax,x=receptor density 
in x; Kp,u,x=tissue-to-unbound plasma partition coefficient; RDx=concentration of 
drug-receptor complex in x; Agut=the amount of drug in the gut absorption 
compartment; ka=oral absorption rate constant; kmcc,lung=mucociliary clearance rate 
constant in the lung; kmcc,nasal=mucociliary clearance rate constant in the nose; F=oral 
bioavailability; Nj,i=number of particles of size class i in region j; Ai=amount of drug 
in a particle of size class i; rj,i=radius of a particle of size class i in region j; 
CL=clearance; Cfluid,j=concentration of drug in the epithelial lining fluid (ELF) or the 
nasal lining fluid; fu,fluid=unbound fraction in ELF or the nasal lining fluid; 
D=diffusion coefficient; Cs=solubility of the drug; Asurf,j=surface area in region j; 
ρ=particle density 
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Subscripts: 
sp=spleen; ri=richly perfused tissues; po=poorly perfused tissues; adi=adipose 
tissues; h=hepatic; g=gut; A=arterial; ve=venous; lung,p=peripheral lung tissue; 
lung,c=central lung tissue; n=nose; CO=cardiac output; c=central; p=peripheral 
 
